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The effects of low marine ingredient diets supplemented with graded levels (L1, L2, L3) of a 26 
micronutrient package (NP) on growth and metabolic responses were studied in diploid and 27 
triploid salmon parr. Diploids fed L2 showed significantly improved growth and reduced liver, 28 
hepatic steatosis, and viscerosomatic indices, while fish fed L3 showed suppressed growth rate 29 
14 weeks post feeding. In contrast, dietary NP level had no effect on triploid performance. 30 
Whole body mineral composition, with exception of copper, did not differ between diet or 31 
ploidy. Whole fish total AAs and N-metabolites showed no variation by diet or ploidy. Free 32 
circulating AAs and white muscle N-metabolites were higher in triploids than diploids, while 33 
branch-chained amino acids were higher in diploids than triploids. Diploids had higher whole 34 
body α-tocopherol and hepatic vitamins K1 and K2 than triploids. Increased tissue B-vitamins 35 
for niacin and whole-body folate with dietary NP supplementation were observed in diploids 36 
but not triploids, while whole body riboflavin was higher in diploids than triploids. Hepatic 37 
transcriptome profiles showed that diploids fed diet L2 was more similar to that observed in 38 
triploids fed diet L3. In particular, sterol biosynthesis pathways were down-regulated, whereas 39 
cytochrome P450 metabolism was up-regulated. One-carbon metabolism was also affected by 40 
increasing levels of supplementation in both ploidies. Collectively, results suggested that, for 41 
optimised growth and liver function, micronutrient levels be supplemented above current 42 
National Research Council (2011) recommendations for Atlantic salmon when fed low marine 43 
ingredient diets. The study also suggested differences in nutritional requirements between 44 
ploidy. 45 
 46 
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1. Introduction 48 
All animals, including fish, have specific macro- and micronutrient requirements for 49 
optimal growth, development and health (Halver and Hardy, 2002). Whereas macro-nutrient 50 
requirements (e.g. protein and lipid) have been extensively studied in Atlantic salmon (Salmo 51 
salar L.) (e.g. Hillestad and Johnsen, 1994; Einen and Roem, 1997; Grisdale-Helland et al., 52 
2013), micronutrients (e.g. vitamins and minerals) have been less well researched and only a 53 
few have been the subject of empirical studies (see Waagbø, 2010; NRC, 2011; Hansen et al., 54 
2015; Hamre, et al., 2016; Hemre, et al., 2016). This lack of empirically derived data in salmon 55 
for many micronutrients has not prevented the development of a large and highly successful 56 
salmon farming industry worldwide (Kontali, 2015). Traditionally, many of the micronutrients 57 
were provided by raw materials, such as fishmeal (FM) and fish oil (FO) (NRC, 2011). 58 
However, FM and FO are finite, on an annual basis, and limited resources (Shepherd and 59 
Jackson, 2013; IFFO, 2014) and, with steadily increasing price, their use in fish feed has 60 
become commercially less viable (Tacon and Metian, 2008; Jackson and Shepherd, 2012).  61 
Plant products have increasingly replaced FM and FO in salmon feeds (Gatlin et al., 62 
2007; Hardy et al., 2010; Turchini et al., 2011). For example, in Norwegian salmon feeds from 63 
1990 to 2013, the proportions of marine ingredients decreased from almost 90 % to under 30 64 
%, with plant ingredients increasing from very low levels to around 67 % of feeds (Ytrestøyl et 65 
al., 2015). This has been a progressive change as shown by the levels in 2000 (65 % marine and 66 
33 % plant) and 2010 (42 % marine and 56 % plant). Therefore today, commercially available 67 
feeds for salmon are predominantly formulated with plant ingredients, with consequent changes 68 
to the nutritional profile (Sissener et al., 2013). While it seems that salmon can tolerate and 69 
grow well on diets with very low levels of marine ingredients, such that they can be considered 70 
as net producers of marine protein and oil (Bendiksen et al., 2011; Crampton et al., 2010; 71 
Sanden et al., 2011), in some cases high dietary levels of plant proteins and vegetable oils (VO) 72 
can result in lower weight gain, increased adiposity and lower feed efficiency in salmon, even 73 
when requirements for all essential nutrients are met (Torstensen et al., 2008, 2011; Collins et 74 
al., 2013). Furthermore, replacement of FM and FO with plant-based alternatives has been 75 
shown to have a wide range of metabolic effects that can also impact on fish development and 76 
health, as well as nutritional quality of the final product (Montero and Izquierdo, 2011; 77 
Rosenlund et al., 2011; Oliva-Teles, 2012; Pohlenz and Gatlin, 2014). There are now concerns 78 
that, with these major changes in raw materials, low marine / high plant feeds will affect not 79 
only the composition and contents of nutrients, but also the bioavailability and, combined with 80 
the limited knowledge of micronutrient requirements for Atlantic salmon, this might impact 81 
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growth performance and health of the fish (Bell and Waagbø, 2008; Hemre et al., 2009; 82 
Torstensen and Tocher, 2011; Tocher and Glencross, 2015; Shepherd et al., 2017). Therefore, 83 
knowledge of practical nutrient requirements of Atlantic salmon when fed plant-based diets is 84 
pivotal (Hansen et al., 2015). 85 
In this respect, there is growing interest within the Scottish and Norwegian farming 86 
sector to consider commercial implementation of triploid Atlantic salmon within certain 87 
farming localities. Triploid salmons are fish carrying a chromosomal abnormality (i.e. an extra 88 
set of chromosomes) that can be artificially induced by hydrostatic pressure, thermal or 89 
chemical shock (Benfey, 2016). As a result of their chromosomal state, triploids are sterile, 90 
hence offering potential advantages for farming such as reproductive containment of escapees 91 
and potential for faster growth with subsequent reduction of production cycle length (Benfey, 92 
2016). However, specific dietary requirement trials in triploids are limited to date, although it 93 
was previously suggested that differences between ploidy might exist (Fjelldal & Hansen, 94 
2010). Apparent digestibility coefficients for dry matter, protein, or lipid do not appear to differ 95 
between ploidy (Burke et al., 2010; Tibbetts et al., 2013), whereas energy and nitrogen retention 96 
efficiencies may be higher in triploids than diploids (Burke et al., 2010). Evidence exists to 97 
hypothesise that triploids may have higher dietary requirement for certain macro-minerals such 98 
as phosphorous, which must be met to prevent the onset of skeletal deformities (Fjelldal et al., 99 
2015). In addition, a higher requirement for the essential amino acid histidine was also reported 100 
to prevent cataract formation in post-smolts and, possibly, to improve feed conversion 101 
efficiency (Taylor et al., 2015). It stands to reason that, similar to phosphorus and histidine, 102 
other dietary requirements may vary between ploidy, especially in respect to nutrient profile 103 
alterations in low marine ingredients diets. However, few studies have examined triploid 104 
performance in response to a diet with low levels of FM or FO (Ganga et al., 2015), or how 105 
dietary micronutrient supplementation would affect growth and metabolism. It is therefore 106 
essential to establish the dietary requirements of triploid Atlantic salmon, and ensure their 107 
performance is at least equal or better than their diploid counterparts under a dietary regime 108 
with low marine ingredients in order to establish their viability for integration in commercial 109 
operations. 110 
The present study investigated the effects of feeding graded levels of a nutrient package 111 
(NP) containing 24 nutrients in total (NRC, 2011 minimum nutrient recommendations for 112 
Atlantic salmon modified based on the studies by Hamre et al., 2016; Hemre et al. 2016) 113 
supplemented to feeds formulated with low levels of marine ingredients in diploid and triploid 114 
Atlantic salmon from parr until smolt. Specifically, fish were fed a diet supplemented with one 115 
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of three inclusion levels of the NP (L1, 100 %; L2, 200 % and L3, 400% NP) and the effects 116 
on growth performance, biochemical composition, liver histology, hepatic gene expression 117 
(transcriptome) and smoltification efficiency determined. 118 
 119 
2. Methods and Materials 120 
2.1 Fish Stock 121 
All experimental procedures and husbandry practices were conducted in compliance 122 
with the Animals Scientific Procedures Act 1986 (Home Office Code of Practice) in accordance 123 
with EU regulation (EC Directive 2010/63/EU) and approved by the Animal Ethics and Welfare 124 
Committee of the University of Stirling. All fish were monitored daily by the Named Animal 125 
Care and Welfare Officer (NACWO).  126 
The feeding trial was carried out at the Niall Bromage Freshwater Research Facility, 127 
University of Stirling (Buckieburn, Scotland) for just over a year from March one year to April 128 
the following year using a mixed population of fish obtained from a commercial Atlantic 129 
salmon stock (Landcatch Natural Selection, Ormsary, UK). Briefly, ova and milt were collected 130 
from a total of 20 unrelated dams and 5 sires. Per dam, ova were fertilised as one batch and a 1 131 
L sub-sample was removed to induce triploidy using hydrostatic pressure shock (9500 PSI 132 
applied 300 degree minutes post-fertilisation at 8 ˚C for a duration of 6.25 min). This procedure 133 
was repeated for each dam x sire cross creating 20 diploid incubators and 20 triploid incubators, 134 
reared in constant darkness at 8.0 ± 0.5 ˚C. Eyed ova (380 °days post fertilisation) were shipped 135 
to University of Stirling facilities and ova were pooled per ploidy and reared in 6 x 250 L tanks 136 
in complete darkness until first feeding (~ 850 °dpf). At first feeding, diploids were fed a 137 
standard commercial salmon fry feed (Inicio Plus, BioMar, UK; 13.0g kg-1 total phosphorus) 138 
whereas triploids were fed the same standard commercial formulation but with a boosted 139 
phosphorous level (16.7g kg-1 total phosphorus) based on data obtained in previous studies on 140 
triploid salmon (Smedley et al., 2018). All other dietary components were comparable between 141 
starter feeds. Fry were reared under constant light, and feed was supplied throughout the 24 h 142 
by belt feeders according to manufacturer’s tables (specific feeding rate [SFR], 2-3 % body 143 
weight day-1).  144 
To verify ploidy status, smears were prepared according to Woznicki & Kuzminski, 145 
(2002) from blood collected following the caudal peduncle from euthanised fish at 5 g (100 / 146 
ploidy). After air drying, slides were fixed in 100 % methanol and then placed into Giemsa 147 
stain for 10 min. Erythrocyte length and diameter were measured at 100× magnification using 148 
image capture software (Image-Pro Premier, MediaCybernetics, Rockville, USA). A total of 20 149 
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randomly chosen nuclei per slide were measured to the nearest 0.01 μm. Diploid control groups 150 
had significantly smaller erythrocyte nuclear lengths with no overlaps with the pressure shock 151 
triploid groups (2N 6.8–7.7 μm; 3N 9.0–10.2 μm) confirming that the majority of fish subjected 152 
to hydrostatic pressure shock were likely to be triploids. Cumulative mortality from first-153 
feeding to start of the feeding trial was 2.8 ± 0.02 % for diploids and 3.5 ± 0.01 % for triploids.  154 
 155 
2.2 Feeding Trial 156 
Two groups of Atlantic salmon parr of mean weight 37.5 ± 2.2 g (diploid) and 27.4 ± 157 
0.7 g (triploid) were stocked into 12 x 1.8 m3 circular fibreglass tanks (6 tanks / ploidy, n = 158 
1000 / tank). Fish were acclimated to the experimental conditions for 2 weeks before being fed 159 
the experimental diets. Duplicate groups were fed low FM / FO diets (≡ 15% FM / 8% FO) 160 
formulated to have identical protein / oil content (480 / 215 g kg-1 respectively of which 72 / 17 161 
g kg-1 were of marine origin) and supplemented with a nutrient package (NP) at graded 162 
inclusion levels. The NP contained 24 nutrients in total these being; vitamins (A, D3, E, K3, C, 163 
thiamin, riboflavin, B6, B12, niacin, pantothenic acid, folic acid and biotin), minerals (Ca, Co, 164 
I, Se, Fe, Mn, Cu and Zn), crystalline amino acids (L-histidine and taurine) and cholesterol. 165 
Specifically, the NP was added at three inclusion levels to produce 3 dietary treatments: L1, 166 
100 % NP; L2, 200 % NP; L3, 400 % NP, the assumption being that the 100% NP package 167 
should contain 100 % of assumed requirement based on the given requirement levels reported 168 
for Atlantic salmon at the time (NRC, 2011) and modified according to an earlier trial as part 169 
of the EU-funded ARRAINA project (Hamre et al., 2016). Total and available phosphorus were 170 
fixed in all diets at 13.0 and 9.0 g kg-1 respectively, and magnesium at 1.5 g kg-1, and were not 171 
part of the NP. Pellet size was adjusted according to fish weight, with a 2 mm pellet fed for 23 172 
weeks and a 3 mm pellet fed for the final 8 weeks. All non-oil ingredients were mixed and 173 
pellets produced by extrusion to produce three base pellets that had oil added by vacuum 174 
coating. All feeds were produced at the BioMar Tech-Centre (Brande, Denmark). Feed 175 
formulations, added micronutrient concentrations within the nutrient package and analysed 176 
micronutrient concentration are provided in Tables 1, 2 and 3 respectively, while fatty acid 177 
profiles are provided in Supplementary file 1. With the exception of histidine, there were 178 
generally positive relationships between added and analysed nutrients in the 2 mm pellet (Table 179 
3). In the 3 mm pellet, vitamin A, vitamin K3, pantothenic and folic acid, vitamin C, iron and 180 
manganese deviated from the positive relationship.  181 
Fish were fed continuously during the light period of the light-dark cycle by automatic 182 
feeders (Arvotec T2000, Arvotec, Finland) controlled by a PC system. Although feed collection 183 
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was not possible due to system constraints, presence of waste feed was ensured each day prior 184 
to tank flushing. Specific feeding rates (SFR; % tank biomass per day) were adjusted 185 
automatically according to predicted growth and daily temperature. A simulated natural 186 
photoperiod (SNP) was applied to produce S1+ smolts, with lighting provided by two 28 W 187 
fluorescent daylight bulbs (4000 °K, RS Components, UK) mounted centrally within the tank 188 
lid. Water was supplied by an upstream reservoir under flow through conditions (10 L min-1), 189 
with ambient temperatures decreasing from 15.5 ˚C (September) to 2.0 ˚C (February), and 190 
increasing to 9 ˚C by April. Oxygen levels were consistently >8 mg L-1. 191 
 192 
2.3 Sampling Procedures 193 
Fish were sampled for growth at 3, 7, 14 and 31 weeks post application of the 194 
experimental feeds. At each time point, 50 fish / tank were anaesthetised (MS222, PHARMAQ, 195 
UK), individual weights (± 0.1 g) and fork lengths (± 1.0 mm) measured, and fish allowed to 196 
recover in aerated water before returning to experimental tanks. Sex was not assessed. Fulton’s 197 
condition factor (K) was calculated using: K = (WL−3)100; where W is body weight (g) and L 198 
is fork length (cm). Weight data were used to calculate specific growth rate (SGRwt), and feed 199 
conversion rate (FCR) for each sampling period where SGRwt was calculated as: (e
g-1)×100, 200 
where g = (ln(Wf) − ln(Wi)) × (t2−t1) -1. Relative Weight gain (RWG) was calculated as (Wf-201 
Wi)/Wi x 100. FCR was calculated as: F / (Bf−Bi+Bm)-1 where F is the feed fed (kg), Bf is the 202 
final biomass (kg), Bi is the initial biomass (kg), and Bm is the mortality biomass for the period 203 
(kg). Uneaten feed recovery was not feasible for this study and, therefore, FCR provided only 204 
a crude estimate of feed conversion.  205 
At the end of the feeding trial (31 weeks), a total of 7 fish / tank were euthanised by an 206 
overdose of MS222 and 3 carcasses frozen at -20 ˚C for whole fish proximate composition 207 
analyses. Livers were dissected from the remaining 4 fish / tank (n = 8  / diet) and a small 208 
sample (~ 100 mg) collected into RNALater® (Sigma, Poole, UK) for transcriptomic analyses, 209 
before the liver was divided into two portions. One portion was stored in 10 % neutral buffered 210 
formalin prior to histological analyses with the remaining portion snap frozen in liquid nitrogen, 211 
then stored at -20 ˚C prior to fatty acid composition analysis. Finally, further 10 fish / tank were 212 
euthanised and viscera (intestines and associated fat deposits without liver or gonad) and livers 213 
dissected, individually weighed to calculate viscerosomatic (VSI, %) and hepatosomatic (HSI, 214 
%) indices: where VSI was calculated as viscera weight / (body weight – viscera weight) x 100; 215 
and HSI as liver weight / (body weight – liver weight) x 100.  216 
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Liver and white muscle were dissected after fish were anaesthetised from five fish per 217 
tank, divided into two, and used for analysis of vitamins, S-adenosylmethionine (SAM), S-218 
adenosylhomocysteine (SAH) and free amino acids at week 31. Samples were frozen at -30 C 219 
until analysed. In addition, samples of whole fish were collected, minced and analysed for total 220 
amino acids and vitamins. Whole fish were pooled into 3 samples of 2 fish (1 per tank/replicate) 221 
and homogenised in a blender (Waring Laboratory Science, Winsted, CT, USA) to produce 222 
pates, and feeds were ground prior to analyses. 223 
 224 
2.4 Histological analysis 225 
Formalin-fixed livers from 4 fish per tank (n = 8 / diet) were assessed for micro- and 226 
macro-vesicular steatosis by light microscopy of haematoxylin and eosin-stained sections (Gu 227 
et al., 2013). Sections were viewed at 20 × original magnification and scored for presence of 228 
vesicles in individual hepatocytes. The term steatosis was applied when clear vacuoles with a 229 
diameter greater than 5 μm were observed in the hepatocytes, and measurement was achieved 230 
using a four-point scoring system (Fig.1; 0 - no vacuolation; 1 - mild vacuolation, < 25 % of 231 
hepatocyte area (one small vacuole not displacing the nucleus); 2 - moderate vacuolation, 25-232 
75 % of hepatocyte area (one or more small vacuoles mildly displacing the nucleus); and 3 - 233 
severe vacuolation, > 75 % of hepatocyte area (one large vacuole filling the cytoplasm, and 234 
displacing the nucleus). 235 
 236 
2.5 Biochemical analysis of diets, whole fish and liver 237 
Proximate compositions of feeds and whole fish were determined according to standard 238 
procedures (AOAC, 2000). Moisture contents were obtained after drying in an oven at 110 °C 239 
for 24 h and ash content determined after incineration at 600 °C for 16 h. Crude protein content 240 
was measured by determining nitrogen content (N × 6.25) using automated Kjeldahl analysis 241 
(Tecator Kjeltec Auto 1030 analyser, Foss, Warrington, U.K), and crude lipid content 242 
determined after acid hydrolysis followed by Soxhlet lipid extraction (Tecator Soxtec system 243 
2050 Auto Extraction apparatus, Foss, Warrington, U.K). Total lipid was extracted from liver 244 
by homogenisation in chloroform/methanol (2:1, v/v) and content determined gravimetrically 245 
(Folch et al., 1957). Fatty acid methyl esters (FAME) were prepared from total lipid by acid-246 
catalysed transesterification at 50 ˚ C for 16 h (Christie, 2003), and FAME extracted and purified 247 
as described previously (Tocher and Harvie, 1988). FAME were separated and quantified by 248 
gas-liquid chromatography using a Fisons GC-8160 (Thermo Scientific, Milan, Italy) equipped 249 
with a 30 m × 0.32 mm i.d. × 0.25 μm ZB-wax column (Phenomenex, Cheshire, UK), on-250 
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column injector and a flame ionisation detector. Data were collected and processed using 251 
Chromcard for Windows (version 2.01; Thermoquest Italia S.p.A., Milan, Italy). Individual 252 
FAME were identified by comparison to known standards and published data (Tocher and 253 
Harvie, 1988). Whole fish samples were hydrolysed in 6M HCL for 22 h before being analysed 254 
for total amino acid content and composition by UPLC as described (Espe et al., 2014), while 255 
free amino acids and N-metabolites in muscle and liver were analysed after deproteinisation 256 
using sulfosalicylic acid, and separated on Biochrome and detected by post-column 257 
derivatisation with ninhydrin, as described elsewhere (Espe et al., 2006). Liver, plasma and 258 
muscle samples were analysed for SAM and SAH after extraction using 4 % per chloric acid 259 
and separated on HPLC as described in detail previously (Espe et al., 2008). The B-vitamins, 260 
biotin, niacin, folate, pantothenic acid and cobalamin were all determined by microbiological 261 
methods (Feldsine et al., 2002; Mæland et al., 2000). Other B-vitamins were determined by 262 
HPLC; thiamine (CEN, 2003), vitamin B6 (CEN, 2006) and riboflavin (Brønstad et al., 2002). 263 
Ascorbic acid was determined by HPLC (Mæland and Waagbø, 1998), as were tocopherols and 264 
vitamin K (CEN, 1999). Total TBARS was determined according to Hamre et al. (2001). Multi-265 
element determination of macro- and microminerals in the feed and tissue samples was 266 
performed by ICP-MS (inductively coupled plasma mass spectrometry) (Julshamn et al., 1999). 267 
 268 
2.6 Smoltification assessment  269 
  Smoltification was confirmed through a combination of smolt index scoring (Sigholt et 270 
al, 1995), gill Na+K+-ATPase activity, and 24 h saltwater challenge and plasma chloride 271 
analysis were conducted during the feeding trial on 28-Jan, 27-Feb, 21-Mar, and at final smolt, 272 
21-Apr 2014 (equivalent to 122, 199, 324 and 430 ˚days post-winter solstice rise in daylength 273 
respectively). Thirty individuals per tank were scored for smolt index. Na+K+-ATPase activity 274 
was determined from 5 individual gill biopsy / tank (3-6 gill filaments in 100 µl SEI buffer, 275 
snap frozen in liquid nitrogen), with a kinetic assay run in 96-well microplates at 26 °C and 276 
read at a wavelength of 340 nm for 10 min according to the method of McCormick (1993). 277 
Protein concentrations were determined thereafter using a BCA (Bicinchoninic acid) protein 278 
assay kit (SIGMA, Aldrich, UK). Saltwater challenge was conducted for 24 h in 100 L tanks of 279 
10 °C aerated seawater (35 ppt) (Instant Ocean; Animal House, Batley, UK). Ten individual 280 
fish per diet (5 / tank) were placed into separate 100 L saltwater challenge tanks at  respective 281 
time points, and following challenge, all fish were removed, numbers of surviving fish counted 282 
to determine seawater survival, and were then culled and blood removed from the caudal vein 283 
before centrifugation at 500 g for 15 min at 4 °C. Plasma was collected and stored at −20 °C 284 
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until analysis using a chloride analyser (Sherwood Instruments Inc., UK). Plasma samples were 285 
analysed in triplicate per individual and the average taken of the three technical replicates. 286 
  287 
2.7 Hepatic transcriptome analysis 288 
Transcriptomic analysis was conducted using a custom-made 4 x 44K Atlantic salmon 289 
oligo microarray (Agilent Technologies, Wokingham, UK; ArrayExpress accession no. A-290 
MEXP-2065) as described in detail previously (Tacchi et al., 2011). Furthermore, this salmon 291 
custom array and the laboratory protocols used in the present study have been used widely and 292 
validated by previous studies (Morais et al., 2012; Betancor et al., 2016; Vera et al., 2017). 293 
Briefly, RNA was extracted from 50 mg of liver tissue, originating from six individual fish 294 
from each feed group, using TRI Reagent (Sigma-Aldrich, Dorset, UK). The resulting RNA 295 
samples were amplified using TargetAmp™ 1-Round Aminoallyl-aRNA Amplification Kit, 296 
(Epicentre Technologies Corporation, Madison, Wisconsin, USA) following recommended 297 
procedures. Aminoallyl-amplified RNA (aRNA) samples were labelled with Cy3 dye (GE 298 
HealthCare Life Sciences, Buckinghamshire, UK) while a pool of all aRNA samples was 299 
labelled with Cy5 dye (GE HealthCare Life Sciences) and used as a common reference in a 300 
dual-label common reference design, and finally hybridised to one array. Scanning was 301 
performed using a GenePix 4200 AL Scanner (Molecular Devices (UK) Ltd., Wokingham, 302 
UK), and the resulting images analysed with Agilent Feature Extraction Software v.9.5 (Agilent 303 
Technologies) to extract intensity values and identify the features. Features considered outliers 304 
(i.e., defined as those probes whose background intensity was between the 0.05th and 99.95th 305 
percentile of the distribution) in two or more replicates within at least one treatment were 306 
excluded from further analyses. Additionally, features consistently expressed just above 307 
background noise (defined as those features whose intensity was lower than 5th percentile of 308 
the distribution in 75 % or more of the analysed samples) were also removed. The full protocol 309 
for microarray laboratory and data analysis has been reported previously (De Santis et al., 310 
2015). The output of the microarray experiment was submitted to ArrayExpress under accession 311 
number E-MTAB-6302. In order to avoid confounding effects associated with differential 312 
expression associated with the increased genetic material possessed by triploid fish, the two 313 
ploidy were analysed separately and independently and are herein presented relative to diet L1.  314 
 315 
2.8 Statistical and data analysis 316 
Differences between weight, condition factor (K), plasma chloride and gill Na+K+-317 
ATPase activity were assessed using a general linear model (GLM) and two-way ANOVA (diet 318 
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x ploidy) with replicate tank nested within treatment. Percentage data (Mortality, SGRwt, HSI 319 
and VSI) were subjected to arcsine square-root transformation prior to statistical analyses. Data 320 
were tested for normality and homogeneity of variances with Levene's test prior to two-way 321 
ANOVA (diet x ploidy) followed by a Tukey–Kramer HSD multiple comparisons of means. 322 
Contingency Chi-square tests were used to compare significant differences between survival 323 
under saltwater challenge. Vitamins, minerals, amino acids, SAM and SAH were analysed by 324 
two-way ANOVA (ploidy x diet) using the tank means as the statistical unit. ANOVA was used 325 
to test the hypothesis that diet was more influential than ploidy. Tank means were accepted as 326 
statistical different at p < 0.05. Results are reported as mean ± standard deviation (SD).  327 
Transcriptomic data analysis was performed using Bioconductor v.2.13 (Gentleman et 328 
al., 2004). Quality control, data pre-processing and analysis of differential expression were 329 
conducted using the software package limma (Smyth, 2004). To avoid redundancy, features 330 
representing the same target gene as implied from KEGG annotation were reduced into a unique 331 
value obtained by selecting the feature with the highest F-value calculated on all contrasts. For 332 
analysis of gene expression, gene-set testing was adopted using the function roast of the limma 333 
package (Wu et al., 2010). Gene set testing is a differential expression analysis in which a set 334 
of a priori defined (putatively co-regulated) genes is treated as a unit. All p-values reported in 335 
this work were corrected for false discovery rate (FDR) unless otherwise specified (Benjamini 336 
and Hochberg, 1995). 337 
  338 
3. Results 339 
3.1 Mortality, Maturation, Growth and Deformity 340 
 There were no significant differences in cumulative mortality between dietary 341 
treatments or between ploidy (Table 4). However, in diploids, for diet L1 there was a tank 342 
effect, in which one tank showed higher mortality due to fungus in the final 3 weeks of the trial 343 
(7.5 % out of 9.1 % total mortality). 344 
 Precocious parr-maturation (n = 50 /tank) was not observed in any of the populations 345 
assessed any time point. 346 
Diploids had a significantly higher initial weight than triploids that was maintained for 347 
the 31 weeks of experimental feeding until smolt (Table 4). However, diet significantly affected 348 
weight in diploids, with fish fed diet L2 having a significantly higher final smolt weight than 349 
fish fed diets L1 and L3. In contrast, diet did not affect final smolt weight in triploids (Table 4). 350 
Although weight differed between ploidy, overall growth rate (SGRwt) and subsequent weight 351 
gain did not differ between ploidy and diet, with the exception of diploids fed diet L2, which 352 
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showed a significantly higher SGRwt than all other treatments. However, examining growth 353 
profiles over time showed that diploids fed diets L2 and L3 exhibited the fastest weight gain, 354 
with significant differences evident as early as 3 weeks of feeding on the experimental diets. 355 
By 14 weeks post-feeding, diet L3 weight gain slowed, such that weight of fish fed diets L3 356 
and L1 were no longer significantly different (Fig. 2). As such, ploidy did not affect relative % 357 
weight gain (RWG, p = 0.215), while a significant effect of diet and an interaction with ploidy 358 
was evident (Table 4). RWG was not statistically different between ploidy in fish fed diet L1, 359 
significantly higher in triploids fed diet L3 relative to diploids, but significantly lower in 360 
triploids fed diet L2 relative to diploids. Within triploids, RWG did not differ between diets, 361 
while in diploids RWG was significantly higher in fish fed diet L2 than diets L1 and L3. The 362 
crude FCR data suggested an interaction between diet and ploidy, whereby diploids fed diet L2 363 
had lower FCR than triploids fed L2, while there were no other significant effects on FCR 364 
between ploidy or diet (Table 4).  365 
Both VSI and HSI were affected by diet, ploidy and their interaction (Table 4). Within 366 
diploids, fish fed diet L2 had a significantly lower VSI and HSI than fish fed diets L1 and L3, 367 
while in triploids VSI and HSI were not affected by diet. Within diets, VSI and HSI differed 368 
only in diet L1 between ploidy.  369 
Externally visible deformity was < 1 % in fish fed all diets and ploidy at the end of the 370 
freshwater phase. 371 
 372 
3.2 Proximate composition of fish and fatty acid composition of liver 373 
Whole fish % oil and ash composition did not differ significantly between dietary 374 
micronutrient inclusion level or ploidy (Table 5). Triploids had significantly lower whole body 375 
% protein and a higher % moisture at smolt than diploids, but was not affected by diet. Although 376 
not always statistically different, the fatty acid compositions of liver showed some trends that 377 
might be informative. Specifically, in diploids the proportion of total saturated fatty acids, 378 
particularly 16:0, significantly increased, and total monoenes, especially 18:1n-9 and 20:1n-9, 379 
significantly decreased with increasing micronutrient supplementation (Table 5). Furthermore, 380 
there was an increasing trend, albeit non-significant, in the proportions of total polyunsaturated 381 
fatty acids (PUFA) and total n-3 PUFA, due mainly to increasing trends in eicosapentaenoic 382 
(EPA, 20:5n-3) and docosahexaenoic (DHA, 22:6n-3) acids, whereas the proportions of n-6 383 
PUFA showed a decreasing trend with increasing dietary micronutrient concentrations. 384 
The effect of dietary micronutrient supplementation on liver fatty acid composition in 385 
triploid salmon was less pronounced than in diploids and the trends appeared to be in the 386 
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opposite direction compared with diploid fish (Table 5). Thus, in triploids lower proportions of 387 
saturated fatty acids and n-3 PUFA, and higher proportions of monoenes and n-6 PUFA were 388 
found in fish fed diet L3 compared to those fed diet L1. 389 
 390 
3.3 Total amino acid concentration in whole body and free amino acids and N-metabolites in 391 
white muscle tissue 392 
Whole fish total amino acids and N-metabolites, at the end of the experiment, showed 393 
no variation by treatment (Table 6). There was a tendency that whole fish taurine was slightly 394 
higher in triploids than in diploids (p = 0.048). Muscle free amino acids and N-metabolites 395 
including taurine, asparagine, hydroxyproline, glutamine, glutamate, and β-alanine were all 396 
higher in triploids than in diploids, while branched chain amino acids, lysine and anserine were 397 
higher in diploids than in triploids (Table 7). All the other metabolites analysed in muscle were 398 
not affected by treatments (data not shown). The varying dietary nutrient package had little 399 
influence on muscle free amino acids or N-metabolites as only a significant increase in 400 
threonine and a decrease in cystathionine was observed.   401 
 402 
3.4 Vitamin concentrations in whole fish and tissues 403 
For the B-vitamins, increasing dietary levels led to increasing tissue levels for niacin (p 404 
= 0.006), while whole body pantothene showed a trend of dietary effect (p = 0.051) (Table 8). 405 
Whole body folate increased in diploids, but not in triploids, giving a significant interaction 406 
between diet and ploidy (p = 0.035). Riboflavin was higher in whole body of diploids compared 407 
to triploids (p = 0.016). The tissue concentrations of the lipid soluble vitamins and vitamin C 408 
increased with increasing concentration in the diet (p < 0.015), except for muscle α-TOH where 409 
the apparent increase was non-significant. Αlpha-tocopherol (TOH) and vitamin K showed 410 
higher retention in diploids compared to triploids (p < 0.001). Gamma-TOH, which was present 411 
in the feed ingredients but not supplemented in the diets, decreased in response to increasing 412 
nutrient supplementation in both muscle and whole body (p < 0.001). 413 
 414 
3.5 Mineral concentrations in whole fish 415 
Whole body mineral concentrations were not affected by diet (Table 9). Diploid fish 416 
had a slightly higher whole body concentration of Cu than triploid fish (p = 0.01) but the other 417 
minerals were not affected by ploidy. 418 
 419 
3.6 Liver histology and steatosis 420 
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A significant interaction between diet and ploidy was evident (p = 0.003). In diploids, 421 
steatosis was significantly greater in fish fed diet L2 than fish fed diet L1, but not diet L3, while 422 
fish fed diets L1 and L3 were comparable (Table 4). Steatosis did not differ significantly 423 
between diets in triploids. However, steatosis was affected by ploidy (p = 0.004), and was 424 
generally higher in triploids than diploids. Surprisingly, steatosis scores appeared to be 425 
inversely related to HSI (Table 4). 426 
 427 
3.7 Smoltification efficiency 428 
Diploid salmon fed dietary treatment L2 showed 100 % survival during seawater 429 
challenge from 28-Jan final smolt (21-Apr) (Fig. 3). Diploids fed diet L1 had 100 % mortality 430 
on 28-Jan 2014. A slight dip in survival was observed in diploids fed diets L1 and L3 at 300 431 
˚days post-winter solstice (21-Mar), but survival at smolt (21-Apr) was 100 % irrespective of 432 
diet. In triploid salmon, seawater challenge mortalities were only observed on 28-Jan, thereafter 433 
and irrespective of diet, survival was 100 % during seawater challenge until smolt (21-Apr). 434 
In both ploidy, plasma chloride levels decreased with time post-winter solstice (Fig. 3). 435 
Significant differences were apparent between diploids fed diets L2 and L3 on 28-Jan, and 436 
between fish fed diet L1 and diets L2 and L3 on 21-Mar (~300 ˚days), however, no differences 437 
were apparent between dietary treatments at final smolt (21-Apr 2014). In triploids, fish fed 438 
diet L1 had significantly higher plasma chloride levels on 28-Jan 2014 (~100 ˚days) than fish 439 
fed diet L2, with fish fed diet L3 intermediary to both. Thereafter, plasma chloride level steadily 440 
declined to smolt, at which point triploids fed diet L3 had a significantly higher plasma chloride 441 
level than fish fed either diets L1 or L2. 442 
       In both ploidy, gill Na+,K+-ATPase activity increased post-winter solstice until final 443 
smolt 21-Apr 2014 (Fig. 3). In diploids, fish fed diet L1 showed lower activity than fish fed 444 
diets L2 and L3 on 21-Mar (~300 ˚days), which correlated with differences evident in seawater 445 
challenge survival at this time point. At no other time point were significant differences 446 
observed between diets in diploids. In triploids, no significant differences were observed 447 
between fish fed the different diets at any time point. 448 
 449 
3.8 Liver gene expression 450 
At individual gene level and using cut-off measures generally applied to microarray 451 
studies (i.e. FDR p < 0.1, Fold Change, FC > 1.3) no significant differences were found in any 452 
of the contrasts except for diet L3 versus L1 in triploids, where 7 differentially expressed genes 453 
(DEGs) were identified. However, to identify interesting trends similarly affected in both 454 
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ploidies a less stringent cut-off was used (p < 0.05, FC > 1.3). Under these conditions a larger 455 
number of affected genes were identified (L2dip vs. L1dip = 300, L3dip vs. L1dip = 192, L2trip vs. 456 
L1trip =134, L2trip vs. L3trip =398). To restrict the range of potentially interesting pools of 457 
candidate markers affected by micronutrient supplementation, genes affected in diploids (either 458 
diets L2 or L3 versus L1) were intersected with those affected in triploids (either L2 or L3 459 
versus L1) (Fig. 4). A total of 63 DEGs were obtained explaining common mechanisms affected 460 
in diploids and triploids. Noteworthy, this pool of markers suggested that diet L2 in diploids 461 
triggered a hepatic profile that highly resembled that triggered by diet L3 in triploids, sharing 462 
approximately 80 % of the similarities. This list of genes contained several genes regulating the 463 
terpenoid backbone biosynthesis and sterol biosynthetic processes, such as sterol 14-464 
demethylase, 7-dehydrocholesterol reductase, squalene monooxygenase genes, and farnesyl 465 
diphosphate synthase. KEGG pathway analysis suggested that the DEGs were enriched for 466 
biological processes involved in cholesterol and lipid biosynthetic process, whereas for the 467 
cellular components indicated that endoplasmic reticulum and membranes structures were 468 
differentially regulated between diet groups. In addition, microarray analysis revealed that lipid 469 
digestion and absorption, steroid biosynthesis and PPAR signalling pathways were significantly 470 
altered due to diet nutrient package.   471 
Gene-set testing enables focus on biologically meaningful processes and provides a 472 
more powerful and robust approach than traditional gene-wise tests as evidence is accumulated 473 
from many genes. Using this approach, a significantly higher number of processes potentially 474 
affected by dietary micronutrient supplementation was identified (Supplementary file 2). In 475 
diploids, diets L2 and L3 differed from L1 for only one gene-set, respectively circadian rhythm 476 
(increased expression in fish fed diet L2 vs. L1) and insulin signalling pathway (lower 477 
expression in fish fed diet L3 vs. L1). In contrast, triploid livers appeared to be more affected 478 
by dietary treatments compared with diploids. In fact, diet L2 resulted in at least six gene-sets 479 
significantly affected whereas diet L3 triggered the response of 43 gene-sets. Within these 43 480 
sets, up-regulation of key pathways involved in carbohydrate  481 
metabolism, digestion and absorption of carbohydrate, protein and lipid as well as bile acid 482 
biosynthesis was observed. Immune functions were also up-regulated in triploid salmon fed diet 483 
L3 (complement and coagulation cascades, leukocyte transendothelial migration and intestinal 484 
immune network for IgA production), as well as metabolism of xenobiotics by cytochrome 485 
P450. However, diet L3 in triploids resulted in down-regulation of steroid biosynthesis, 486 
terpenoid backbone biosynthesis and energy metabolism (oxidative phosphorylation). In 487 
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addition, several functional categories within genetic information processing were also down-488 
regulated (RNA degradation, proteasome, RNA polymerase, spliceosome and ribosome).  489 
     Different supplementation levels of micronutrients affected the expression of key enzymes 490 
involved in one-carbon metabolism in both ploidies. In particular, increasing levels of 491 
supplementation resulted in up-regulation of genes involved in cysteine biosynthesis and 492 
catabolism (cysteine beta-synthase, cysteine dioxygenase), methionine synthesis (betaine-493 
homocysteine S-methyltransferase), folate homeostasis (folylpolyglutamate synthase), histidine 494 
catabolism and glutamate synthesis (glutamate formiminotransferase) and serine conversion to 495 
glycine and tetrahydrofolate (glycine hydroxymethyltransferase). In diploids, several genes 496 
involved in carbohydrate and lipid metabolism, and using B-vitamins as cofactors and 497 
coenzymes, were also affected. Thus, acetyl-CoA carboxylase (fatty acid biosynthesis), 6-498 
phosphogluconate dehydrogenase and transketolase (pentose phosphate pathway) were up-499 
regulated in diploid fish fed diet L2 (compared to fish fed diet L1). In addition, the expression 500 
of specific cytochrome P450 genes were also up-regulated in fish fed diets L2 and L3 in both 501 
diploids and triploids (Supplementary file 3).  502 
 503 
4. Discussion  504 
In the present study, diploids were significantly larger at the start of the trial, and 505 
maintained a significantly greater weight than their triploid siblings irrespective of dietary 506 
micronutrient supplementation. However, growth rates (SGRwt) were comparable between 507 
ploidy and relative weight gain did not differ between ploidy, with the exception of diet L2. 508 
Recent studies have shown triploids to have greater growth potential than diploids in freshwater 509 
phases of development (Fjelldal & Hansen, 2010; Taylor et al., 2012; Fraser et al., 2013; Taylor 510 
et al., 2013; Fjelldal et al., 2016), so the apparent lack of better growth was unexpected. This 511 
may in part be due to higher water temperatures (15-16 °C) experienced for 7 weeks prior to, 512 
and the initial first two weeks of feeding at start of the trial, under which conditions triploids 513 
have been reported to show sub-optimal growth (Sambraus et al., 2017). However, specific 514 
dietary requirement trials in triploids are also limited to date, although it has been suggested 515 
that differences between ploidy might exist (Fjelldal & Hansen, 2010) particularly with regards 516 
to energy and nitrogen retention efficiencies (Burke et al., 2010), dietary phosphorous (Fjelldal 517 
et al., 2015; Smedley et al., 2018) and histidine requirements (Taylor et al., 2015; Sambraus et 518 
al., 2017). To date, no study has examined the interaction of ploidy and micronutrients when 519 
fed low marine ingredient diets. However, the results of the current study may indicate that 520 
specific dietary micronutrients could be different between diploid and triploid siblings when 521 
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they are fed low marine feeds. More specifically, the present data may suggest that dietary 522 
micronutrient levels could be rate-limiting for triploid growth potential when fed low marine 523 
ingredient diets. However, the specific nutrients that may be rate-limiting could not be 524 
determined within the present study. As such, it was evident that diploids supplemented with 525 
double the nutrient package levels significantly outperformed their diploid siblings and all 526 
triploid groups when fed a low marine ingredient diet. They also had lower HSI and VSI than 527 
the diploids fed the L1 diet, which was consistent with results from Hemre et al., (2016). Given 528 
the approximate halving of the FM/FO content compared to a traditional marine ingredient 529 
based salmon diet, it appeared that a doubling of the specific nutrients is required to satisfy all 530 
dietary requirements for growth in diploid Atlantic salmon at least. However, care must be 531 
taken with respect to regulation for feed additive inclusion that they do not exceed current EU 532 
limits (Supplementary File 4). Should recommendations for any nutrient exceed current limits, 533 
then successful implementation within industrial aquafeeds may require revision of current 534 
legislation. Of further interest was the apparent loss in growth performance of diploids fed diet 535 
L3 (400 % premix) after 14 weeks of feeding. Collectively, the results suggest that, for minerals 536 
at least, dietary levels provided by diet L1 were probably sufficient, as there was no significant 537 
effect on whole body mineral composition of diet or ploidy with the exception of copper. It is 538 
plausible that the addition of extra minerals and vitamins, especially with respect to diet L3 in 539 
the case of diploids, may require that the fish expend additional energy in detoxification and 540 
excretion, which may subsequently be the cause of reduced growth in these fish towards the 541 
latter part of the experiment. In fact, high levels of some minerals in fish diets has been 542 
previously associated with reduced growth and feed efficiency (Al-Ghanem, 2011; Berntssen 543 
et al., 2017), indicating that mineral levels in fish diets need to be optimised and that their 544 
inclusion in excess might be counterproductive. 545 
Regarding amino acid and N-metabolite concentrations, higher levels of free amino 546 
acids and N-metabolites including taurine, asparagine, hydroxyproline, glutamine, glutamate 547 
and β-alanine were observed in muscle of triploids. Methionine was not included in the nutrient 548 
package thus the higher taurine present in muscle in triploids might indicate that more 549 
methionine has been trans-sulfurated to taurine in triploids as compared to diploids (Espe et al 550 
2008). Free amino acids are precursors for protein synthesis and so these data are consistent 551 
with other studies that have provided evidence of higher nitrogen retention and growth potential 552 
in triploid salmon as compared to diploids (Burke et al., 2010; Smedley et al., 2016). In 553 
particular, elevated levels of free hydroxyproline have been associated to high connective tissue 554 
degradation and protein turnover for remodelling of protein in white muscle during growth 555 
 18 
(Rungruangsak-Torrissen and Fosseidengen, 2007). In addition, glutamine has been shown to 556 
inhibit muscle proteolysis and correlates with muscle protein synthesis (Millward, 1989), 557 
whereas high levels of free alanine and taurine may be related to higher intracellular buffering 558 
capacity in white muscle (Rungruangsak Torrissen and Male, 2000).  559 
Although some variation in plasma chloride and gill Na+,K+-ATPase activity was 560 
observed during the spring increase in daylength, diet or ploidy appeared to have little effect on 561 
achieving successful parr-smolt transformation and osmotic competence. However, in diploids, 562 
it was apparent that the rate of increase in gill Na+,K+-ATPase activity was slower in fish fed 563 
diet L1 than in fish fed diets L2 and L3. This may reflect a stimulatory effect on increased gill 564 
ion excretion following increased dietary mineral supplementation as in diets L2 and L3, which 565 
has been previously reported to stimulate osmoregulatory adaptation in salmonids (Zaugg, 566 
1992). Conversely, it may also represent a deficiency in certain minerals such as magnesium, 567 
which have been reported to impair osmoregulation when in deficit (El-Mowafi et al., 1997). 568 
This effect was, however, not evident in triploids, but may reflect differential patterns of 569 
smoltification between ploidy (Taylor et al., 2012) or differences in gill architecture between 570 
ploidy (Leclercq et al., 2011) and cellular physiology and function (Maxime, 2008). 571 
Microarray analysis revealed that the hepatic transcriptome profile of diploid fish fed 572 
diet L2 was more similar to that observed in triploids fed diet L3 than to those fed L2, suggesting 573 
that micronutrient requirements of triploid salmon may differ from levels accepted in diploid 574 
salmon, as reported previously (Taylor et al., 2015; Fjelldall et al., 2016; Smedley et al., 2016). 575 
Different levels of micronutrient supplementation affected the expression of key genes involved 576 
in lipid metabolism. In particular sterol biosynthesis pathways (steroid and terpenoid backbone 577 
synthesis) were down-regulated in both L2-fed diploids and L3-fed triploids, when compared 578 
with diet L1-fed diploids and triploids, respectively. This effect on gene expression may be in 579 
response to the increased supplementation of cholesterol in the L2 and L3 diets, as part of the 580 
micronutrient premix, and therefore probably reflects increased requirement and synthesis of 581 
this lipid in fish fed diet L1. However, bile acid biosynthesis was up-regulated in these groups. 582 
These results are consistent with a previous study by Kortner et al. (2014) showing that 583 
supplementation of plant-based diets with cholesterol suppressed cholesterol synthesis and 584 
induced bile acid production in Atlantic salmon. In fact, the conversion of cholesterol into bile 585 
acids represents the main route for cholesterol elimination in fish and, consequently, the 586 
transcriptomic response observed in the present study would be a mechanism of cholesterol 587 
homeostasis in fish being fed diets containing higher levels of cholesterol.  588 
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Gene sets analysis showed an up-regulation of genes involved in immune processes in 589 
triploid salmon fed diet L3. This fact might be related to higher levels of vitamin C in whole 590 
body and liver as well as higher vitamin E levels in whole body of fish from this experimental 591 
group, when compared to triploid salmon fed diet L1. In particular, there was an up-regulation 592 
of complement and coagulation cascades, which agreed with previous research showing an 593 
effect of vitamin C supplementation on complement activity in Atlantic salmon (Hardie et al., 594 
1991). Vitamin E content in salmon diets has also been correlated to variations in the response 595 
of fish to infectious diseases and immune response (Hardie et al., 1990). Both vitamin C and E 596 
can improve the immune status of fish due to their antioxidant activity and previous studies 597 
have indicated interaction between these vitamins (Hamre et al., 1997, 2011). In diploid salmon, 598 
there was also a positive correlation between increasing levels of micronutrient 599 
supplementation and body content of vitamins C and E, however no sets of genes involved in 600 
immune functions were differentially expressed. This fact further supports the hypothesis that 601 
triploid salmon may have different micronutrient requirements and responses to feed 602 
supplementation with vitamins. The expression of cytochrome P450 enzymes was also up-603 
regulated in response to higher levels of micronutrient supplementation in both ploidies. These 604 
enzymes are involved in the activation of vitamin D to its hormonal form, which then regulates 605 
the expression of a broad range of genes, including osteocalcin, osteopontin, calbindin and 606 
calcium channels that play key roles in the control of calcium homeostasis and skeletal integrity 607 
(Suzuki et al., 2008). In addition, different P450 enzymes control vitamin D metabolism and 608 
inactivation, which can also be induced by vitamin D itself via CYP24A1 activation (Schuster, 609 
2011). In the present study, up-regulation of cyp24a1 (vitamin D3 24-hydroxylase) was 610 
observed in diploid salmon fed diet L3. However, in triploid fish the expression of this gene 611 
was not affected by diet. In the present study, vitamin D was included in the micronutrient mix 612 
and therefore vitamin D concentration in diet L3 was four times higher than in diet L1, which 613 
might have induced the expression of its metabolising enzyme, suggesting that levels in diet L3 614 
may be excessive for diploid Atlantic salmon. However, the microarray results also suggested 615 
that this may not be the case for triploids. In fact, triploid salmon have a higher predisposition 616 
to develop skeletal deformities, when compared to diploid fish, which seems to be reduced 617 
when feeds are supplemented with phosphorus (Fjelldal et al., 2016; Smedley et al., 2016, 618 
2018). It is also known that vitamin D is an important regulator of phosphorus metabolism 619 
(DeLuca, 1980) and, consequently, results suggest that vitamin D requirements in triploid 620 
salmon may also be different, although further research is required to define its optimal 621 
concentration in feeds for triploids.  622 
 20 
Another biological category affected by diet in triploid salmon was genetic information 623 
processing. In fish fed diet L3, down-regulation of RNA degradation, proteasome, RNA 624 
polymerase, spliceosome and ribosome was observed, suggesting a decrease in protein turnover 625 
in this group, which may indicate a decrease in energy expenditure (Houlihan et al., 1995) that 626 
was consistent with down-regulation of oxidative phosphorylation in this group. However, this 627 
was in contrast to the growth and feed conversion rates observed in triploid fish, since no 628 
differences were found in these parameters between dietary treatments. In contrast, growth was 629 
affected by micronutrient supplementation in diploid salmon that showed better performance 630 
when fed diet L2. In addition, microarray data also revealed higher expression of igf1 in this 631 
group. Regarding carbohydrate metabolism, there was up-regulation of key pathways in 632 
triploids fed diet L3, which could be related to higher availability of B-vitamins, when 633 
compared to L1-fed fish. Vitamins B1 (thiamine), B7 (biotine) and B12 (cobalamine) are 634 
involved in several reactions of carbohydrate metabolism, acting as coenzymes, and vitamin 635 
B12 deficiency has been linked to gluconeogenesis impairment in mammals (Mahmood, 2014). 636 
In diploids, microarray analysis also found a number of vitamin B-dependent genes that were 637 
up-regulated in the fish fed diet L2. In particular, these genes were involved in lipid and 638 
carbohydrate metabolism, in accordance with the functions previously reported for these 639 
vitamins (Waagbø, 2010).  640 
One-carbon metabolism comprises a number of biochemical reactions that provide 641 
methyl groups for biological methylation of proteins, phospholipids and nucleic acids (Friso et 642 
al., 2017). B-vitamins act as coenzymes and methyl acceptors and donors in one-carbon 643 
metabolism and, consequently, deficiency of some of these vitamins can have an impact on 644 
these biochemical processes. In the present study, one-carbon metabolism was affected by diet 645 
in diploid and triploid salmon. In diploids, homocysteine re-methylation to form methionine by 646 
betaine-homocysteine S-methyltransferase (bhmt) was up-regulated in fish fed L2 compared to 647 
L1. Previous studies have shown an inverse correlation between B-vitamins status and 648 
homocysteine concentrations (Wallace et al., 2008) and therefore higher dietary levels of these 649 
vitamins may increase methionine synthesis from homocysteine. In addition, homocysteine can 650 
also enter the transulfuration pathway and be degraded to cystathionine by cysteine beta-651 
synthase (cbs) and then to cysteine, which can be metabolised ultimately into glutathione and 652 
taurine (Friso et al., 2017). In diploids fed diet L2, there was up-regulation of cbs and cysteine 653 
catabolism by cysteine dioxygenase that, in turn, could be related to up-regulation of glutathione 654 
metabolism in this group, since cysteine is one of the major determinants of glutathione 655 
synthesis (Stipanuk et al., 2006). Regarding triploid salmon, microarray data revealed up-656 
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regulation of glycine hydroxymethyltransferase, a vitamin B6-containing enzyme that converts 657 
glycine to serine, and tetrahydrofolate (THF) to 5,10-methylenetetrahydrofolate (5,10-MTHF) 658 
in the folate cycle (Friso et al., 2017), suggesting than higher dietary levels of B-vitamins may 659 
have induced up-regulation of this key pathway within one-carbon metabolism. In addition, 660 
glutamate formiminotrasferase was also up-regulated in this group. This enzyme is involved in 661 
glutamate synthesis and depends on histidine and folate (Mahmood, 2014).  662 
 663 
Conclusions  664 
As the industry moves towards achieving increased sustainability and greater utilisation 665 
of plant-based ingredients there is a clear need adjust micronutrient supplementation 666 
accordingly to ensure optimal growth and metabolic function. Results, certainly in the case of 667 
diploids, suggest that under low marine ingredient diets, while micromineral requirements 668 
appear to be met within the refined NP levels as suggested by the short-term studies of Hamre 669 
et al., (2016) and Hemre et al., (2016), that for other micronutrients (specific amino acids, 670 
water- and fat-soluble vitamins) it is recommended that levels be supplemented above current 671 
NRC (2011) recommendations for optimised growth and liver function of Atlantic salmon in 672 
long-term freshwater grow out. The differential effect between ploidy for certain micronutrients 673 
also supports the hypothesis that there are yet further differences in nutritional requirements 674 
beyond the previously established increased histidine and phosphorous requirements of triploid 675 
salmon. 676 
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Figure Legends 956 
Figure 1. Scoring system for hepatocyte steatosis. Representative examples of the 957 
histopathological scoring of steatosis in hepatic sections. Bars represent 100 µm. 958 
 959 
Figure 2. Weight gain profiles (mean ± SD) of diploid and triploid Atlantic salmon parr fed a 960 
low FM/FO formulation (15/8 %) supplemented with a micronutrient premix (modified NRC 961 
2011 recommendation) at three inclusion levels: Diet L1 100 % premix, Diet L2 200 % premix, 962 
and Diet L3 400 % premix. Superscripts denote significant differences (Two-Way ANOVA, p 963 
< 0.05) between dietary treatments.  964 
 965 
Figure 3. Changes in survival, plasma chloride concentration of seawater (SWC) challenged 966 
(24h, 35ppt at 10˚C) and gill Na+,K+-ATPase of diploid and triploid Atlantic salmon parr fed a 967 
low FM/FO formulation (15/8 %) supplemented with a micronutrient premix (modified NRC 968 
2011 recommendation) at three inclusion levels: Diet L1 100 % premix, Diet L2 200 % premix, 969 
and Diet L3 400 % premix. Superscripts denote significant differences (Two-Way ANOVA, p 970 
< 0.05) between diets. SWC or gill Na+,K+-ATPase were conducted were conducted on 28-Jan, 971 
27-Feb, 21-Mar, and 21-Apr 2014 (equivalent to 122, 199, 324 and 430 ˚days post-winter 972 
solstice rise in daylength respectively). 973 
 974 
Figure 4. Heatmap of differentially expressed genes (p < 0.05, FC > 1.3) in both diploids (either 975 
diets L2 or L3 compared with diet L1) and triploids (either diets L2 or L3 compared with diet 976 
L1). Red denotes upregulation whereas green denotes downregulation. Expression data is log2 977 
transformed. P-values were corrected for false discovery rate. The heatmap was generated using 978 
the package gplots (Warnes et al., 2013).  979 
 980 
Supplementary File Captions 981 
Supplementary File 1. Fatty acid compositions (percentage of total fatty acids) of the 982 
experimental base feed. 983 
Supplementary File 2. Gene sets significantly affected by different micronutrient 984 
supplementation in diploid and triploid salmon. Red denotes upregulation and green 985 
downregulation. 986 
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Supplementary File 3. - List of genes differentially expressed and affected by different 987 
micronutrient levels in diploid and triploid salmon. Red denotes upregulation and green 988 
downregulation. 989 
Supplementary File 4. Current EU limits for additive inclusion within fish feeds  990 
  991 
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Table 1. Formulation (g.100g diet-1) and proximate composition (analysed) of experimental 992 
diets 993 
  Diet  
Ingredients L1 L2 L3 
Fish Meal1 13.00 13.00 13.00 
Krill Meal2 2.00 2.00 2.00 
Soy Protein Concentrate3 17.94 18.00 17.65 
Corn Gluten4 4.49 3.00 3.00 
Pea Protein Concentrate5 17.94 18.49 18.15 
Wheat Gluten4 14.36 14.79 14.52 
Wheat6 8.63 8.26 7.46 
Fish Oil7 8.00 8.00 8.00 
Rapeseed oil4 5.25 5.32 5.47 
Linseed oil 1.27 1.28 1.32 
Palm kernel oil 3.17 3.21 3.30 
ARRAINA Nutrient Package8†‡  0.75 1.50 3.00 
Monosodium phosphate 2.52 2.53 2.54 
Amino acid Premix9,* 0.68 0.62 0.59 
 
Proximate Composition (Analysed) 
   
Moisture (%) 6.3 6.8 6.1 
Crude lipid (%) 20.8 21.1 22.7 
Crude protein (%) 48.9 47.0 48.1 
Ash (%) 6.5 6.8 7.4 
Energy (MJ / kg) 23.4 23.4 23.4 
 994 
1Feed Services, Bremen, Germany; 2Aker Biomarine, Norway; 3Caramuru, Brazil; 4Cargill, Germany; 995 
5Agrident, Germany; 6WN Lindsey, UK; 7ED & F Man, Germany; 8DSM, Netherlands; 9Evonik, 996 
Germany; †Added as components of the nutrient package (NP), and times requirement based on NRC 997 
(2011) minimum requirement for Atlantic salmon and modified according to Hamre et al., (2016), diet 998 
L1 achieving assumed 100 % minimum requirement; *Balanced for lysine, methionine, threonine and 999 
valine. Contains antioxidant. 1000 
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Table 2. Added micronutrient concentrations (mg.kg-1) within the nutrient package (NP): 1002 
selected amino acids (histidine and taurine), minerals, vitamins and cholesterol. 1003 
  Diet  
Premix Formulations L1 L2 L3 
Vitamin A 3.79 7.58 15.16 
Vitamin D3 0.05 0.10 0.20 
Vitamin E 102.44 204.88 409.76 
Vitamin K3 9.82 19.64 39.28 
    
Thiamin 2.67 5.34 10.68 
Riboflavin 8.30 16.60 33.20 
B6 4.77 9.54 19.08 
B12 0.25 0.50 1.00 
Niacin 24.80 49.60 99.20 
Pantothenic Acid 17.15 34.30 68.60 
Folic Acid 2.82 5.64 11.28 
Biotin 0.14 0.28 0.56 
    
Vitamin C 80 160 320 
    
Calcium 0.4 0.8 1.6 
Cobalt 0.94 1.88 3.76 
Iodine 0.67 1.34 2.68 
Selenium 0.23 0.46 0.92 
Iron 32.64 65.28 130.56 
Manganese 12.03 24.06 48.12 
Copper 3.24 6.48 12.96 
Zinc 66.92 133.84 267.68 
    
Taurine 2450 4900 9800 
Histidine 1400 2800 5600 
    
Cholesterol 1100 2200 4400 
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Table 3. Analysed concentrations of selected amino acids (taurine, histidine and methionine 1005 
g.kg-1) macro-minerals (calcium, magnesium and phosphorous, g.kg-1) micro-minerals and 1006 
vitamins (mg.kg-1) of the experimental diets for the 2 mm and 3 mm pellets. Nutrients added at 1007 
graded levels to the feeds are shown with an asterisk. “-“ denotes not analysed. 1008 
Pellet Size  2mm   3mm   
 L1 L2 L3 L1 L2 L3 NRC 2011‡ 
Vitamin A* 5.2 7.2 14.2 6.2 5.1 7.2 0.75a 
Vitamin D3* 0.17 0.19 0.29 0.17 0.18 0.26 0.04a 
Vitamin E* 85 146 203 75 151 273 60b 
Vitamin K3* 0.43 0.78 1.60 0.70 1.12 1.12 <10b 
        
Thiamin* 3.3 5.8 9.3 3.7 20.2 29.9 1a, 
Riboflavin* 12.1 20.6 35.8 11.7 34.4 57.6 4a,  
Vitamin B6* 11.5 14.3 22.2 11.0 18.1 30.5 5b 
Vitamin B12* 0.17 0.30 0.49 0.14 0.34 0.66 NT 
Niacin* 75 107 163 80 221 434 10a,  
Pantothenic acid* 18.6 33.2 50.2 20.2 74.3 66.0 20a, 
Folic acid* 2.82 - 7.53 2.82 19.95 12.54 1a 
Biotin* 0.44 0.71 1.03 0.47 1.10 1.91 0.15a 
        
Vitamin C* 83 180 312 77 238 244 20b 
        
Cobalt* 1.0 1.6 3.5 0.95 2.3 3.4 NT 
Iodine* - - - 1.1 3.4 6.1 1.1a 
Selenium* 1.2 1.5 2.2 1.3 1.6 2.5 0.15a 
Iron* 300 330 510 330 310 410 30-60b 
Manganese* 43 57 110 47 49 75 10b 
Copper* 10 12 19 10 13 19 5b 
Zinc* 160 190 300 100 200 350 37b 
        
Taurine* 2.8 4.6 8.1 2.7 5.0 9.5 NRb 
Methionine 8.7 8.8 8.6 9.0 8.8 9.1 7.0b 
Histidine* 11.6 11.7 14.0 11.9 13.1 14.5 8.0b 
        
Calcium* 6.6 6.9 8.6 6.3 6.7 7.5 NRb* 
Magnesium 1.5 1.5 1.5 1.3 1.3 1.3 0.4b 
Phosphorus 12.0 12.0 12.0 11.0 11.0 11.0 8.0b 
        
Cholesterol* n.a. n.a. n.a n.a n.a. n.a. NR 
‡Current NRC, 2011 minimum requirement recommendations determined in a rainbow trout, b 1009 
Atlantic salmon are shown for comparison. n.a. not analysed; NR* no requirement freshwater; 1010 
NT, not tested.  1011 
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Table 4. Mortality, initial and final weight and somatic indices recorded at the end (week 31) of freshwater rearing of juvenile diploid and triploid 1012 
Atlantic salmon fed low marine diets (FM 15 % / FO 8 %) diets with differing micronutrient supplementation level (diets L1, L2 and L3). 1013 
Superscripts denote significant differences between diets and ploidy.  1014 
  Diploid   Triploid   P values  
Diet L1 L2 L3  L1 L2 L3  P D P * D 
Mortality (%)† (n=2) 4.8 ± 4.3 1.4 ± 0.6 0.6 ± 0.1  1.6 ± 0.5 1.1 ± 0.2 1.1 ± 0.3  n/a n/a n/a 
Initial Parr Wt (g) (n=50) 37.2 ± 1.8 a 37.2 ± 1.8 a 37.2 ± 1.8 a  27.6 ± 0.8 b 27.6 ± 0.8 b 27.6 ± 0.8 b  0.005 0.378 0.299 
Final Smolt Wt (g) (n=50) 94.4 ± 14.2 b 113.8 ± 9.4 a 94.1 ± 15.7 b  75.4 ± 6.8 c 75.2 ± 2.6 c 77.5 ± 0.9 c  0.001 0.065 0.036 
SGRwt (n=2) 0.62 ± 0.02 b 0.70 ± 0.04 a 0.61 ± 0.04 b  0.63 ± 0.02 b 0.61 ± 0.03 b 0.63 ± 0.02 b  0.056 0.063 0.001 
RWG (%) (n=2) 150.8 ± 12.2 bc 206.5 ± 4.8 a 138.9 ± 17.2 c  175.3 ± 13.0 ab 163.3 ± 13.6 bc 180.2 ± 8.8 ab  0.215 0.008 0.001 
FCR (n=2) 0.90 ± 0.24 ab 0.71 ± 0.10 b 0.87 ± 0.03 ab  0.93 ± 0.12 ab 1.02 ± 0.18 a 0.92 ± 0.00 ab  0.015 0.716 0.050 
VSI (%) (n=10) 8.61 ± 0.55 a 7.24 ± 0.23 b 8.48 ± 0.65a  6.99 ± 0.32b 7.11 ± 0.09 b 7.42 ± 0.21ab  0.001 0.009 0.031 
HSI (%) (n=10) 1.36 ± 0.19 a 1.19 ± 0.03 b 1.35 ± 0.25 a  1.05 ± 0.06 b 1.12 ± 0.07 ab 1.15 ± 0.01 ab  0.057 0.018 0.006 
Hepatic Steatosis (%) (n=4) 1.6 ± 0.8 c 2.5 ± 0.5 ab 1.7 ± 0.2 bc  2.3 ± 0.5 abc 2.2 ± 0.2 abc 2.8 ± 0.1a  0.004 0.183 0.003 
Data are presented as means ± SD.  † Mortality data analysed by Contingency Chi-square tests 1015 
FCR, feed conversion ratio; HSI, hepatosomatic index; RWG, relative weight gain (%); SGRwt, specific growth rate weight (% day-1); VSI, viscerosomatic index 1016 
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Table 5. Whole fish proximate composition (%) and fatty acid compositions (% of total fatty acids) of liver of diploid and triploid salmon fed 1018 
low marine diets with differing micronutrient supplementation level. Significant effect is highlighted in bold and superscripts denote significant 1019 
differences between diets and ploidy (two-way ANOVA). 1020 
Ploidy (P)  Diploid    Triploid    p values  







68.9 ± 0.1 
10.4 ± 1.0 
17.5 ± 0.6 
2.3 ± 0.1 
 
2.3 ± 0.3ab 
68.2 ± 0.1 
10.5 ± 0.4 
18.1 ± 0.6 
2.3 ± 0.1 
 
2.3 ± 0.3a 
69.0 ± 0.2 
10.4 ± 0.1 
17.7 ± 0.6 
2.2 ± 0.1 
 
1.9 ± 0.1ab 
 69.7 ±0.3 
9.9 ± 0.0 
17.2 ± 0.4 
2.3 ± 0.0 
 
1.7 ± 0.1b 
69.2 ± 0.1 
10.6 ± 0.0 
16.8 ± 0.1 
2.3 ± 0.0 
 
1.7 ± 0.3b 
69.2 ± 0.7 
10.5 ± 0.3 
16.9 ± 0.6 
2.3 ± 0.0 
 



















16:0 16.1 ± 0.6b 17.5 ± 0.5ab 18.7 ± 0.8a  18.4 ± 1.8a 18.8 ± 0.5a 16.9 ± 0.9b  0.250 0.354 0.015 
18:0 4.7 ± 0.2a 4.3 ± 0.5ab 4.2 ± 0.4ab  4.6 ± 0.3a 4.2 ± 0.5ab 3.6 ± 0.2b  0.126 0.009 0.508 
Total Saturated1 23.4 ± 0.3b 24.4 ± 0.5ab 25.1 ± 0.5a  25.0 ± 1.7a 25.0 ± 0.7a 22.9 ± 0.9b  0.968 0.457 0.017 
            
16:1n-7 2.4 ± 0.3a 2.2 ± 0.3ab 1.9 ± 0.1ab  1.8 ± 0.0b 1.8 ± 0.1b 2.1 ± 0.2ab  0.009 0.777 0.009 
18:1n-9 21.6 ± 2.9a 17.3 ± 1.9ab 16.5 ± 0.8b  15.3 ± 1.6b 14.7 ± 1.1b 18.0 ± 2.5ab  0.019 0.130 0.015 
18:1n-7 2.8 ± 0.3a 2.4 ± 0.2ab 2.3 ± 0.1ab  2.2 ± 0.2b 2.0 ± 0.0b 2.1 ± 0. b  0.001 0.056 0.177 
20:1n-9 2.5 ± 0.4a 2.4 ± 0.2ab 1.8 ± 0.0b  1.7 ± 0.3b 1.7 ± 0.6b 2.6 ± 0.4a  0.213 0.756 0.002 
22:1n-11 0.6 ± 0.1 0.6 ± 0.1 0.4 ± 0.1  0.5 ± 0.1 0.5 ± 0.2 0.7 ± 0.1  0.307 0.865 0.150 
Total Monoenes2 31.3 ± 3.7a 26.3 ± 2.6ab 24.2 ± 0.7b  23.3 ± 1.6 b 22.4 ± 2.2b 27.4 ± 3.2ab  0.031 0.168 0.007 
            
18:2n-6 6.8 ± 0.7ab 6.6 ± 0.2 ab 5.9 ± 0.1 ab  5.5 ± 0.7b 6.1 ± 1.1ab 7.4 ± 0.1a  0.710 0.412 0.004 
20:4n-6 2.3 ± 0.1a 1.6 ± 0.1bc 2.1 ± 0.3ab  1.9 ± 0.2 abc 1.8 ± 0.3 abc 1.4 ± 0.2c  0.017 0.008 0.10 
Total n-6 PUFA3 12.0 ± 0.6 10.8 ± 0.3 10.5 ± 1.0  9.7 ± 1.3 9.9 ± 1.0 11.6 ± 0.6  0.103 0.447 0.022 
            
18:3n-3 1.7 ± 0.3 1.9 ± 0.1 1.6 ± 0.1  1.5 ± 0.1 1.8 ± 0.3 2.0 ± 0.3  0.460 0.226 0.066 
18:4n-3 0.4 ± 0.2 0.3 ± 0.0 0.3 ± 0.0  0.3 ± 0.0 0.3 ± 0.1 0.4 ± 0.0  0.824 0.329 0.156 
20:4n-3 0.7 ± 0.2 b 0.9 ± 0.1 ab 0.7 ± 0.1 b  0.8 ± 0.1 ab 0.9 ± 0.2 ab 1.1 ± 0.1a  0.023 0.80 0.058 
20:5n-3 4.4 ± 0.5 5.0 ± 0.3 5.3 ± 0.4  4.7 ± 0.3 4.9 ± 0.2 5.2 ± 0.2  0.744 0.017 0.600 
22:5n-3 0.9 ± 0.2 1.1 ± 0.1 1.2 ± 0.2  1.1 ± 0.0 1.1 ± 0.1 1.2 ± 0.1  0.288 0.049 0.833 
22:6n-3 25.0 ± 3.5 b 29.0 ± 2.5 ab 30.9 ± 1.5 ab  33.3 ± 0.7a 33.3 ± 3.4 a 27.8 ± 2.9 ab  0.020 0.337 0.006 
Total n-3 PUFA4 33.2 ± 4.1 b 38.3 ± 2.7 ab 40.1 ± 1.0 ab  41.9 ± 0.6 a 42.6 ± 2.5 a 38.0 ± 3.0 ab  0.011 0.186 0.010 
            
Total PUFA5 45.3 ± 3.5 b 49.2 ±3.0 ab 50.7 ± 0.3 ab  51.6 ± 1.2 a 52.6 ± 1.5a 49.6 ± 2.6 ab  0.019 0.201 0.45 
Data are mean ± SD (n = 2). 1Totals include 15:0, 20:0, 22:0 and 24:0 at up to 0.3%; 2Totals include 16:1n-9, 20:1n-11, 20:1n-7, 22:1n-9 and 24:1n-9 at up to 1.9%; 3Totals 1021 
include 18:3n-6, 20:2n-6, 20:3n-6 and 22:5n-6 at up to 2.9%; 4Totals include20:3n-3 at up to 0.2%; 5Includes C16 PUFA at up to 0.1% 1022 
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Table 6. Whole fish total amino acids (g.kg wet wt-1) in diploid and triploid salmon fed low 1023 
marine diets with differing micronutrient supplementation level. The supplemented amino 1024 
acids (histidine, taurine and methionine) are marked with an asterisk (*). Superscripts denote 1025 
significant differences between diets within ploidy (two-way ANOVA). 1026 
Ploidy (P) Diploids  Triploids  p-values 
Diet (D) L1 L2 L3  L1 L2 L3  Ploidy Diet P * D 
OH-pro 0.7±0.0 0.7±0.0 0.7±0.2  0.6±0.0 0.8±0.0 0.6±0.0  0.59 0.32 0.35 
His* 3.9±0.0 4.1±0.1 4.1±0.2  4.0±0.1 4.1±0.0 3.9±0.1  0.64 0.42 0.61 
Taurine* 1.2±0.0 1.1±0.0 1.2±0.1  1.4±0.1 1.3±0.0 1.2±0.0  0.048 0.29 0.65 
Ser 6.7±0.0 7.0±0.2 6.9±0.1  6.9±0.0 7.0±0.0 6.6±0.0  0.72 0.07 0.06 
Arg 9.0±0.0 9.2±0.1 9.0±0.2  9.0±0.3 9.2±0.0 8.7±0.1  0.59 0.16 0.73 
Gly 9.1±0.1 9.2±0.1 8.9±0.3  9.5±0.9 9.2±0.0 8.8±0.2  0.74 0.52 0.77 
Asp 17.0±1 18±1 17±1  17.3±0.6 17.9±0.2 17.6±0.3  0.67 0.31 0.93 
Glu 23±0 24±0 22±1  22.7±0.6 23.1±0.1 22.4±0.1  0.64 0.19 0.91 
Thr 7.6±0.1 7.9±0.1 7.9±0.1  7.7±0.1 7.9±0.0 7.6±0.1  0.76 0.09 0.24 
Ala 9.9±0.1 10±0.2 9.9±0.3  9.8±0.0 10.1±0.1 9.9±0.0  0.67 0.22 0.82 
Pro 5.9±0.0 6.2±0.1 6.0±0.2  6.1±0.2 6.1±0.0 5.9±0.1  0.79 0.30 0.58 
Lys 15±1 16±0 16±1  15.3±0.8 16.1±0.3 16.0±0.3  0.95 0.35 0.84 
Tyr 5.3±0.0 5.4±0.0 5.5±0.1  5.3±0.2 5.5±0.0 5.2±0.1  0.60 0.23 0.17 
Met* 5.0±0.0 5.2±0.1 5.1±0.1  5.1±0.0 5.2±0.0 4.9±0.1  0.67 0.08 0.09 
Val 8.8±0.1 9.2±0.1 8.7±0.5  8.4±0.0 8.6±0.2 8.7±0.2  0.16 0.44 0.63 
Ile 7.0±0.1 5.5±1.9 7.0±0.4  6.7±0.0 7.0±0.2 7.0±0.2  0.61 0.63 0.55 
Leu 13±0.0 13±0.2 13±0.4  12.6±0.2 13.0±0.1 12.6±0.3  0.63 0.11 0.69 
Phe 6.8±0.0 6.9±0.1 7.0±0.1  6.9±0.2 7.1±0.0 6.6±0.1  0.87 0.39 0.21 
Data are presented as mean ± SD (n=2). 1027 
  1028 
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Table 7. Free amino acids and N-metabolites within white muscle tissues (µmol / 100g wet wt) 1029 
of diploid and triploid salmon fed low marine diets with differing micronutrient 1030 
supplementation level. Only the N-metabolites being significantly affected are shown (two-way 1031 
ANOVA, Tukey p < 0.05, Kruskall Wallis when not fulfilling ANOVA assumptions). Histidine 1032 
and taurine were supplemented in graded levels. Significant effect is highlighted in bold and 1033 
superscripts denote significant differences between diets within ploidy (two-way ANOVA). 1034 
 1035 
Ploidy (P) Diploids  Triploids  p-values 
Diet (D) L1 L2 L3  L1 L2 L3  Ploidy Diet P * D 
Taurine* 195±21 124±7 195±46  266±19 222±47 260±22  0.020 0.192 0.85 
Asp 9±0.3 10±2. 9±0.4  12±1 13±0.6 15±0.7  0.008 0.41 0.40 
OH-pro 19±11 40±12 25±15  53±5 45±7 48±7  0.021 0.81 0.44 
Thr 55±2b 65±1a 68±5a  45±1b 55±4a 53±4a  0.24 0.019 0.69 
Glu 60±5 55±4 57±3  66±3 67±5 71±1  0.021 0.78 0.58 
Gln 22±3 26±8 23±5  35±0.5 30±2 34±1  0.035 0.99 0.62 
Val 39±4 27±3 37±5  23±1 27±0.1 28±0.1  0.024 0.26 0.11 
Cystath 4±0.3a 1±0.3b 3±1b  5±0.4a 2±0.1b 1±0.1b  0.85 0.004 0.13 
Ile 23±1 13±2 20±4  11±0.1 14±0.6 14±0.1  0.025 0.32 0.12 
Leu 36±2 25±1 34±6  22±2 26±1 26±1  0.025 0.26 0.06 
β-Ala 69±14 63±12 41±5  104±3 105±25 93±11  0.006 0.315 0.80 
Lys 23±3 15±2 24±2  10±1 14±3 15±1  0.007 0.17 0.09 
Anserine 1810±71 1972±184 21441  1560±7 1756±15 1710±9  0.014 0.057 0.41 
Data are presented as mean ± SD (n=2). Muscle N-metabolites (µmol/100g wet wt, n=2), Cystath, cystathionine. 1036 
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Table 8. Concentrations of vitamins (mg kg-1 wet wt) in whole body, muscle, liver and gill in 1038 
diploid and triploid salmon fed low marine diets with differing micronutrient supplementation 1039 
level (Diets L1, L2 and L3). The supplemented vitamins are marked with an asterisk. 1040 
Significant effect is highlighted in bold and superscripts denote significant differences between 1041 
diets within ploidy (two-way ANOVA). 1042 
Ploidy (P) Diploid  Triploid  p-values 
Diet (D) L1 L2 L3  L1 L2 L3  Ploidy Diet P * D 
Whole body            
Biotin* 63±4 67±10 60±4  80±4 74±9 74±4  0.129 0.925 0.546 
Folate* 0.21±0.04 0.27±0.05 0.30±0.01  0.27±0.01 0.26±0.01 0.27±0.01  0.084 0.149 0.035 
Niacin* 43±3a 48±4 ab 54±4 b  41±1 a 45±1 ab 49±2 b  0.273 0.006 0.083 
Pantothene* 5.3±2.1 7.3±0.4 8.0±1.9  5.5±0.6 7.4±0.8 6.9±0.3  0.372 0.051 0.184 
Riboflavine* 1.60±0.14 b 1.75±0.07 b 1.90±0.14 b  1.50±0.00 a 1.55±0.21 a 1.50±0.00 a  0.016 0.286 0.286 
Thiamin* 0.70±0.14 0.80±0.14 0.90±0.14  0.75±0.07 0.80±0.00 0.80±0.00  0.791 0.304 0.609 
Vit-C* 11.1±1.3 a 18.5±0.1 ab 26±10 b  12.6±0.5 a 19.7±1.5 ab 23.1±0.6 b  0.994 0.015 0.746 
α-TOH* 28±0 a 41±0 c 48±2c  28±1 a 30±3 bc 40±4 c  <0.001 <0.001 0.037 
γ-TOH 2.8±0.4 b 2.6±0.1 b 1.7±0.0 a  3.1±0.4 b 2.6±0.3 b 1.6±0.1 a  0.922 <0.001 0.559 
            
Muscle            
Vit-B6* 5.6±0.1 6.3±1.1 5.0±2.4  4.8±0.4 5.3±0.4 5.8±0.4  0.331 0.416 0.593 
Riboflavin* 1.10±0.00 0.95±0.07 1.15±0.21  1.10±0.00 1.05±0.07 1.05±0.07  0.631 0.475 0.475 
Thiamin* 0.55±0.21 0.80±0.28 0.55±0.21  0.85±0.07 0.70±0.14 0.90±0.42  0.128 0.962 0.594 
α-TOH*  12.0±0.0 14.5±0.7 17.0±5.7  12.0±4.2 13.0±0.0 16.0±2.8  0.521 0.063 0.981 
γ-TOH 1.60±0.14 b 1.25±0.07 a 0.90±0.28 a  1.85±0.35 b 1.25±0.07 a 0.80±0.14 a  0.527 <0.001 0.594 
            
Liver            
Folate* 7.4±1.6 8.5±0.8 7.9±0.9  7.3±0.8 8.9±0.7 9.4±0.7  0.689 0.132 0.281 
A1* 9.5±2.1a 12.0±2.8 a 21.5±6.4 b  7.5±2.1 a 14.0±5.7 a 19.0±2.8 b  0.446 0.012 0.746 
A2 70±12 a 83±21 a 135±21 b  51±5 a 79±30 a 115±7 b  0.089 0.004 0.849 
C* 82±5 a 108±18 b 114±2 c  78±7 a 102±5 b 140±10 c  0.914 <0.001 0.052 
K11 40±9 37±12 31±4  20±8 12±3 17±0  0.001 0.004 0.238 
MK41 31±4 34±10 40±5  14±0 14±3 17±1  <0.001 0.051 0.292 
Gill            
Pantothene* 5.3±1.8 8.9±1.1 9.1±0.1  7.2 7.3±0.0 6.1±3.0  0.423 0.416 0.248 
Data are presented as mean ± SD (n=2). 1Menadione sodium bisulfate (vitamin K3) was added. 1043 
 1044 
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Table 9. Concentrations of minerals (mg kg-1 wet wt) in whole body of diploid and triploid 1046 
salmon fed low marine diets with differing micronutrient supplementation level. The 1047 
supplemented elements are marked with an asterisk. Significant effect is highlighted in bold 1048 
(two-way ANOVA) 1049 
Ploidy (P)  Dip    Trip   p-values 
Diet (D) L1 L2 L3  L1 L2 L3  Ploidy Diet P *D 
Ca* 3782±1018 4788±1182 4634±565  4094±684 3536±378 3850±981  0.28 0.87 0.45 
Cu* 0.98±0 0.96±0 1±0  0.9±0 0.9±0 0.85±0  0.01 0.96 0.36 
Fe* 9.03±0.7 8.8±0 10±1  10±0.8 10±0.7 10±0.3  0.24 0.27 0.7 
I* 0.08±0 n.d. 0.12±0  0.30±0.3 0.14±0 0.25±0.1  0.11 0.66 0.61 
K 3528±40 3663±18 3469±118  3523±2 3570±56 3609±262  0.84 0.54 0.43 
Mn* 1.6±0.4 1.8±0.2 2±0  1.7±0.2 1.3±0 1±0.3  0.19 0.83 0.43 
Mg 274±3 292±7 283±16  291±6 277±7 287±33  0.85 0.96 0.39 
Na 551±24 605±88 588±9  669±56 600±5 589±63  0.24 0.83 0.23 
P 3925±369 4616±748 4423±352  4135±324 3918±220 4064±560  0.33 0.73 0.42 
Se* 0.22±0 0.25±0 0.26±0  0.25±0 0.2±0 0.3±0  0.46 0.09 0.60 
Zn* 32±1.8 42±11 34±6  39±6 28±0.8 32±1  0.19 0.83 0.43 
Data are presented as mean ± SD (n=2).  1050 
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Figure 1.  1052 
  1053 
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Figure 2.  1055 
  1056 
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Supplementary File 1. 1063 
  L1-L3 
14:0 5.3 ± 0.2 
16:0 11.8 ± 0.3 
18:0 2.5 ± 0.0 
Total Saturates1 25.7 ± 0.3 
16:1n-7 3.6 ± 0.1 
18:1n-9 26.3 ± 0.2 
18:1n-7 2.7 ± 0.1 
20:1n-9 3.9 ± 0.2 
22:1n-11 4.7 ± 0.2 
Total Monoenes2 42.8 ± 0.6 
18:2n-6 12.9 ± 0.1 
20:4n-6 0.3 ± 0.0 
Total  n-6 PUFA3 13.5 ± 0.1 
18:3n-3 6.9 ± 1.1 
18:4n-3 1.1  ±  0.0 
20:4n-3 0.3 ± 0.0 
20:5n-3 4.5 ± 0.1 
22:5n-3 0.5 ± 0.0 
22:6n-3 3.6 ± 0.1 
Total n-3 PUFA4 16.8 ± 0.9 
Total PUFA5 31.5 ± 0.8 
Values are the averaged data for the L1, L2, and L3 in both 2 and 3 mm feeds (± SD provided 1064 
to illustrate variance between feeds).  1065 
PUFA, polyunsaturated fatty acids.  1066 
1Totals include 14:0, 15:0, 20:0 and 22:0;  1067 
2Totals include 16:1n-9, 20:1n-11, 20:1n-722:1n-9 and 24:1n-9;  1068 
3Totals include 18:3n-6, 20:2n-6, and 22:5n-6; 1069 
 4Totals include 20:3n-3; 5Totals include C16 PUFA. 1070 
 1071 
  1072 
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Supplementary File 2. 1073 
   1074 
Diet Ploidy Pathway NGenes Prop Down Prop Up FDR Class
L2 DIPLOIDS ko04710 Circadian rhythm 19 5.3% 52.6% 0.0124 Environmental adaptation
L3 DIPLOIDS ko04910 Insulin signaling pathway 67 28.4% 13.4% 0.0185 Endocrine system
L2 TRIPLOIDS ko00562 Inositol phosphate metabolism 34 8.8% 17.6% 0.0648 Carbohydrate metabolism
L2 TRIPLOIDS ko04973 Carbohydrate digestion and absorption 16 6.3% 31.3% 0.0648 Digestive system
L2 TRIPLOIDS ko03018 RNA degradation 53 34.0% 7.5% 0.0648 Folding, sorting and degradation
L2 TRIPLOIDS ko04740 Olfactory transduction 11 0.0% 27.3% 0.0679 Sensory system
L2 TRIPLOIDS ko04512 ECM-receptor interaction 45 6.7% 35.6% 0.0371 Signaling molecules and interaction
L2 TRIPLOIDS ko04514 Cell adhesion molecules (CAMs) 71 9.9% 25.4% 0.0667 Signaling molecules and interaction
L3 TRIPLOIDS ko00360 Phenylalanine metabolism 12 8.3% 33.3% 0.0854 Amino acid metabolism
L3 TRIPLOIDS ko00010 Glycolysis / Gluconeogenesis 32 15.6% 40.6% 0.0854 Carbohydrate metabolism
L3 TRIPLOIDS ko00040 Pentose and glucuronate interconversions 13 0.0% 53.8% 0.0967 Carbohydrate metabolism
L3 TRIPLOIDS ko00052 Galactose metabolism 17 5.9% 41.2% 0.0807 Carbohydrate metabolism
L3 TRIPLOIDS ko00500 Starch and sucrose metabolism 21 0.0% 52.4% 0.0025 Carbohydrate metabolism
L3 TRIPLOIDS ko04510 Focal adhesion 120 17.5% 25.8% 0.0278 Cell communication
L3 TRIPLOIDS ko04520 Adherens junction 56 12.5% 25.0% 0.0278 Cell communication
L3 TRIPLOIDS ko04810 Regulation of actin cytoskeleton 116 15.5% 23.3% 0.0497 Cell motility
L3 TRIPLOIDS ko04973 Carbohydrate digestion and absorption 16 6.3% 56.3% 0.0025 Digestive system
L3 TRIPLOIDS ko04974 Protein digestion and absorption 41 12.2% 26.8% 0.0497 Digestive system
L3 TRIPLOIDS ko04975 Fat digestion and absorption 19 15.8% 47.4% 0.0278 Digestive system
L3 TRIPLOIDS ko04976 Bile secretion 43 11.6% 25.6% 0.0270 Digestive system
L3 TRIPLOIDS ko03320 PPAR signaling pathway 43 11.6% 44.2% 0.0434 Endocrine system
L3 TRIPLOIDS ko04910 Insulin signaling pathway 68 14.7% 25.0% 0.0497 Endocrine system
L3 TRIPLOIDS ko04916 Melanogenesis 46 13.0% 23.9% 0.0436 Endocrine system
L3 TRIPLOIDS ko00190 Oxidative phosphorylation 107 45.8% 15.9% 0.0872 Energy metabolism
L3 TRIPLOIDS ko03018 RNA degradation 53 45.3% 5.7% 0.0053 Folding, sorting and degradation
L3 TRIPLOIDS ko03050 Proteasome 40 72.5% 2.5% 0.0025 Folding, sorting and degradation
L3 TRIPLOIDS ko04610 Complement and coagulation cascades 57 5.3% 54.4% 0.0587 Immune system
L3 TRIPLOIDS ko04623 Cytosolic DNA-sensing pathway 36 36.1% 8.3% 0.0484 Immune system
L3 TRIPLOIDS ko04662 B cell receptor signaling pathway 43 23.3% 30.2% 0.0967 Immune system
L3 TRIPLOIDS ko04670 Leukocyte transendothelial migration 64 20.3% 32.8% 0.0293 Immune system
L3 TRIPLOIDS ko04672 Intestinal immune network for IgA production 26 7.7% 26.9% 0.0232 Immune system
L3 TRIPLOIDS ko00100 Steroid biosynthesis 14 57.1% 0.0% 0.0233 Lipid metabolism
L3 TRIPLOIDS ko00140 Steroid hormone biosynthesis 23 4.3% 34.8% 0.0612 Lipid metabolism
L3 TRIPLOIDS ko00564 Glycerophospholipid metabolism 48 14.6% 37.5% 0.0025 Lipid metabolism
L3 TRIPLOIDS ko00830 Retinol metabolism 22 9.1% 45.5% 0.0340 Metabolism of cofactors and vitamins
L3 TRIPLOIDS ko00900 Terpenoid backbone biosynthesis 16 50.0% 0.0% 0.0270 Metabolism of terpenoids and polyketides
L3 TRIPLOIDS ko00230 Purine metabolism 111 27.9% 17.1% 0.0755 Nucleotide metabolism
L3 TRIPLOIDS ko00240 Pyrimidine metabolism 73 35.6% 8.2% 0.0270 Nucleotide metabolism
L3 TRIPLOIDS ko03420 Nucleotide excision repair 36 44.4% 11.1% 0.0325 Replication and repair
L3 TRIPLOIDS ko04740 Olfactory transduction 11 0.0% 27.3% 0.0293 Sensory system
L3 TRIPLOIDS ko04742 Taste transduction 12 0.0% 16.7% 0.0484 Sensory system
L3 TRIPLOIDS ko04012 ErbB signaling pathway 50 14.0% 34.0% 0.0807 Signal transduction
L3 TRIPLOIDS ko04020 Calcium signaling pathway 89 13.5% 20.2% 0.0445 Signal transduction
L3 TRIPLOIDS ko04310 Wnt signaling pathway 73 15.1% 26.0% 0.0379 Signal transduction
L3 TRIPLOIDS ko04340 Hedgehog signaling pathway 23 13.0% 26.1% 0.0325 Signal transduction
L3 TRIPLOIDS ko04512 ECM-receptor interaction 45 20.0% 24.4% 0.0484 Signaling molecules and interaction
L3 TRIPLOIDS ko04514 Cell adhesion molecules (CAMs) 71 11.3% 25.4% 0.0025 Signaling molecules and interaction
L3 TRIPLOIDS ko03020 RNA polymerase 27 44.4% 0.0% 0.0053 Transcription
L3 TRIPLOIDS ko03040 Spliceosome 111 43.2% 11.7% 0.0235 Transcription
L3 TRIPLOIDS ko03010 Ribosome 120 61.7% 5.8% 0.0270 Translation
L3 TRIPLOIDS ko00980 Metabolism of xenobiotics by cytochrome P450 15 0.0% 46.7% 0.0278 Xenobiotics biodegradation and metabolism
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Supplementary File 3. 1075 
Diploid L2 vs L1 1076 
  1077 
KOID Gene Abbreviation KEGG Annotation Class Log Fold Change P Value adj P Val
K00061 RDH5 11-cis-retinol dehydrogenase [EC:1.1.1.315] ko00830 Retinol metabolism -1.05 0.0006 0.285374
K00069 HPGD 15-hydroxyprostaglandin dehydrogenase (NAD) [EC:1.1.1.141] ko05202 Transcriptional misregulation in cancer -0.38 0.0494 0.36668
K13373 HSD17B7 17beta-estradiol 17-dehydrogenase / 3beta-hydroxysteroid 3-dehydrogenase [Eko00100 Steroid biosynthesis; ko00140 Steroid hormone biosynthesis; ko04913 Ovarian steroidogenesis -1.07 0.0001 0.285374
K02731 PSMA7 20S proteasome subunit alpha 4 [EC:3.4.25.1] ko03050 Proteasome 0.46 0.0149 0.334596
K02729 PSMA5 20S proteasome subunit alpha 5 [EC:3.4.25.1] ko03050 Proteasome 0.43 0.0408 0.361087
K07439 CYP39A1 24-hydroxycholesterol 7alpha-hydroxylase [EC:1.14.13.99] ko00120 Primary bile acid biosynthesis 0.65 0.0285 0.356921
K14458 MOGAT1, MGAT1 2-acylglycerol O-acyltransferase 1 [EC:2.3.1.22] NA 1.23 0.0045 0.322942
K14457 MOGAT2, MGAT2 2-acylglycerol O-acyltransferase 2 [EC:2.3.1.22] ko04975 Fat digestion and absorption 1.05 0.0018 0.320209
K08683 HSD17B10 3-hydroxyacyl-CoA dehydrogenase / 3-hydroxy-2-methylbutyryl-CoA dehydrogenko00280 Valine, leucine and isoleucine degradation; ko05010 Alzheimer's disease 0.43 0.0266 0.356414
K01724 PCBD, phhB 4a-hydroxytetrahydrobiopterin dehydratase [EC:4.2.1.96] NA 0.47 0.0246 0.355469
K13524 ABAT 4-aminobutyrate aminotransferase / (S)-3-amino-2-methylpropionate transaminaseko00250 Alanine, aspartate and glutamate metabolism; ko00280 Valine, leucine and isoleucine degradation; ko00410 beta-Alanine metabolism; ko00640 Propanoate metabolism; ko00650 Butanoate metabolism; ko04727 GABAergic synapse0.89 .0067 0.322942
K00457 HPD, hppD 4-hydroxyphenylpyruvate dioxygenase [EC:1.13.11.27] ko00130 Ubiquinone and other terpenoid-quinone biosynthesis; ko00350 Tyrosine metabolism; ko00360 Phenylalanine metabolism-0.56 0.0445 0.361087
K07127 uraH, pucM, hiuH 5-hydroxyisourate hydrolase [EC:3.5.2.17] ko00230 Purine metabolism -0.76 0.0093 0.322942
K19029 PFKFB2 6-phosphofructo-2-kinase / fructose-2,6-biphosphatase 2 [EC:2.7.1.105 3.1.3. NA -0.69 0.0115 0.327913
K00033 PGD, gnd, gntZ 6-phosphogluconate dehydrogenase [EC:1.1.1.44 1.1.1.343] ko00030 Pentose phosphate pathway; ko00480 Glutathione metabolism 0.55 0.0266 0.356414
K00213 DHCR7 7-dehydrocholesterol reductase [EC:1.3.1.21] ko00100 Steroid biosynthesis -1.37 0.0004 0.285374
K17816 NUDT1, MTH1 8-oxo-dGTP diphosphatase / 2-hydroxy-dATP diphosphatase [EC:3.6.1.55 3. NA 0.40 0.0441 0.361087
K11259 ILVBL acetolactate synthase-like protein [EC:2.2.1.-] NA 0.56 0.0165 0.339247
K11262 ACAC acetyl-CoA carboxylase / biotin carboxylase [EC:6.4.1.2 6.3.4.14] ko00061 Fatty acid biosynthesis; ko00620 Pyruvate metabolism; ko00640 Propanoate metabolism; ko04910 Insulin signaling pathway1.87 0.0040 0.322942
K05756 ARPC3 actin related protein 2/3 complex, subunit 3 ko04666 Fc gamma R-mediated phagocytosis; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05132 Salmonella infection-0.52 0.0147 0.334596
K05755 ARPC4 actin related protein 2/3 complex, subunit 4 ko04666 Fc gamma R-mediated phagocytosis; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05132 Salmonella infection0.41 0.0392 0.361087
K18532 AK6, FAP7 adenylate kinase [EC:2.7.4.3] NA -0.59 0.0044 0.322942
K01756 purB, ADSL adenylosuccinate lyase [EC:4.3.2.2] ko00230 Purine metabolism; ko00250 Alanine, aspartate and glutamate metabolism 0.53 0.0074 0.322942
K07296 ACDC adiponectin ko03320 PPAR signaling pathway; ko04920 Adipocytokine signaling pathway; ko04930 Type II diabetes mellitus; ko04932 Non-alcoholic fatty liver disease (NAFLD)0.77 0.0380 0.359115
K12333 ADM adrenomedullin ko04270 Vascular smooth muscle contraction 0.49 0.0208 0.348275
K00827 AGXT2 alanine-glyoxylate transaminase / (R)-3-amino-2-methylpropionate-pyruvate trako00250 Alanine, aspartate and glutamate metabolism; ko00260 Glycine, serine and threonine metabolism 0.63 0.0214 0.348275
K00002 AKR1A1, adh alcohol dehydrogenase (NADP+) [EC:1.1.1.2] ko00010 Glycolysis / Gluconeogenesis; ko00561 Glycerolipid metabolism; ko00930 Caprolactam degradation -0.41 0.0099 0.322942
K00011 E1.1.1.21, AKR1 aldehyde reductase [EC:1.1.1.21] ko00040 Pentose and glucuronate interconversions; ko00051 Fructose and mannose metabolism; ko00052 Galactose metabolism; ko00561 Glycerolipid metabolism; ko00620 Pyruvate metabolism0.58 0.0436 0.361087
K15537 AGMO alkylglycerol monooxygenase [EC:1.14.16.5] NA 0.61 0.0168 0.34213
K03910 A2M alpha-2-macroglobulin ko04610 Complement and coagulation cascades -0.43 0.0383 0.359115
K01231 MAN2 alpha-mannosidase II [EC:3.2.1.114] ko00510 N-Glycan biosynthesis; ko00513 Various types of N-glycan biosynthesis 0.38 0.0016 0.320209
K00764 purF, PPAT amidophosphoribosyltransferase [EC:2.4.2.14] ko00230 Purine metabolism; ko00250 Alanine, aspartate and glutamate metabolism -0.68 0.0066 0.322942
K09821 AGT angiotensinogen ko04270 Vascular smooth muscle contraction; ko04614 Renin-angiotensin system; ko05410 Hypertrophic cardiomyopathy (HCM)-0.59 0.0219 0.351561
K17093 ANXA4 annexin A4 NA 0.46 0.0321 0.356921
K16646 ANXA5 annexin A5 NA 0.63 0.0251 0.355469
K08760 APOA4 apolipoprotein A-IV ko04975 Fat digestion and absorption; ko04977 Vitamin digestion and absorption 0.93 0.0186 0.34213
K05641 ABCA1 ATP-binding cassette, subfamily A (ABC1), member 1 ko02010 ABC transporters; ko04975 Fat digestion and absorption 0.52 0.0425 0.361087
K05654 ABCB3, TAP2 ATP-binding cassette, subfamily B (MDR/TAP), member 3 ko02010 ABC transporters; ko04145 Phagosome; ko04612 Antigen processing and presentation; ko05168 Herpes simplex infection; ko05340 Primary immunodeficiency-0.74 0.0123 0.327913
K05668 ABCC5 ATP-binding cassette, subfamily C (CFTR/MRP), member 5 ko02010 ABC transporters 0.78 0.0105 0.322942
K17675 SUPV3L1, SUV3 ATP-dependent RNA helicase SUPV3L1/SUV3 [EC:3.6.4.13] NA -0.57 0.0268 0.356414
K07970 B3GNT3 beta-1,3-N-acetylglucosaminyltransferase 3 [EC:2.4.1.-] ko00601 Glycosphingolipid biosynthesis - lacto and neolacto series -0.65 0.0034 0.322942
K00544 BHMT betaine-homocysteine S-methyltransferase [EC:2.1.1.5] ko00260 Glycine, serine and threonine metabolism; ko00270 Cysteine and methionine metabolism 1.40 0.0018 0.320209
K04663 BMP5 bone morphogenetic protein 5 ko04350 TGF-beta signaling pathway; ko04390 Hippo signaling pathway 0.46 0.0378 0.359115
K12873 BUD31, G10 bud site selection protein 31 ko03040 Spliceosome -0.55 0.0136 0.328871
K04001 SERPING1, C1INH C1 inhibitor ko04610 Complement and coagulation cascades; ko05133 Pertussis -0.44 0.0105 0.322942
K17610 CHP, CHP1 calcineurin B homologous protein 1 NA -0.48 0.0224 0.351668
K10364 CAPZA capping protein (actin filament) muscle Z-line, alpha NA 0.55 0.0250 0.355469
K01948 CPS1 carbamoyl-phosphate synthase (ammonia) [EC:6.3.4.16] ko00250 Alanine, aspartate and glutamate metabolism; ko00330 Arginine and proline metabolism; ko00910 Nitrogen metabolism-0.58 0.0006 0.285374
K11540 CAD carbamoyl-phosphate synthase / aspartate carbamoyltransferase / dihydroorotaseko00240 Pyrimidine metabolism; ko00250 Alanine, aspartate and glutamate metabolism 0.45 0.0134 0.328871
K03927 CES2 carboxylesterase 2 [EC:3.1.1.1 3.1.1.84 3.1.1.56] ko00983 Drug metabolism - other enzymes -0.42 0.0498 0.36668
K01294 CPE carboxypeptidase E [EC:3.4.17.10] ko04940 Type I diabetes mellitus -0.45 0.0414 0.361087
K02187 CASP3 caspase 3 [EC:3.4.22.56] ko04010 MAPK signaling pathway; ko04115 p53 signaling pathway; ko04210 Apoptosis; ko04650 Natural killer cell mediated cytotoxicity; ko04668 TNF signaling pathway; ko04726 Serotonergic synapse; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05014 Amyotrophic lateral sclerosis (ALS); ko05016 Huntington's disease; ko05120 Epithelial cell signaling in Helicobacter pylori infection; ko05133 Pertussis; ko05134 Legionellosis; ko05145 Toxoplasmosis; ko05146 Amoebiasis; ko05152 Tuberculosis; ko05161 Hepatitis B; ko05168 Herpes simplex infection; ko05200 Pathways in cancer; ko05203 Viral carcinogenesis; ko05205 Proteoglycans in cancer; ko05206 MicroRNAs in cancer; ko05210 Colorectal cancer; ko05416 Viral myocarditis0.53 0.0068 0.322942
K04396 CASP6 caspase 6 [EC:3.4.22.59] ko04210 Apoptosis 0.56 0.0070 0.322942
K04397 CASP7 caspase 7 [EC:3.4.22.60] ko04210 Apoptosis; ko04668 TNF signaling pathway; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05133 Pertussis; ko05134 Legionellosis0.52 0.0085 0.322942
K12801 CARD8, CARDINAL caspase recruitment domain-containing protein 8 ko04621 NOD-like receptor signaling pathway -0.48 0.0296 0.356921
K09055 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05200 Pathways in cancer; ko05202 Transcriptional misregulation in cancer; ko05221 Acute myeloid leukemia0.41 0.0198 0.346585
K00720 UGCG ceramide glucosyltransferase [EC:2.4.1.80] ko00600 Sphingolipid metabolism -0.58 0.0223 0.351668
K18283 PDE2A cGMP-dependent 3',5'-cyclic phosphodiesterase [EC:3.1.4.17] NA -0.40 0.0153 0.336403
K05011 CLCN2 chloride channel 2 ko04978 Mineral absorption -0.45 0.0073 0.322942
K12408 HSD3B7 cholest-5-ene-3beta,7alpha-diol 3beta-dehydrogenase [EC:1.1.1.181] ko00120 Primary bile acid biosynthesis 0.66 0.0402 0.361087
K00489 CYP7A1 cholesterol 7alpha-monooxygenase [EC:1.14.13.17] ko00120 Primary bile acid biosynthesis; ko00140 Steroid hormone biosynthesis; ko03320 PPAR signaling pathway; ko04976 Bile secretion1.49 .0024 0.322942
K11367 CHD1 chromodomain-helicase-DNA-binding protein 1 [EC:3.6.4.12] NA -0.47 0.0116 0.327913
K05752 C3ORF10, HSPC300 chromosome 3 open reading frame 10 ko04810 Regulation of actin cytoskeleton 0.47 0.0406 0.361087
K03902 F5 coagulation factor V (labile factor) ko04610 Complement and coagulation cascades -0.49 0.0257 0.356234
K01320 F7 coagulation factor VII [EC:3.4.21.21] ko04610 Complement and coagulation cascades 0.50 0.0394 0.361087
K17513 CLEC17A C-type lectin superfamily 17 member A NA -0.43 0.0276 0.356921
K09048 CREB3 cyclic AMP-responsive element-binding protein 3 ko04151 PI3K-Akt signaling pathway; ko04668 TNF signaling pathway; ko04725 Cholinergic synapse; ko04728 Dopaminergic synapse; ko04911 Insulin secretion; ko04915 Estrogen signaling pathway; ko04916 Melanogenesis; ko04918 Thyroid hormone synthesis; ko04962 Vasopressin-regulated water reabsorption; ko05016 Huntington's disease; ko05030 Cocaine addiction; ko05031 Amphetamine addiction; ko05034 Alcoholism; ko05161 Hepatitis B; ko05203 Viral carcinogenesis; ko05215 Prostate cancer0.42 0.0021 0.320209
K01697 E4.2.1.22, CBS cystathionine beta-synthase [EC:4.2.1.22] ko00260 Glycine, serine and threonine metabolism; ko00270 Cysteine and methionine metabolism 0.42 0.0314 0.356921
K04487 iscS, NFS1 cysteine desulfurase [EC:2.8.1.7] ko00730 Thiamine metabolism; ko04122 Sulfur relay system 0.40 0.0251 0.355469
K00456 CDO1 cysteine dioxygenase [EC:1.13.11.20] ko00270 Cysteine and methionine metabolism; ko00430 Taurine and hypotaurine metabolism 0.69 0.0076 0.322942
K08342 ATG4 cysteine protease ATG4 [EC:3.4.22.-] ko04140 Regulation of autophagy 0.70 0.0312 0.356921
K17494 CSRNP cysteine/serine-rich nuclear protein NA -0.39 0.0300 0.356921
K18184 COX20 cytochrome c oxidase assembly protein subunit 20 NA -0.93 0.0053 0.322942
K02263 COX4 cytochrome c oxidase subunit 4 ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.77 0.0488 0.36668
K07416 CYP2F cytochrome P450, family 2, subfamily F [EC:1.14.14.1] ko00980 Metabolism of xenobiotics by cytochrome P450 0.42 0.0470 0.366052
K17858 CYP2X cytochrome P450, family 2, subfamily X NA 0.86 0.0368 0.356921
K07424 CYP3A cytochrome P450, family 3, subfamily A [EC:1.14.14.1] ko00140 Steroid hormone biosynthesis; ko00591 Linoleic acid metabolism; ko00627 Aminobenzoate degradation; ko00830 Retinol metabolism; ko00980 Metabolism of xenobiotics by cytochrome P450; ko00982 Drug metabolism - cytochrome P450; ko00983 Drug metabolism - other enzymes; ko05204 Chemical carcinogenesis0.45 .0413 0.361087
K00326 E1.6.2.2 cytochrome-b5 reductase [EC:1.6.2.2] ko00520 Amino sugar and nucleotide sugar metabolism 0.46 0.0329 0.356921
K16342 PLA2G4, CPLA2 cytosolic phospholipase A2 [EC:3.1.1.4] ko00564 Glycerophospholipid metabolism; ko00565 Ether lipid metabolism; ko00590 Arachidonic acid metabolism; ko00591 Linoleic acid metabolism; ko00592 alpha-Linolenic acid metabolism; ko04010 MAPK signaling pathway; ko04270 Vascular smooth muscle contraction; ko04370 VEGF signaling pathway; ko04664 Fc epsilon RI signaling pathway; ko04724 Glutamatergic synapse; ko04726 Serotonergic synapse; ko04730 Long-term depression; ko04912 GnRH signaling pathway; ko04913 Ovarian steroidogenesis-0.42 0. 48 0.322942
K01493 comEB dCMP deaminase [EC:3.5.4.12] ko00240 Pyrimidine metabolism -0.53 0.0404 0.361087
K06051 DLL delta ko04330 Notch signaling pathway -0.50 0.0047 0.322942
K00222 TM7SF2, ERG24 delta14-sterol reductase [EC:1.3.1.70] ko00100 Steroid biosynthesis -0.39 0.0462 0.364258
K11995 DNASE1L deoxyribonuclease-1-like protein [EC:3.1.21.-] NA 0.74 0.0284 0.356921
K11160 DGAT2 diacylglycerol O-acyltransferase 2 [EC:2.3.1.20 2.3.1.75] ko00561 Glycerolipid metabolism; ko04975 Fat digestion and absorption 0.80 0.0174 0.34213
K01278 DPP4 dipeptidyl-peptidase 4 [EC:3.4.14.5] ko04974 Protein digestion and absorption -0.55 0.0331 0.356921
K01597 MVD, mvaD diphosphomevalonate decarboxylase [EC:4.1.1.33] ko00900 Terpenoid backbone biosynthesis -0.63 0.0412 0.361087
K03509 POLH DNA polymerase eta [EC:2.7.7.7] ko03460 Fanconi anemia pathway -0.57 0.0436 0.361087
K03027 RPC40, POLR1C DNA-directed RNA polymerases I and III subunit RPAC1 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko04623 Cytosolic DNA-sensing pathway; ko05169 Epstein-Barr virus infection0.44 0.0424 0.361087
K03009 RPB12, POLR2K DNA-directed RNA polymerases I, II, and III subunit RPABC4 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko04623 Cytosolic DNA-sensing pathway; ko05016 Huntington's disease; ko05169 Epstein-Barr virus infection-0.38 0.0117 0.327913
K10428 DCTN6 dynactin 6 ko04962 Vasopressin-regulated water reabsorption -0.56 0.0218 0.351561
K10408 DNAH dynein heavy chain, axonemal ko05016 Huntington's disease -0.51 0.0172 0.34213
K12172 RANBP2, NUP358 E3 SUMO-protein ligase RanBP2 ko03013 RNA transport 0.40 0.0021 0.320209
K10249 ELOVL4 elongation of very long chain fatty acids protein 4 [EC:2.3.1.199] ko00062 Fatty acid elongation 0.40 0.0146 0.33425
K10244 ELOVL5 elongation of very long chain fatty acids protein 5 [EC:2.3.1.199] ko00062 Fatty acid elongation; ko01040 Biosynthesis of unsaturated fatty acids 0.53 0.0470 0.366052
K10203 ELOVL6 elongation of very long chain fatty acids protein 6 [EC:2.3.1.199] ko00062 Fatty acid elongation; ko01040 Biosynthesis of unsaturated fatty acids 1.14 0.0100 0.322942
K01415 ECE endothelin-converting enzyme [EC:3.4.24.71] NA 0.43 0.0332 0.356921
K07511 ECHS1 enoyl-CoA hydratase [EC:4.2.1.17] ko00062 Fatty acid elongation; ko00071 Fatty acid degradation; ko00280 Valine, leucine and isoleucine degradation; ko00310 Lysine degradation; ko00362 Benzoate degradation; ko00380 Tryptophan metabolism; ko00410 beta-Alanine metabolism; ko00627 Aminobenzoate degradation; ko00640 Propanoate metabolism; ko00650 Butanoate metabolism; ko00930 Caprolactam degradation0.48 0.0193 0.343412
K17277 EPS8 epidermal growth factor receptor kinase substrate 8 NA -0.52 0.0087 0.322942
K10084 EDEM1 ER degradation enhancer, mannosidase alpha-like 1 ko04141 Protein processing in endoplasmic reticulum -0.84 0.0049 0.322942
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K00894 ETNK, EKI ethanolamine kinase [EC:2.7.1.82] ko00564 Glycerophospholipid metabolism 0.85 0.0125 0.327913
K15593 ETV5 ets translocation variant 5 ko05202 Transcriptional misregulation in cancer -0.38 0.0443 0.361087
K18645 EIF4EBP3 eukaryotic translation initiation factor 4E binding protein 3 NA 0.81 0.0263 0.356414
K00787 FDPS farnesyl diphosphate synthase [EC:2.5.1.1 2.5.1.10] ko00900 Terpenoid backbone biosynthesis; ko05164 Influenza A; ko05166 HTLV-I infection -1.23 0.0036 0.322942
K02373 FADD FAS-associated death domain protein ko04210 Apoptosis; ko04620 Toll-like receptor signaling pathway; ko04622 RIG-I-like receptor signaling pathway; ko04668 TNF signaling pathway; ko05010 Alzheimer's disease; ko05142 Chagas disease (American trypanosomiasis); ko05152 Tuberculosis; ko05161 Hepatitis B; ko05168 Herpes simplex infection; ko05200 Pathways in cancer0.41 0.0193 0.343412
K10226 FADS2 fatty acid desaturase 2 (delta-6 desaturase) [EC:1.14.19.-] ko00592 alpha-Linolenic acid metabolism; ko01040 Biosynthesis of unsaturated fatty acids; ko03320 PPAR signaling pathway-0.44 0.0424 0.361087
K00665 FASN fatty acid synthase, animal type [EC:2.3.1.85] ko00061 Fatty acid biosynthesis; ko04910 Insulin signaling pathway 1.15 0.0329 0.356921
K08751 FABP2 fatty acid-binding protein 2, intestinal ko03320 PPAR signaling pathway; ko04975 Fat digestion and absorption 1.68 0.0141 0.330936
K05717 FN1 fibronectin 1 ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05146 Amoebiasis; ko05200 Pathways in cancer; ko05205 Proteoglycans in cancer; ko05222 Small cell lung cancer-0.42 0.0187 0.34213
K01930 FPGS folylpolyglutamate synthase [EC:6.3.2.17] ko00790 Folate biosynthesis 0.59 0.0111 0.327913
K03096 FRAT2 frequently rearranged in advanced T-cell lymphomas 2 ko04310 Wnt signaling pathway 0.68 0.0272 0.356732
K02133 ATPeF1B, ATP5B, ATP2F-type H+-transporting ATPase subunit beta [EC:3.6.3.14] ko00190 Oxidative phosphorylation; ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.50 0.0354 0.356921
K02135 ATPeF1E, ATP5E, ATP15F-type H+-transporting ATPase subunit epsilon ko00190 Oxidative phosphorylation; ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.47 0.0106 0.324819
K02140 ATPeFG, ATP5L, ATP20F-type H+-transporting ATPase subunit g ko00190 Oxidative phosphorylation 0.39 0.0468 0.366052
K02136 ATPeF1G, ATP5C1, ATP3F-type H+-transporting ATPase subunit gamma ko00190 Oxidative phosphorylation; ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.42 0.0188 0.34213
K01555 FAH, fahA fumarylacetoacetase [EC:3.7.1.2] ko00350 Tyrosine metabolism; ko00643 Styrene degradation 0.95 0.0401 0.361087
K08892 FRK, PTK5 fyn-related kinase [EC:2.7.10.2] NA 0.54 0.0056 0.322942
K13134 GEMIN6, SIP2 gem associated protein 6 ko03013 RNA transport -0.39 0.0237 0.354448
K01084 G6PC glucose-6-phosphatase [EC:3.1.3.9] ko00010 Glycolysis / Gluconeogenesis; ko00052 Galactose metabolism; ko00500 Starch and sucrose metabolism; ko04151 PI3K-Akt signaling pathway; ko04910 Insulin signaling pathway; ko04920 Adipocytokine signaling pathway; ko04973 Carbohydrate digestion and absorption-0.40 0.0 32 0.328024
K02366 EXT1 glucuronyl/N-acetylglucosaminyl transferase EXT1 [EC:2.4.1.224 2.4.1.225] ko00534 Glycosaminoglycan biosynthesis - heparan sulfate / heparin -1.15 0.0044 0.322942
K11205 GCLM glutamate--cysteine ligase regulatory subunit ko00480 Glutathione metabolism 0.60 0.0042 0.322942
K01196 AGL glycogen debranching enzyme [EC:2.4.1.25 3.2.1.33] ko00500 Starch and sucrose metabolism 0.42 0.0307 0.356921
K18443 GBF1 golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 NA -0.60 0.0259 0.356414
K01495 GCH1, folE GTP cyclohydrolase I [EC:3.5.4.16] ko00790 Folate biosynthesis 0.70 0.0068 0.322942
K01487 E3.5.4.3, guaD guanine deaminase [EC:3.5.4.3] ko00230 Purine metabolism 0.79 0.0037 0.322942
K03283 HSPA1_8 heat shock 70kDa protein 1/8 ko03040 Spliceosome; ko04010 MAPK signaling pathway; ko04141 Protein processing in endoplasmic reticulum; ko04144 Endocytosis; ko04612 Antigen processing and presentation; ko04915 Estrogen signaling pathway; ko05134 Legionellosis; ko05145 Toxoplasmosis; ko05162 Measles; ko05164 Influenza A; ko05169 Epstein-Barr virus infection0.53 0.0173 0.34213
K00510 HMOX, hmuO, ho heme oxygenase [EC:1.14.99.3] ko00860 Porphyrin and chlorophyll metabolism; ko04978 Mineral absorption 1.28 0.0052 0.322942
K02503 HINT1, hinT, hit histidine triad (HIT) family protein NA 0.52 0.0417 0.361087
K11253 H3 histone H3 ko05034 Alcoholism; ko05202 Transcriptional misregulation in cancer; ko05322 Systemic lupus erythematosus0.41 0.0363 0.356921
K11424 WHSC1, MMSET, NSD2histone-lysine N-methyltransferase NSD2 [EC:2.1.1.43] ko00310 Lysine degradation; ko05202 Transcriptional misregulation in cancer -0.51 0.0457 0.363386
K00451 HGD, hmgA homogentisate 1,2-dioxygenase [EC:1.13.11.5] ko00350 Tyrosine metabolism; ko00643 Styrene degradation 0.76 0.0280 0.356921
K16817 PLA2G16 HRAS-like suppressor 3 [EC:3.1.1.32 3.1.1.4] ko00564 Glycerophospholipid metabolism; ko00565 Ether lipid metabolism; ko00590 Arachidonic acid metabolism; ko00591 Linoleic acid metabolism; ko00592 alpha-Linolenic acid metabolism-0.53 0. 32 0.322942
K06092 INADL, PATJ InaD-like protein ko04390 Hippo signaling pathway; ko04530 Tight junction -0.60 0.0402 0.361087
K00463 INDO indoleamine 2,3-dioxygenase [EC:1.13.11.52] ko00380 Tryptophan metabolism; ko05143 African trypanosomiasis 0.56 0.0374 0.359115
K15046 NS1BP influenza virus NS1A-binding protein ko05164 Influenza A 0.51 0.0068 0.322942
K01107 INPP1 inositol polyphosphate 1-phosphatase [EC:3.1.3.57] ko00562 Inositol phosphate metabolism; ko04070 Phosphatidylinositol signaling system -0.41 0.0327 0.356921
K01109 INPP4 inositol polyphosphate-4-phosphatase [EC:3.1.3.66] ko00562 Inositol phosphate metabolism; ko04070 Phosphatidylinositol signaling system -0.71 0.0101 0.322942
K05459 IGF1 insulin-like growth factor 1 ko04066 HIF-1 signaling pathway; ko04114 Oocyte meiosis; ko04115 p53 signaling pathway; ko04150 mTOR signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04730 Long-term depression; ko04913 Ovarian steroidogenesis; ko04914 Progesterone-mediated oocyte maturation; ko04960 Aldosterone-regulated sodium reabsorption; ko05200 Pathways in cancer; ko05202 Transcriptional misregulation in cancer; ko05205 Proteoglycans in cancer; ko05214 Glioma; ko05215 Prostate cancer; ko05218 Melanoma; ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy0.64 0.0242 0.355 69
K05719 ITGB1 integrin beta 1 ko04145 Phagosome; ko04151 PI3K-Akt signaling pathway; ko04360 Axon guidance; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko04514 Cell adhesion molecules (CAMs); ko04670 Leukocyte transendothelial migration; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05133 Pertussis; ko05140 Leishmaniasis; ko05145 Toxoplasmosis; ko05200 Pathways in cancer; ko05205 Proteoglycans in cancer; ko05222 Small cell lung cancer; ko05410 Hypertrophic cardiomyopathy (HCM); ko05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC); ko05414 Dilated cardiomyopathy-0.42 0.0205 0.348275
K05132 IFNGR1, CD119 interferon gamma receptor 1 ko04060 Cytokine-cytokine receptor interaction; ko04066 HIF-1 signaling pathway; ko04380 Osteoclast differentiation; ko04630 Jak-STAT signaling pathway; ko04650 Natural killer cell mediated cytotoxicity; ko05132 Salmonella infection; ko05140 Leishmaniasis; ko05142 Chagas disease (American trypanosomiasis); ko05145 Toxoplasmosis; ko05152 Tuberculosis; ko05162 Measles; ko05164 Influenza A; ko05168 Herpes simplex infection; ko05321 Inflammatory bowel disease (IBD)-0.72 0.0044 0.322942
K05076 IL13RA1 interleukin 13 receptor alpha-1 ko04060 Cytokine-cytokine receptor interaction; ko04630 Jak-STAT signaling pathway -0.47 0.0403 0.361087
K05055 IL6R interleukin 6 receptor ko04060 Cytokine-cytokine receptor interaction; ko04066 HIF-1 signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04630 Jak-STAT signaling pathway; ko04640 Hematopoietic cell lineage; ko04932 Non-alcoholic fatty liver disease (NAFLD)-0.50 0.0093 0. 22942
K05050 IL8RB, CXCR2 interleukin 8 receptor beta ko04060 Cytokine-cytokine receptor interaction; ko04062 Chemokine signaling pathway; ko04144 Endocytosis; ko05120 Epithelial cell signaling in Helicobacter pylori infection-0.51 0. 144 0.333013
K01823 idi, IDI isopentenyl-diphosphate delta-isomerase [EC:5.3.3.2] ko00900 Terpenoid backbone biosynthesis -0.91 0.0232 0.353307
K00253 IVD, ivd isovaleryl-CoA dehydrogenase [EC:1.3.8.4] ko00280 Valine, leucine and isoleucine degradation 0.53 0.0176 0.34213
K03898 KNG kininogen ko04610 Complement and coagulation cascades -0.41 0.0156 0.337954
K09228 KRAB KRAB domain-containing zinc finger protein NA -0.72 0.0035 0.322942
K09208 KLF9S, BTEB krueppel-like factor 9/13/14/16 NA 0.99 0.0049 0.322942
K01852 E5.4.99.7, LSS, ERG7 lanosterol synthase [EC:5.4.99.7] ko00100 Steroid biosynthesis -0.42 0.0410 0.361087
K00227 SC5DL, ERG3 lathosterol oxidase [EC:1.14.21.6] ko00100 Steroid biosynthesis -0.42 0.0355 0.356921
K02431 fucU, FUOM L-fucose mutarotase [EC:5.1.3.29] NA -0.39 0.0372 0.359115
K15013 ACSBG long-chain-fatty-acid--CoA ligase ACSBG [EC:6.2.1.3] ko00071 Fatty acid degradation; ko03320 PPAR signaling pathway; ko04920 Adipocytokine signaling pathway 1.34 0.0022 0.320209
K03159 TNFRSF3, LTBR lymphotoxin beta receptor TNFR superfamily member 3 ko04060 Cytokine-cytokine receptor interaction; ko04064 NF-kappa B signaling pathway; ko04066 HIF-1 signaling pathway; ko04672 Intestinal immune network for IgA production; ko05166 HTLV-I infection; ko05203 Viral carcinogenesis-0.49 0.0457 0.3 3326
K04294 LPAR3, EDG7 lysophosphatidic acid receptor 3 ko04080 Neuroactive ligand-receptor interaction; ko04151 PI3K-Akt signaling pathway -0.99 0.0182 0.34213
K12387 LAPTM lysosomal-associated transmembrane protein ko04142 Lysosome -0.38 0.0314 0.356921
K13646 PLOD3 lysyl hydroxylase/galactosyltransferase/glucosyltransferase [EC:1.14.11.4 2.4 ko00310 Lysine degradation; ko00514 Other types of O-glycan biosynthesis -1.29 0.0028 0.322942
K04679 MADHIP, SARA MAD, mothers against decapentaplegic interacting protein ko04144 Endocytosis; ko04350 TGF-beta signaling pathway -0.45 0.0226 0.351668
K09262 MEF2D MADS-box transcription enhancer factor 2D NA -0.68 0.0049 0.322942
K00029 E1.1.1.40, maeB malate dehydrogenase (oxaloacetate-decarboxylating)(NADP+) [EC:1.1. ko00620 Pyruvate metabolism; ko00710 Carbon fixation in photosynthetic organisms 0.94 0.0158 0.337954
K00140 mmsA, iolA, ALDH6A1 malonate-semialdehyde dehydrogenase (acetylating) / methylmalon ko00280 Valine, leucine and isoleucine degradation; ko00410 beta-Alanine metabolism; ko00562 Inositol phosphate metabolism; ko00640 Propanoate metabolism0.76 0.0019 0.320209
K06560 MRC mannose receptor, C type ko04145 Phagosome; ko05152 Tuberculosis -0.52 0.0233 0.353307
K07994 MMP13 matrix metalloproteinase-13 (collagenase 3) [EC:3.4.24.-] NA -1.35 0.0263 0.356414
K08001 MMP23 matrix metalloproteinase-23 (CA-MMP) [EC:3.4.24.-] NA 0.50 0.0313 0.356921
K01394 MMP3 matrix metalloproteinase-3 (stromelysin 1, progelatinase) [EC:3.4.24.17] ko04668 TNF signaling pathway; ko05202 Transcriptional misregulation in cancer; ko05323 Rheumatoid arthritis-1.32 0.0232 0.353307
K01403 MMP9 matrix metalloproteinase-9 (gelatinase B) [EC:3.4.24.35] ko04668 TNF signaling pathway; ko04670 Leukocyte transendothelial migration; ko04915 Estrogen signaling pathway; ko05161 Hepatitis B; ko05200 Pathways in cancer; ko05202 Transcriptional misregulation in cancer; ko05205 Proteoglycans in cancer; ko05206 MicroRNAs in cancer; ko05219 Bladder cancer-1.31 0.0164 0.339247
K05607 AUH methylglutaconyl-CoA hydratase [EC:4.2.1.18] ko00280 Valine, leucine and isoleucine degradation 0.42 0.0386 0.359621
K00869 E2.7.1.36, MVK, mvaK1mevalonate kinase [EC:2.7.1.36] ko00900 Terpenoid backbone biosynthesis; ko04146 Peroxisome -0.71 0.0024 0.322942
K14463 MTTP, MTP microsomal triglyceride transfer protein large subunit ko04975 Fat digestion and absorption 0.79 0.0117 0.327913
K17885 MTCH mitochondrial carrier NA 0.42 0.0344 0.356921
K17781 TIM13 mitochondrial import inner membrane translocase subunit TIM13 NA -0.40 0.0360 0.356921
K17804 TIM44 mitochondrial import inner membrane translocase subunit TIM44 NA 0.64 0.0193 0.343412
K17732 PMPCB, MAS1 mitochondrial-processing peptidase subunit beta [EC:3.4.24.64] NA 0.59 0.0111 0.327913
K02539 MCL1 myeloid leukemia cell differntiation protein MCL-1 ko04151 PI3K-Akt signaling pathway; ko05206 MicroRNAs in cancer 0.68 0.0001 0.285374
K12751 MYL6 myosin light chain 6 ko04270 Vascular smooth muscle contraction -0.53 0.0090 0.322942
K12757 MYL12 myosin regulatory light chain 12 ko04510 Focal adhesion; ko04530 Tight junction; ko04670 Leukocyte transendothelial migration; ko04810 Regulation of actin cytoskeleton0.56 0.0129 0.328024
K03375 SIAT7E, ST6GalNAc V N-acetylgalactosaminide alpha-2,6-sialyltransferase (sialyltran ko00604 Glycosphingolipid biosynthesis - ganglio series -0.44 0.0124 0.327913
K00781 SIAT6 N-acetyllactosaminide alpha-2,3-sialyltransferase (sialyltransferase 6) [EC:2 ko00513 Various types of N-glycan biosynthesis; ko00514 Other types of O-glycan biosynthesis; ko00533 Glycosaminoglycan biosynthesis - keratan sulfate; ko00601 Glycosphingolipid biosynthesis - lacto and neolacto series-0.59 0.0038 0.322942
K18458 ACY3 N-acyl-aromatic-L-amino acid amidohydrolase [EC:3.5.1.114] NA 0.47 0.0172 0.34213
K00775 E2.4.2.31, ART NAD(P)-arginine ADP-ribosyltransferase [EC:2.4.2.31] NA -0.56 0.0214 0.348275
K00858 ppnK, NADK NAD+ kinase [EC:2.7.1.23] ko00760 Nicotinate and nicotinamide metabolism -0.60 0.0056 0.322942
K03957 NDUFB1 NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 1 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.43 0.0342 0.356921
K03963 NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 7 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.38 0.0356 0.356921
K03968 NDUFC2 NADH dehydrogenase (ubiquinone) 1 subunit C2 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.47 0.0423 0.361087
K03936 NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3 [EC:1.6.5.3 1.6.99.3] ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.47 0.0314 0.356921
K08008 NOX, GP91 NADPH oxidase ko04066 HIF-1 signaling pathway; ko04145 Phagosome; ko04380 Osteoclast differentiation; ko04670 Leukocyte transendothelial migration-0.44 0.0157 0.337954
K05750 NCKAP1, NAP125 NCK-associated protein 1 ko04810 Regulation of actin cytoskeleton -0.43 0.0102 0.322942
K06757 NFASC neurofascin ko04514 Cell adhesion molecules (CAMs) -0.44 0.0194 0.343412
K08011 NCF1, P47PHOX neutrophil cytosolic factor 1 ko04062 Chemokine signaling pathway; ko04145 Phagosome; ko04380 Osteoclast differentiation; ko04666 Fc gamma R-mediated phagocytosis; ko04670 Leukocyte transendothelial migration; ko05140 Leishmaniasis-1.11 0.0077 0.322942
K00767 nadC, QPRT nicotinate-nucleotide pyrophosphorylase (carboxylating) [EC:2.4.2.19] ko00760 Nicotinate and nicotinamide metabolism -0.56 0.0010 0.320209
K14461 NPC1L1 Niemann-Pick C1-like protein 1 ko04975 Fat digestion and absorption -0.48 0.0320 0.356921
K18764 CCRN4L nocturnin [EC:3.1.13.4] NA -0.50 0.0243 0.355469
K17108 GBA2 non-lysosomal glucosylceramidase [EC:3.2.1.45] ko00511 Other glycan degradation; ko00600 Sphingolipid metabolism -0.57 0.0338 0.356921
K14537 NUG2, GNL2 nuclear GTP-binding protein ko03008 Ribosome biogenesis in eukaryotes -0.39 0.0286 0.356921
K14302 NUP37 nuclear pore complex protein Nup37 ko03013 RNA transport -0.50 0.0384 0.359115
K08064 NFYA nuclear transcription factor Y, alpha ko04612 Antigen processing and presentation; ko05152 Tuberculosis -0.50 0.0035 0.322942
K03768 PPIB, ppiB peptidyl-prolyl cis-trans isomerase B (cyclophilin B) [EC:5.2.1.8] NA -0.44 0.0452 0.363326
K13279 PRDX1 peroxiredoxin 1 [EC:1.11.1.15] ko04146 Peroxisome 0.45 0.0093 0.322942
K17594 PHACTR3 phosphatase and actin regulator 3 NA -1.66 0.0073 0.322942
K19404 LIPH_I phosphatidic acid-selective&#160 NA 0.42 0.0304 0.356921
K01079 serB, PSPH phosphoserine phosphatase [EC:3.1.3.3] ko00260 Glycine, serine and threonine metabolism; ko00680 Methane metabolism 0.53 0.0432 0.361087
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K01062 PAFAH platelet-activating factor acetylhydrolase [EC:3.1.1.47] ko00565 Ether lipid metabolism 0.39 0.0316 0.356921
K12862 PLRG1, PRL1, PRP46 pleiotropic regulator 1 ko03040 Spliceosome -0.41 0.0354 0.356921
K04917 KCNK6 potassium channel subfamily K member 6 NA 0.43 0.0275 0.356921
K00318 PRODH proline dehydrogenase [EC:1.5.-.-] ko00330 Arginine and proline metabolism -0.62 0.0120 0.327913
K14443 TOB protein Tob/BTG ko03018 RNA degradation 0.46 0.0044 0.322942
K18041 PTP4A protein tyrosine phosphatase type IVA [EC:3.1.3.48] NA -0.44 0.0033 0.322942
K00573 E2.1.1.77, pcm protein-L-isoaspartate(D-aspartate) O-methyltransferase [EC:2.1.1.77 NA 0.60 0.0480 0.366158
K01021 TPST protein-tyrosine sulfotransferase [EC:2.8.2.20] NA 0.60 0.0060 0.322942
K05762 RDX radixin ko04810 Regulation of actin cytoskeleton; ko05205 Proteoglycans in cancer; ko05206 MicroRNAs in cancer 0.72 0.0206 0.348275
K07855 RERG Ras-related and estrogen-regulated growth inhibitor NA 0.46 0.0237 0.354448
K06109 RAB13 Ras-related protein Rab-13 ko04530 Tight junction -0.39 0.0469 0.366052
K08847 RIPK3 receptor-interacting serine/threonine-protein kinase 3 [EC:2.7.11.1] ko04623 Cytosolic DNA-sensing pathway; ko04668 TNF signaling pathway -0.45 0.0104 0.322942
K06778 PTPRS receptor-type tyrosine-protein phosphatase S [EC:3.1.3.48] NA -0.43 0.0105 0.322942
K10754 RFC1 replication factor C subunit 1 ko03030 DNA replication; ko03420 Nucleotide excision repair; ko03430 Mismatch repair -0.45 0.0184 0.34213
K08526 NR2B3, RXRG retinoid X receptor gamma ko03320 PPAR signaling pathway; ko04920 Adipocytokine signaling pathway; ko05200 Pathways in cancer; ko05202 Transcriptional misregulation in cancer; ko05216 Thyroid cancer; ko05222 Small cell lung cancer; ko05223 Non-small cell lung cancer0.54 0.0163 0.339247
K03539 RPP1, RPP30 ribonuclease P/MRP protein subunit RPP1 [EC:3.1.26.5] ko03008 Ribosome biogenesis in eukaryotes; ko03013 RNA transport 0.63 0.0125 0.327913
K14000 RRBP1 ribosome-binding protein 1 ko04141 Protein processing in endoplasmic reticulum -0.63 0.0204 0.348275
K15216 RRN3, TIFIA RNA polymerase I-specific transcription initiation factor RRN3 NA -0.60 0.0214 0.348275
K14411 MSI RNA-binding protein Musashi ko03015 mRNA surveillance pathway -0.46 0.0090 0.322942
K00789 metK S-adenosylmethionine synthetase [EC:2.5.1.6] ko00270 Cysteine and methionine metabolism -0.59 0.0177 0.34213
K00314 SARDH sarcosine dehydrogenase [EC:1.5.8.3] ko00260 Glycine, serine and threonine metabolism 0.65 0.0082 0.322942
K14381 SQSTM1 sequestosome 1 ko04380 Osteoclast differentiation 0.58 0.0195 0.343412
K00654 SPT serine palmitoyltransferase [EC:2.3.1.50] ko00600 Sphingolipid metabolism -0.45 0.0134 0.328871
K16312 STK40, SHIK serine/threonine-protein kinase 40 [EC:2.7.11.1] NA -0.61 0.0081 0.322942
K02977 RP-S27Ae, RPS27A small subunit ribosomal protein S27Ae ko03010 Ribosome -0.45 0.0087 0.322942
K02978 RP-S27e, RPS27 small subunit ribosomal protein S27e ko03010 Ribosome -0.71 0.0128 0.328024
K17409 MRPS30 small subunit ribosomal protein S30 NA 0.41 0.0156 0.337954
K17412 MRPS34 small subunit ribosomal protein S34 NA 0.42 0.0249 0.355469
K02993 RP-S7e, RPS7 small subunit ribosomal protein S7e ko03010 Ribosome 0.54 0.0291 0.356921
K05855 SYK spleen tyrosine kinase [EC:2.7.10.2] ko04064 NF-kappa B signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04380 Osteoclast differentiation; ko04650 Natural killer cell mediated cytotoxicity; ko04662 B cell receptor signaling pathway; ko04664 Fc epsilon RI signaling pathway; ko04666 Fc gamma R-mediated phagocytosis; ko05152 Tuberculosis; ko05169 Epstein-Barr virus infection; ko05203 Viral carcinogenesis-0.40 0.0081 0.322942
K13219 SFPQ, PSF splicing factor, proline- and glutamine-rich NA -0.70 0.0080 0.322942
K00511 SQLE, ERG1 squalene monooxygenase [EC:1.14.13.132] ko00909 Sesquiterpenoid and triterpenoid biosynthesis -0.44 0.0068 0.322942
K00507 SCD, desC stearoyl-CoA desaturase (delta-9 desaturase) [EC:1.14.19.1] ko01040 Biosynthesis of unsaturated fatty acids; ko03320 PPAR signaling pathway 1.04 0.0013 0.320209
K05917 CYP51 sterol 14-demethylase [EC:1.14.13.70] ko00100 Steroid biosynthesis -0.89 0.0105 0.322942
K06669 SMC3, CSPG6 structural maintenance of chromosome 3 (chondroitin sulfate proteoglyca ko04110 Cell cycle; ko04111 Cell cycle - yeast; ko04113 Meiosis - yeast; ko04114 Oocyte meiosis -0.65 0.0078 0.322942
K00237 SDHD, SDH4 succinate dehydrogenase (ubiquinone) membrane anchor subunit ko00020 Citrate cycle (TCA cycle); ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.48 0.0222 .351668
K17254 SDCBP syntenin-1 NA -0.67 0.0111 0.327913
K00384 trxB thioredoxin reductase (NADPH) [EC:1.8.1.9] ko00240 Pyrimidine metabolism; ko00450 Selenocompound metabolism 0.68 0.0001 0.285374
K07754 DIO3 thyroxine 5-deiodinase [EC:1.97.1.11] NA 0.65 0.0338 0.356921
K12567 TTN titin [EC:2.7.11.1] ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy -0.92 0.0364 0.356921
K00616 E2.2.1.2, talA, talB transaldolase [EC:2.2.1.2] ko00030 Pentose phosphate pathway 0.56 0.0492 0.36668
K09275 TFCP2 transcription factor CP2 and related proteins NA 0.42 0.0356 0.356921
K16796 SOX2 transcription factor SOX2 (SOX group B) ko04390 Hippo signaling pathway -0.40 0.0260 0.356414
K00615 E2.2.1.1, tktA, tktB transketolase [EC:2.2.1.1] ko00030 Pentose phosphate pathway; ko00710 Carbon fixation in photosynthetic organisms; ko01051 Biosynthesis of ansamycins0.61 0.0016 0.320209
K03113 EIF1, SUI1 translation initiation factor 1 ko03013 RNA transport -0.48 0.0263 0.356414
K03254 EIF3A translation initiation factor 3 subunit A ko03013 RNA transport -0.49 0.0347 0.356921
K03247 EIF3H translation initiation factor 3 subunit H ko03013 RNA transport; ko05162 Measles 0.87 0.0264 0.356414
K03262 EIF5 translation initiation factor 5 ko03013 RNA transport 0.52 0.0098 0.322942
K01046 E3.1.1.3 triacylglycerol lipase [EC:3.1.1.3] ko00561 Glycerolipid metabolism -0.99 0.0049 0.322942
K12015 TRIM39 tripartite motif-containing protein 39 [EC:6.3.2.19] NA -0.50 0.0427 0.361087
K12034 TRIM69 tripartite motif-containing protein 69 [EC:6.3.2.19] NA -0.72 0.0097 0.322942
K10375 TPM4 tropomyosin 4 ko04260 Cardiac muscle contraction; ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy0.44 0.0207 0.348275
K05865 TNNC1 troponin C, slow skeletal and cardiac muscles ko04020 Calcium signaling pathway; ko04260 Cardiac muscle contraction; ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy-0.39 0.0004 0.285374
K17262 TBCB, CKAP1, ALF1 tubulin-folding cofactor B NA 0.47 0.0091 0.322942
K05147 CD265, TNFRSF11A tumor necrosis factor receptor superfamily, member 11a, activator ko04060 Cytokine-cytokine receptor interaction; ko04064 NF-kappa B signaling pathway; ko04380 Osteoclast differentiation; ko04917 Prolactin signaling pathway; ko05323 Rheumatoid arthritis-0.87 0.0019 0.320209
K06737 TACSTD1 tumor-associated calcium signal transducer 1 NA 0.38 0.0251 0.355469
K12842 SR140 U2-associated protein SR140 ko03040 Spliceosome -0.45 0.0267 0.356414
K12626 LSM7 U6 snRNA-associated Sm-like protein LSm7 ko03018 RNA degradation; ko03040 Spliceosome -0.54 0.0198 0.346585
K08770 UBC ubiquitin C ko03320 PPAR signaling pathway -0.57 0.0180 0.34213
K10596 UBE4A ubiquitin conjugation factor E4 A [EC:6.3.2.19] ko04120 Ubiquitin mediated proteolysis -0.50 0.0158 0.337954
K14016 UFD1 ubiquitin fusion degradation protein 1 ko04141 Protein processing in endoplasmic reticulum 0.38 0.0372 0.359115
K06689 UBE2D_E, UBC4, UBC5 ubiquitin-conjugating enzyme E2 D/E [EC:6.3.2.19] ko04120 Ubiquitin mediated proteolysis; ko04141 Protein processing in endoplasmic reticulum -0.44 0.0075 0.322942
K14012 SHP1, UBX1, NSFL1C UBX domain-containing protein 1 ko04141 Protein processing in endoplasmic reticulum 0.40 0.0364 0.356921
K00365 uaZ urate oxidase [EC:1.7.3.3] ko00230 Purine metabolism; ko00232 Caffeine metabolism 0.77 0.0326 0.356921
K00757 udp, UPP uridine phosphorylase [EC:2.4.2.3] ko00240 Pyrimidine metabolism; ko00983 Drug metabolism - other enzymes 0.88 0.0451 0.363326
K01348 PLAU urokinase plasminogen activator [EC:3.4.21.73] ko04064 NF-kappa B signaling pathway; ko04610 Complement and coagulation cascades; ko05202 Transcriptional misregulation in cancer; ko05205 Proteoglycans in cancer; ko05206 MicroRNAs in cancer-0.50 0.0090 0.322942
K15040 VDAC2 voltage-dependent anion channel protein 2 ko04020 Calcium signaling pathway; ko05012 Parkinson's disease; ko05016 Huntington's disease; ko05166 HTLV-I infection0.52 0.0488 0.36668
K02144 ATPeV1H V-type H+-transporting ATPase subunit H ko00190 Oxidative phosphorylation; ko04142 Lysosome; ko04145 Phagosome; ko04721 Synaptic vesicle cycle; ko05110 Vibrio cholerae infection; ko05120 Epithelial cell signaling in Helicobacter pylori infection; ko05152 Tuberculosis; ko05323 Rheumatoid arthritis0.38 0.0350 0.356921
K13128 ZCCHC8 zinc finger CCHC domain-containing protein 8 NA -0.62 0.0365 0.356921
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KOID Gene Abbreviation KEGG Annotation Class Log Fold Change P Value adj P Val
K00725 B4GALNT1, GALGT (N-Acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosami ko00604 Glycosphingolipid biosynthesis - ganglio series 1.00 0.0194 0.401932
K11517 HAO (S)-2-hydroxy-acid oxidase [EC:1.1.3.15] ko00630 Glyoxylate and dicarboxylate metabolism; ko04146 Peroxisome -0.48 0.0166 0.398783
K02731 PSMA7 20S proteasome subunit alpha 4 [EC:3.4.25.1] ko03050 Proteasome 0.39 0.0370 0.437297
K02741 PSMB9, LMP2 20S proteasome subunit beta 9 [EC:3.4.25.1] ko03050 Proteasome -2.05 0.0062 0.398783
K06692 PSMD5 26S proteasome non-ATPase regulatory subunit 5 NA -0.59 0.0093 0.398783
K03030 PSMD14, RPN11, POH1 26S proteasome regulatory subunit N11 ko03050 Proteasome; ko05169 Epstein-Barr virus infection 0.49 0.0133 0.398783
K05692 ACTB_G1 actin beta/gamma 1 ko04145 Phagosome; ko04390 Hippo signaling pathway; ko04391 Hippo signaling pathway - fly; ko04510 Focal adhesion; ko04520 Adherens junction; ko04530 Tight junction; ko04670 Leukocyte transendothelial migration; ko04745 Phototransduction - fly; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05110 Vibrio cholerae infection; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05132 Salmonella infection; ko05164 Influenza A; ko05205 Proteoglycans in cancer; ko05410 Hypertrophic cardiomyopathy (HCM); ko05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC); ko05414 Dilated cardiomyopathy; ko05416 Viral myocarditis0.53 0.0250 0.422862
K05756 ARPC3 actin related protein 2/3 complex, subunit 3 ko04666 Fc gamma R-mediated phagocytosis; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05132 Salmonella infection0.67 0.0022 0.382122
K05699 ACTN actinin alpha ko04510 Focal adhesion; ko04520 Adherens junction; ko04530 Tight junction; ko04670 Leukocyte transendothelial migration; ko04810 Regulation of actin cytoskeleton; ko05146 Amoebiasis; ko05203 Viral carcinogenesis; ko05322 Systemic lupus erythematosus; ko05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC)0.70 0.0033 0.382122
K12417 ACOT11 acyl-CoA thioesteraes 11 [EC:3.1.2.-] NA -0.52 0.0275 0.436634
K01512 acyP acylphosphatase [EC:3.6.1.7] ko00620 Pyruvate metabolism; ko00627 Aminobenzoate degradation -0.46 0.0057 0.398783
K08047 ADCY7 adenylate cyclase 7 [EC:4.6.1.1] ko00230 Purine metabolism; ko04020 Calcium signaling pathway; ko04062 Chemokine signaling pathway; ko04114 Oocyte meiosis; ko04270 Vascular smooth muscle contraction; ko04540 Gap junction; ko04713 Circadian entrainment; ko04723 Retrograde endocannabinoid signaling; ko04724 Glutamatergic synapse; ko04725 Cholinergic synapse; ko04727 GABAergic synapse; ko04911 Insulin secretion; ko04912 GnRH signaling pathway; ko04913 Ovarian steroidogenesis; ko04914 Progesterone-mediated oocyte maturation; ko04915 Estrogen signaling pathway; ko04916 Melanogenesis; ko04918 Thyroid hormone synthesis; ko04970 Salivary secretion; ko04971 Gastric acid secretion; ko04972 Pancreatic secretion; ko04976 Bile secretion; ko05032 Morphine addiction; ko05166 HTLV-I infection; ko05414 Dilated cardiomyopathy0.38 0.0223 0.411219
K18532 AK6, FAP7 adenylate kinase [EC:2.7.4.3] NA -0.65 0.0019 0.382122
K07296 ACDC adiponectin ko03320 PPAR signaling pathway; ko04920 Adipocytokine signaling pathway; ko04930 Type II diabetes mellitus; ko04932 Non-alcoholic fatty liver disease (NAFLD)-0.88 0.0188 . 01932
K01242 CD38 ADP-ribosyl cyclase 1 [EC:3.2.2.6 2.4.99.20] ko00760 Nicotinate and nicotinamide metabolism; ko04020 Calcium signaling pathway; ko04970 Salivary secretion; ko04972 Pancreatic secretion; ko05169 Epstein-Barr virus infection-0.41 0.0001 0.357271
K01872 AARS, alaS alanyl-tRNA synthetase [EC:6.1.1.7] ko00970 Aminoacyl-tRNA biosynthesis 0.55 0.0483 0.457001
K03910 A2M alpha-2-macroglobulin ko04610 Complement and coagulation cascades 0.64 0.0032 0.382122
K10331 ASB9 ankyrin repeat and SOCS box protein 9 NA 0.43 0.0275 0.436634
K17092 ANXA2 annexin A2 NA -0.70 0.0061 0.398783
K19502 ANO8, TMEM16H anoctamin-8 NA 0.62 0.0118 0.398783
K01887 RARS, argS arginyl-tRNA synthetase [EC:6.1.1.19] ko00970 Aminoacyl-tRNA biosynthesis 0.43 0.0189 0.401932
K01893 NARS, asnS asparaginyl-tRNA synthetase [EC:6.1.1.22] ko00970 Aminoacyl-tRNA biosynthesis 0.58 0.0382 0.440055
K05655 ABCB8 ATP-binding cassette, subfamily B (MDR/TAP), member 8 ko02010 ABC transporters 0.41 0.0142 0.398783
K12823 DDX5, DBP2 ATP-dependent RNA helicase DDX5/DBP2 [EC:3.6.4.13] ko03040 Spliceosome; ko05202 Transcriptional misregulation in cancer; ko05205 Proteoglycans in cancer1.05 0.0136 0.398783
K11481 AURKA aurora kinase A [EC:2.7.11.1] ko04114 Oocyte meiosis 0.59 0.0399 0.442356
K08331 ATG13 autophagy-related protein 13 ko04140 Regulation of autophagy -0.40 0.0398 0.442356
K03766 B3GNT5 beta-1,3-N-acetylglucosaminyltransferase 5 [EC:2.4.1.206] ko00601 Glycosphingolipid biosynthesis - lacto and neolacto series 0.87 0.0193 0.401932
K06712 BTN butyrophilin NA -0.99 0.0238 0.41936
K01948 CPS1 carbamoyl-phosphate synthase (ammonia) [EC:6.3.4.16] ko00250 Alanine, aspartate and glutamate metabolism; ko00330 Arginine and proline metabolism; ko00910 Nitrogen metabolism0.49 0.0027 0.382122
K03927 CES2 carboxylesterase 2 [EC:3.1.1.1 3.1.1.84 3.1.1.56] ko00983 Drug metabolism - other enzymes -0.45 0.0335 0.436634
K13049 PM20D1 carboxypeptidase PM20D1 [EC:3.4.17.-] NA -0.42 0.0251 0.422862
K08766 CPT2 carnitine O-palmitoyltransferase 2 [EC:2.3.1.21] ko00071 Fatty acid degradation; ko03320 PPAR signaling pathway 0.40 0.0194 0.401932
K04396 CASP6 caspase 6 [EC:3.4.22.59] ko04210 Apoptosis 0.50 0.0149 0.398783
K06454 CD4 CD4 antigen ko04514 Cell adhesion molecules (CAMs); ko04612 Antigen processing and presentation; ko04640 Hematopoietic cell lineage; ko04660 T cell receptor signaling pathway; ko05340 Primary immunodeficiency-0.62 0.0264 0.432607
K15360 STRA13, CENPX, MHF2 centromere protein X ko03460 Fanconi anemia pathway 0.39 0.0314 0.436634
K03998 C8B complement component 8 subunit beta ko04610 Complement and coagulation cascades; ko05020 Prion diseases; ko05146 Amoebiasis; ko05322 Systemic lupus erythematosus0.55 0.0261 0.432086
K06626 CCNE cyclin E ko04110 Cell cycle; ko04114 Oocyte meiosis; ko04115 p53 signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04391 Hippo signaling pathway - fly; ko05161 Hepatitis B; ko05162 Measles; ko05200 Pathways in cancer; ko05203 Viral carcinogenesis; ko05206 MicroRNAs in cancer; ko05215 Prostate cancer; ko05222 Small cell lung cancer0.40 0.0080 0.398783
K01697 E4.2.1.22, CBS cystathionine beta-synthase [EC:4.2.1.22] ko00260 Glycine, serine and threonine metabolism; ko00270 Cysteine and methionine metabolism-0.53 0.0076 0.398783
K02266 COX6A cytochrome c oxidase subunit 6a ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.65 0.0057 0.398783
K07408 CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 [EC:1.14.14.1] ko00140 Steroid hormone biosynthesis; ko00380 Tryptophan metabolism; ko00830 Retinol metabolism; ko00980 Metabolism of xenobiotics by cytochrome P450; ko04913 Ovarian steroidogenesis; ko05204 Chemical carcinogenesis-1.03 0. 149 0.398783
K17854 CYP2K cytochrome P450, family 2, subfamily K NA -0.52 0.0219 0.410937
K17951 CYP27C cytochrome P450, family 27, subfamily C NA 0.41 0.0119 0.398783
K00058 serA, PHGDH D-3-phosphoglycerate dehydrogenase [EC:1.1.1.95] ko00260 Glycine, serine and threonine metabolism; ko00680 Methane metabolism 1.55 0.0035 0.382122
K13989 DERL2_3 Derlin-2/3 ko04141 Protein processing in endoplasmic reticulum 0.55 0.0495 0.457001
K01277 DPP3 dipeptidyl-peptidase III [EC:3.4.14.4] NA 0.51 0.0214 0.409019
K05125 DDR2, TKT discoidin domain receptor family member 2 [EC:2.7.10.1] NA 0.43 0.0146 0.398783
K03509 POLH DNA polymerase eta [EC:2.7.7.7] ko03460 Fanconi anemia pathway 0.69 0.0168 0.398783
K02333 POLG2 DNA polymerase gamma 2 NA -0.43 0.0297 0.436634
K02331 POL5, MYBBP1A DNA polymerase phi [EC:2.7.7.7] NA 0.51 0.0108 0.398783
K03015 RPB7, POLR2G DNA-directed RNA polymerase II subunit RPB7 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko05016 Huntington's disease; ko05169 Epstein-Barr virus infection0.42 0.0115 0.398783
K09504 DNAJA3 DnaJ homolog subfamily A member 3 ko05203 Viral carcinogenesis -0.40 0.0329 0.436634
K12232 HECTD2 E3 ubiquitin-protein ligase HECTD2 [EC:6.3.2.19] NA -0.50 0.0454 0.457001
K17277 EPS8 epidermal growth factor receptor kinase substrate 8 NA 0.43 0.0280 0.436634
K15592 ETV4 ets translocation variant 4 ko05202 Transcriptional misregulation in cancer 0.43 0.0290 0.436634
K06110 EXOC3, SEC6L1 exocyst complex component 3 ko04530 Tight junction -0.46 0.0208 0.406265
K10292 FBXO5, EMI1 F-box protein 5 ko04114 Oocyte meiosis 0.53 0.0122 0.398783
K00522 FTH1 ferritin heavy chain [EC:1.16.3.2] ko00860 Porphyrin and chlorophyll metabolism; ko04978 Mineral absorption -0.53 0.0379 0.440055
K03904 FGB fibrinogen beta chain ko04610 Complement and coagulation cascades 0.92 0.0368 0.437297
K09571 FKBP4_5 FK506-binding protein 4/5 [EC:5.2.1.8] ko04915 Estrogen signaling pathway 0.52 0.0139 0.398783
K03841 FBP, fbp fructose-1,6-bisphosphatase I [EC:3.1.3.11] ko00010 Glycolysis / Gluconeogenesis; ko00030 Pentose phosphate pathway; ko00051 Fructose and mannose metabolism; ko00680 Methane metabolism; ko00710 Carbon fixation in photosynthetic organisms; ko04910 Insulin signaling pathway-0.96 0.0383 0.440055
K02132 ATPeF1A, ATP5A1, ATP1 F-type H+-transporting ATPase subunit alpha ko00190 Oxidative phosphorylation; ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.44 0.0110 0.398783
K00849 galK galactokinase [EC:2.7.1.6] ko00052 Galactose metabolism; ko00520 Amino sugar and nucleotide sugar metabolism 0.51 0.0046 0.398783
K00699 UGT glucuronosyltransferase [EC:2.4.1.17] ko00040 Pentose and glucuronate interconversions; ko00053 Ascorbate and aldarate metabolism; ko00140 Steroid hormone biosynthesis; ko00500 Starch and sucrose metabolism; ko00830 Retinol metabolism; ko00860 Porphyrin and chlorophyll metabolism; ko00980 Metabolism of xenobiotics by cytochrome P450; ko00982 Drug metabolism - cytochrome P450; ko00983 Drug metabolism - other enzymes; ko05204 Chemical carcinogenesis0.59 0.0305 0.436634
K00261 GLUD1_2, gdhA glutamate dehydrogenase (NAD(P)+) [EC:1.4.1.3] ko00250 Alanine, aspartate and glutamate metabolism; ko00330 Arginine and proline metabolism; ko00471 D-Glutamine and D-glutamate metabolism; ko00910 Nitrogen metabolism; ko04964 Proximal tubule bicarbonate reclamation-0.45 0.0140 0.398783
K11204 GCLC glutamate--cysteine ligase catalytic subunit [EC:6.3.2.2] ko00480 Glutathione metabolism -0.46 0.0028 0.382122
K01915 glnA, GLUL glutamine synthetase [EC:6.3.1.2] ko00250 Alanine, aspartate and glutamate metabolism; ko00330 Arginine and proline metabolism; ko00630 Glyoxylate and dicarboxylate metabolism; ko00910 Nitrogen metabolism; ko02020 Two-component system; ko04724 Glutamatergic synapse; ko04727 GABAergic synapse0.73 0.0005 0.382122
K00252 GCDH, gcdH glutaryl-CoA dehydrogenase [EC:1.3.8.6] ko00071 Fatty acid degradation; ko00310 Lysine degradation; ko00380 Tryptophan metabolism -0.73 0.0318 0.436634
K15839 GPSM1, AGS3 G-protein signaling modulator 1 ko05030 Cocaine addiction -0.39 0.0092 0.398783
K04534 GNAO, G-ALPHA-O guanine nucleotide-binding protein G(o) subunit alpha ko04713 Circadian entrainment; ko04723 Retrograde endocannabinoid signaling; ko04724 Glutamatergic synapse; ko04725 Cholinergic synapse; ko04726 Serotonergic synapse; ko04727 GABAergic synapse; ko04728 Dopaminergic synapse; ko04730 Long-term depression; ko04915 Estrogen signaling pathway; ko04916 Melanogenesis; ko05032 Morphine addiction; ko05034 Alcoholism; ko05142 Chagas disease (American trypanosomiasis); ko05145 Toxoplasmosis-0.44 0.0025 0.382122
K04538 GNB4 guanine nucleotide-binding protein subunit beta-4 ko04062 Chemokine signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04713 Circadian entrainment; ko04723 Retrograde endocannabinoid signaling; ko04724 Glutamatergic synapse; ko04725 Cholinergic synapse; ko04726 Serotonergic synapse; ko04727 GABAergic synapse; ko04728 Dopaminergic synapse; ko05032 Morphine addiction; ko05034 Alcoholism-0.50 0.0183 0.401388
K16142 HP haptoglobin NA 0.90 0.0403 0.443212
K09489 HSPA4 heat shock 70kDa protein 4 ko04612 Antigen processing and presentation 0.49 0.0345 0.437297
K13159 HNRNPL heterogeneous nuclear ribonucleoprotein L NA 0.61 0.0035 0.382122
K00844 HK hexokinase [EC:2.7.1.1] ko00010 Glycolysis / Gluconeogenesis; ko00051 Fructose and mannose metabolism; ko00052 Galactose metabolism; ko00500 Starch and sucrose metabolism; ko00520 Amino sugar and nucleotide sugar metabolism; ko00521 Streptomycin biosynthesis; ko00524 Butirosin and neomycin biosynthesis; ko04066 HIF-1 signaling pathway; ko04910 Insulin signaling pathway; ko04930 Type II diabetes mellitus; ko04973 Carbohydrate digestion and absorption-0.38 0.0002 0.357271
K11303 HAT1, KAT1 histone acetyltransferase 1 [EC:2.3.1.48] ko05034 Alcoholism 0.68 0.0029 0.382122
K11424 WHSC1, MMSET, NSD2 histone-lysine N-methyltransferase NSD2 [EC:2.1.1.43] ko00310 Lysine degradation; ko05202 Transcriptional misregulation in cancer 0.69 0.0079 0.398783
K14966 HCFC host cell factor ko05168 Herpes simplex infection -0.47 0.0109 0.398783
K09562 HSPBP1 hsp70-interacting protein ko04141 Protein processing in endoplasmic reticulum 0.48 0.0028 0.382122
K06092 INADL, PATJ InaD-like protein ko04390 Hippo signaling pathway; ko04530 Tight junction 0.71 0.0171 0.398783
K05459 IGF1 insulin-like growth factor 1 ko04066 HIF-1 signaling pathway; ko04114 Oocyte meiosis; ko04115 p53 signaling pathway; ko04150 mTOR signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04730 Long-term depression; ko04913 Ovarian steroidogenesis; ko04914 Progesterone-mediated oocyte maturation; ko04960 Aldosterone-regulated sodium reabsorption; ko05200 Pathways in cancer; ko05202 Transcriptional misregulation in cancer; ko05205 Proteoglycans in cancer; ko05214 Glioma; ko05215 Prostate cancer; ko05218 Melanoma; ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy-0.64 0.0254 0.423939
K18264 ITM2B integral membrane protein 2B NA -0.44 0.0080 0.398783
K05414 IFNA interferon alpha ko04060 Cytokine-cytokine receptor interaction; ko04140 Regulation of autophagy; ko04151 PI3K-Akt signaling pathway; ko04620 Toll-like receptor signaling pathway; ko04622 RIG-I-like receptor signaling pathway; ko04623 Cytosolic DNA-sensing pathway; ko04630 Jak-STAT signaling pathway; ko04650 Natural killer cell mediated cytotoxicity; ko05152 Tuberculosis; ko05160 Hepatitis C; ko05161 Hepatitis B; ko05162 Measles; ko05164 Influenza A; ko05168 Herpes simplex infection; ko05320 Autoimmune thyroid disease0.57 0.0145 0.398783
K09228 KRAB KRAB domain-containing zinc finger protein NA 0.72 0.0032 0.382122
K17845 KLF2 krueppel-like factor 2 NA -0.43 0.0018 0.382122
K02920 RP-L36e, RPL36 large subunit ribosomal protein L36e ko03010 Ribosome -0.46 0.0382 0.440055
K17989 SDS, SDH, CHA1 L-serine/L-threonine ammonia-lyase [EC:4.3.1.17 4.3.1.19] NA -0.44 0.0033 0.382122
K09262 MEF2D MADS-box transcription enhancer factor 2D NA 0.56 0.0171 0.398783
K06751 MHC1 major histocompatibility complex, class I ko04144 Endocytosis; ko04145 Phagosome; ko04514 Cell adhesion molecules (CAMs); ko04612 Antigen processing and presentation; ko04650 Natural killer cell mediated cytotoxicity; ko04940 Type I diabetes mellitus; ko05166 HTLV-I infection; ko05168 Herpes simplex infection; ko05169 Epstein-Barr virus infection; ko05203 Viral carcinogenesis; ko05320 Autoimmune thyroid disease; ko05330 Allograft rejection; ko05332 Graft-versus-host disease; ko05416 Viral myocarditis-0.55 0.0016 0.382122
K09660 MPDU1 mannose-P-dolichol utilization defect 1 NA 0.45 0.0312 0.436634
K17291 MARVELD2 MARVEL domain-containing protein 2 NA -0.45 0.0161 0.398783
K14737 STEAP1 metalloreductase STEAP1 [EC:1.16.1.-] ko04978 Mineral absorption 0.47 0.0024 0.382122
K08199 SLC22A2, OCT2 MFS transporter, OCT family, solute carrier family 22 (organic cation NA -0.61 0.0171 0.398783
K17656 MSS51 mitochondrial splicing suppressor protein 51 NA 0.39 0.0067 0.398783
K04431 MAP2K7, MKK7 mitogen-activated protein kinase kinase 7 [EC:2.7.12.2] ko04010 MAPK signaling pathway; ko04012 ErbB signaling pathway; ko04141 Protein processing in endoplasmic reticulum; ko04380 Osteoclast differentiation; ko04620 Toll-like receptor signaling pathway; ko04660 T cell receptor signaling pathway; ko04664 Fc epsilon RI signaling pathway; ko04668 TNF signaling pathway; ko04722 Neurotrophin signaling pathway; ko04912 GnRH signaling pathway; ko05164 Influenza A; ko05169 Epstein-Barr virus infection0.76 0.0121 0.398783
K04676 SMAD1 mothers against decapentaplegic homolog 1 ko04350 TGF-beta signaling pathway; ko04390 Hippo signaling pathway; ko04391 Hippo signaling pathway - fly; ko05202 Transcriptional misregulation in cancer-0.57 0.0093 .398783
K04729 MYD88 myeloid differentiation primary response protein MyD88 ko04064 NF-kappa B signaling pathway; ko04210 Apoptosis; ko04620 Toll-like receptor signaling pathway; ko05132 Salmonella infection; ko05133 Pertussis; ko05134 Legionellosis; ko05140 Leishmaniasis; ko05142 Chagas disease (American trypanosomiasis); ko05143 African trypanosomiasis; ko05144 Malaria; ko05145 Toxoplasmosis; ko05152 Tuberculosis; ko05161 Hepatitis B; ko05162 Measles; ko05164 Influenza A; ko05168 Herpes simplex infection0.44 0.0 98 0.398783
K10352 MYH myosin heavy chain ko04530 Tight junction; ko05416 Viral myocarditis 0.71 0.0018 0.382122
K10356 MYO1 myosin I NA -0.49 0.0116 0.398783
K12800 NLRP3, PYPAF1 NACHT, LRR and PYD domains-containing protein 3 ko04621 NOD-like receptor signaling pathway; ko05133 Pertussis; ko05164 Influenza A 0.93 0.0014 0.382122
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K01097 NANP N-acylneuraminate-9-phosphatase [EC:3.1.3.29] ko00520 Amino sugar and nucleotide sugar metabolism 0.39 0.0029 0.382122
K00323 NNT NAD(P) transhydrogenase [EC:1.6.1.2] ko00760 Nicotinate and nicotinamide metabolism 0.40 0.0194 0.401932
K12347 SLC11A, NRAMP natural resistance-associated macrophage protein ko04142 Lysosome; ko04978 Mineral absorption -0.46 0.0486 0.457001
K05750 NCKAP1, NAP125 NCK-associated protein 1 ko04810 Regulation of actin cytoskeleton -0.41 0.0137 0.398783
K04573 NEF3, NF-M neurofilament medium polypeptide (neurofilament 3) ko05014 Amyotrophic lateral sclerosis (ALS) 0.75 0.0133 0.398783
K04469 NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 ko04010 MAPK signaling pathway; ko04064 NF-kappa B signaling pathway; ko04380 Osteoclast differentiation; ko05134 Legionellosis; ko05166 HTLV-I infection; ko05169 Epstein-Barr virus infection; ko05200 Pathways in cancer; ko05203 Viral carcinogenesis0.45 0.0066 0.398783
K08126 OGN osteoglycin (osteoinductive factor, mimecan) NA -0.54 0.0057 0.398783
K04441 P38 p38 MAP kinase [EC:2.7.11.24] ko04010 MAPK signaling pathway; ko04011 MAPK signaling pathway - yeast; ko04370 VEGF signaling pathway; ko04380 Osteoclast differentiation; ko04620 Toll-like receptor signaling pathway; ko04621 NOD-like receptor signaling pathway; ko04622 RIG-I-like receptor signaling pathway; ko04660 T cell receptor signaling pathway; ko04664 Fc epsilon RI signaling pathway; ko04668 TNF signaling pathway; ko04670 Leukocyte transendothelial migration; ko04722 Neurotrophin signaling pathway; ko04723 Retrograde endocannabinoid signaling; ko04728 Dopaminergic synapse; ko04912 GnRH signaling pathway; ko04914 Progesterone-mediated oocyte maturation; ko04917 Prolactin signaling pathway; ko05014 Amyotrophic lateral sclerosis (ALS); ko05120 Epithelial cell signaling in Helicobacter pylori infection; ko05131 Shigellosis; ko05132 Salmonella infection; ko05133 Pertussis; ko05140 Leishmaniasis; ko05142 Chagas disease (American trypanosomiasis); ko05145 Toxoplasmosis; ko05152 Tuberculosis; ko05160 Hepatitis C; ko05164 Influenza A; ko05169-0.39 0.0089 0.398783
K13239 PECI peroxisomal 3,2-trans-enoyl-CoA isomerase [EC:5.3.3.8] ko00071 Fatty acid degradation; ko04146 Peroxisome -0.48 0.0226 0.411219
K08530 NR1C3, PPARG peroxisome proliferator-activated receptor gamma ko03320 PPAR signaling pathway; ko04380 Osteoclast differentiation; ko05016 Huntington's disease; ko05200 Pathways in cancer; ko05202 Transcriptional misregulation in cancer; ko05216 Thyroid cancer-0.55 0. 367 0.437297
K01890 FARSB, pheT phenylalanyl-tRNA synthetase beta chain [EC:6.1.1.20] ko00970 Aminoacyl-tRNA biosynthesis 0.50 0.0098 0.398783
K07253 MIF phenylpyruvate tautomerase [EC:5.3.2.1] ko00350 Tyrosine metabolism; ko00360 Phenylalanine metabolism -0.49 0.0088 0.398783
K17594 PHACTR3 phosphatase and actin regulator 3 NA -1.28 0.0340 0.437297
K02649 PIK3R phosphoinositide-3-kinase, regulatory subunit ko04012 ErbB signaling pathway; ko04062 Chemokine signaling pathway; ko04066 HIF-1 signaling pathway; ko04070 Phosphatidylinositol signaling system; ko04150 mTOR signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04210 Apoptosis; ko04370 VEGF signaling pathway; ko04380 Osteoclast differentiation; ko04510 Focal adhesion; ko04620 Toll-like receptor signaling pathway; ko04630 Jak-STAT signaling pathway; ko04650 Natural killer cell mediated cytotoxicity; ko04660 T cell receptor signaling pathway; ko04662 B cell receptor signaling pathway; ko04664 Fc epsilon RI signaling pathway; ko04666 Fc gamma R-mediated phagocytosis; ko04668 TNF signaling pathway; ko04670 Leukocyte transendothelial migration; ko04722 Neurotrophin signaling pathway; ko04725 Cholinergic synapse; ko04810 Regulation of actin cytoskeleton; ko04910 Insulin signaling pathway; ko04914 Progesterone-mediated oocyte maturation; ko04915 Estrogen signaling pathway; ko04917 Prolactin signaling pathway; ko04930 Type II diabetes mellitus; ko04932 Non-al-0.39 0.0383 .440055
K01922 PPCS, coaB phosphopantothenate-cysteine ligase [EC:6.3.2.5] ko00770 Pantothenate and CoA biosynthesis 0.39 0.0171 0.398783
K01952 purL, PFAS phosphoribosylformylglycinamidine synthase [EC:6.3.5.3] ko00230 Purine metabolism 0.41 0.0062 0.398783
K13114 PNN pinin ko03013 RNA transport; ko03015 mRNA surveillance pathway -0.59 0.0107 0.398783
K03982 SERPINE1, PAI1 plasminogen activator inhibitor-1 ko04066 HIF-1 signaling pathway; ko04115 p53 signaling pathway; ko04390 Hippo signaling pathway; ko04610 Complement and coagulation cascades; ko05142 Chagas disease (American trypanosomiasis)0.41 0. 066 0.398783
K13126 PABPC polyadenylate-binding protein ko03013 RNA transport; ko03015 mRNA surveillance pathway; ko03018 RNA degradation -0.49 0.0239 0.41936
K14399 CLP1, HERB polyribonucleotide 5'-hydroxyl-kinase [EC:2.7.1.78] ko03015 mRNA surveillance pathway -0.42 0.0490 0.457001
K05003 KCNJ10 potassium inwardly-rectifying channel subfamily J member 10 ko04971 Gastric acid secretion 0.54 0.0313 0.436634
K12850 PRPF38B pre-mRNA-splicing factor 38B ko03040 Spliceosome 0.42 0.0411 0.444617
K04727 PDCD8, AIF programmed cell death 8 (apoptosis-inducing factor) [EC:1.-.-.-] ko04210 Apoptosis 0.63 0.0121 0.398783
K01322 PREP prolyl oligopeptidase [EC:3.4.21.26] NA 0.39 0.0256 0.425293
K15719 NCOAT, MGEA5 protein O-GlcNAcase / histone acetyltransferase [EC:3.2.1.169 2.3.1.48 NA -0.39 0.0477 0.457001
K12328 PPP1R14A, CPI17 protein phosphatase 1 regulatory subunit 14A ko04270 Vascular smooth muscle contraction 0.66 0.0300 0.436634
K04461 PPM1B, PP2CB protein phosphatase 1B [EC:3.1.3.16] ko04010 MAPK signaling pathway 0.43 0.0250 0.422862
K14004 SEC13 protein transport protein SEC13 ko03013 RNA transport; ko04141 Protein processing in endoplasmic reticulum 0.42 0.0296 0.436634
K14005 SEC31 protein transport protein SEC31 ko04141 Protein processing in endoplasmic reticulum 0.41 0.0109 0.398783
K07342 SEC61G, SSS1, secE protein transport protein SEC61 subunit gamma and related protei ko03060 Protein export; ko04141 Protein processing in endoplasmic reticulum; ko04145 Phagosome; ko05110 Vibrio cholerae infection0.41 0.0444 0.452402
K08773 RALBP1 RalA-binding protein 1 ko05200 Pathways in cancer; ko05212 Pancreatic cancer 0.42 0.0081 0.398783
K07874 RAB1A Ras-related protein Rab-1A ko05134 Legionellosis 0.40 0.0022 0.382122
K10740 RPA3 replication factor A3 ko03030 DNA replication; ko03420 Nucleotide excision repair; ko03430 Mismatch repair; ko03440 Homologous recombination; ko03460 Fanconi anemia pathway0.74 0.0370 0.437297
K06618 RB1 retinoblastoma-associated protein ko04110 Cell cycle; ko05161 Hepatitis B; ko05166 HTLV-I infection; ko05169 Epstein-Barr virus infection; ko05200 Pathways in cancer; ko05203 Viral carcinogenesis; ko05212 Pancreatic cancer; ko05214 Glioma; ko05215 Prostate cancer; ko05218 Melanoma; ko05219 Bladder cancer; ko05220 Chronic myeloid leukemia; ko05222 Small cell lung cancer; ko05223 Non-small cell lung cancer0.41 .0068 0.398783
K10808 RRM2 ribonucleoside-diphosphate reductase subunit M2 [EC:1.17.4.1] ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko00480 Glutathione metabolism; ko04115 p53 signaling pathway0.57 0.0138 0.398783
K12822 RBM25, S164 RNA-binding protein 25 ko03040 Spliceosome 0.77 0.0109 0.398783
K04499 RUVBL1, RVB1, INO80H RuvB-like protein 1 (pontin 52) ko04310 Wnt signaling pathway -0.49 0.0245 0.422862
K12382 PSAP, SGP1 saposin ko04142 Lysosome -0.58 0.0016 0.382122
K06841 SEMA5 semaphorin 5 ko04360 Axon guidance -0.69 0.0033 0.382122
K09646 SCPEP1 serine carboxypeptidase 1 [EC:3.4.16.-] NA -0.43 0.0110 0.398783
K16311 SIK2 serine/threonine-protein kinase SIK2 [EC:2.7.11.1] NA -0.39 0.0496 0.457001
K08269 ULK1_2_3, ATG1 serine/threonine-protein kinase ULK/ATG1 [EC:2.7.11.1] ko04140 Regulation of autophagy; ko04150 mTOR signaling pathway 0.63 0.0113 0.398783
K04382 PPP2C serine/threonine-protein phosphatase 2A catalytic subunit [EC:3.1.3.16] ko03015 mRNA surveillance pathway; ko04111 Cell cycle - yeast; ko04113 Meiosis - yeast; ko04114 Oocyte meiosis; ko04151 PI3K-Akt signaling pathway; ko04350 TGF-beta signaling pathway; ko04390 Hippo signaling pathway; ko04391 Hippo signaling pathway - fly; ko04530 Tight junction; ko04728 Dopaminergic synapse; ko04730 Long-term depression; ko05142 Chagas disease (American trypanosomiasis); ko05160 Hepatitis C-0.41 0.0022 0.382122
K01875 SARS, serS seryl-tRNA synthetase [EC:6.1.1.11] ko00970 Aminoacyl-tRNA biosynthesis 0.51 0.0111 0.398783
K10141 SESN sestrin ko04115 p53 signaling pathway -0.72 0.0089 0.398783
K01070 frmB, ESD, fghA S-formylglutathione hydrolase [EC:3.1.2.12] ko00680 Methane metabolism -0.65 0.0054 0.398783
K02977 RP-S27Ae, RPS27A small subunit ribosomal protein S27Ae ko03010 Ribosome -0.43 0.0116 0.398783
K13151 SNUPN, RNUT1 snurportin-1 ko03013 RNA transport -0.38 0.0212 0.409019
K00802 SMS spermine synthase [EC:2.5.1.22] ko00270 Cysteine and methionine metabolism; ko00330 Arginine and proline metabolism; ko00410 beta-Alanine metabolism; ko00480 Glutathione metabolism-0.56 0.0110 0.398783
K04404 MAP3K7IP2, TAB2 TAK1-binding protein 2 ko04010 MAPK signaling pathway; ko04064 NF-kappa B signaling pathway; ko04380 Osteoclast differentiation; ko04620 Toll-like receptor signaling pathway; ko04621 NOD-like receptor signaling pathway; ko04668 TNF signaling pathway; ko05140 Leishmaniasis; ko05145 Toxoplasmosis; ko05162 Measles; ko05168 Herpes simplex infection; ko05169 Epstein-Barr virus infection0.38 0.0367 0.437297
K12652 TBKBP1 TANK-binding kinase 1-binding protein ko04622 RIG-I-like receptor signaling pathway 0.43 0.0184 0.401388
K06451 CD3E T-cell surface glycoprotein CD3 epsilon chain ko04640 Hematopoietic cell lineage; ko04660 T cell receptor signaling pathway; ko05142 Chagas disease (American trypanosomiasis); ko05162 Measles; ko05166 HTLV-I infection; ko05340 Primary immunodeficiency-0.39 0.0318 0.436634
K04659 THBS2S thrombospondin 2/3/4/5 ko04145 Phagosome; ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko05144 Malaria0.86 0.0133 0.398783
K00857 tdk, TK thymidine kinase [EC:2.7.1.21] ko00240 Pyrimidine metabolism; ko00983 Drug metabolism - other enzymes 1.00 0.0251 0.422862
K10170 TLR8 toll-like receptor 8 ko04620 Toll-like receptor signaling pathway 0.51 0.0025 0.382122
K10161 TLR9 toll-like receptor 9 ko04620 Toll-like receptor signaling pathway; ko05142 Chagas disease (American trypanosomiasis); ko05143 African trypanosomiasis; ko05144 Malaria; ko05152 Tuberculosis; ko05162 Measles; ko05168 Herpes simplex infection0.38 0.0025 0.382122
K16796 SOX2 transcription factor SOX2 (SOX group B) ko04390 Hippo signaling pathway 0.49 0.0081 0.398783
K13525 VCP, CDC48 transitional endoplasmic reticulum ATPase ko04141 Protein processing in endoplasmic reticulum; ko05134 Legionellosis 0.39 0.0415 0.444822
K03254 EIF3A translation initiation factor 3 subunit A ko03013 RNA transport 0.67 0.0053 0.398783
K03257 EIF4A translation initiation factor 4A ko03013 RNA transport -0.56 0.0178 0.401388
K09540 SEC63, DNAJC23 translocation protein SEC63 ko03060 Protein export; ko04141 Protein processing in endoplasmic reticulum -0.38 0.0127 0.398783
K12015 TRIM39 tripartite motif-containing protein 39 [EC:6.3.2.19] NA 0.57 0.0213 0.409019
K01867 WARS, trpS tryptophanyl-tRNA synthetase [EC:6.1.1.2] ko00970 Aminoacyl-tRNA biosynthesis 0.72 0.0137 0.398783
K07374 TUBA tubulin alpha ko04145 Phagosome; ko04540 Gap junction; ko05130 Pathogenic Escherichia coli infection 0.48 0.0336 0.436634
K07604 KRT1 type I keratin, acidic NA -0.43 0.0017 0.382122
K01866 YARS, tyrS tyrosyl-tRNA synthetase [EC:6.1.1.1] ko00970 Aminoacyl-tRNA biosynthesis 0.82 0.0084 0.398783
K17492 UBN ubinuclein NA 0.40 0.0104 0.398783
K00412 CYTB, petB ubiquinol-cytochrome c reductase cytochrome b subunit ko00190 Oxidative phosphorylation; ko02020 Two-component system; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.67 0.0173 0.400261
K11849 USP25_28, UBP2 ubiquitin carboxyl-terminal hydrolase 25/28 [EC:3.4.19.12] NA -0.43 0.0200 0.40587
K14012 SHP1, UBX1, NSFL1C UBX domain-containing protein 1 ko04141 Protein processing in endoplasmic reticulum 0.39 0.0432 0.452056
K06793 VCAN, CSPG2 versican core protein ko04514 Cell adhesion molecules (CAMs) 0.44 0.0260 0.431588
K07436 CYP24A1 vitamin D3 24-hydroxylase [EC:1.14.13.126] ko00100 Steroid biosynthesis; ko05206 MicroRNAs in cancer 1.71 0.0002 0.382122
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K02731 PSMA7 20S proteasome subunit alpha 4 [EC:3.4.25.1] ko03050 Proteasome -0.46 0.0009 0.366431979
K00643 E2.3.1.37, ALAS 5-aminolevulinate synthase [EC:2.3.1.37] ko00260 Glycine, serine and threonine metabolism; ko00860 Porphyrin and chlorophyll metabolism1.53 0.0130 0.406108274
K01081 E3.1.3.5 5'-nucleotidase [EC:3.1.3.5] ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko00760 Nicotinate and nicotinamide metabolism0.41 0.0047 0.406108274
K19028 PFKFB1 6-phosphofructo-2-kinase / fructose-2,6-biphosphatase 1 [EC:2.7.1.105 3.1.3.NA 0.47 0.0387 0.4226574
K05757 ARPC1A_B actin related protein 2/3 complex, subunit 1A/1B ko04666 Fc gamma R-mediated phagocytosis; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05132 Salmonella infection0.79 0.0024 0.406108274
K03910 A2M alpha-2-macroglobulin ko04610 Complement and coagulation cascades 0.61 0.0172 0.406108274
K01176 E3.2.1.1, amyA, malS alpha-amylase [EC:3.2.1.1] ko00500 Starch and sucrose metabolism; ko04973 Carbohydrate digestion and absorption 0.57 0.0079 0.406108274
K11140 ANPEP aminopeptidase N [EC:3.4.11.2] ko00480 Glutathione metabolism; ko04614 Renin-angiotensin system; ko04640 Hematopoietic cell lineage-0.67 0.0039 0.406108274
K03359 APC12, CDC26 anaphase-promoting complex subunit 12 ko04110 Cell cycle; ko04111 Cell cycle - yeast; ko04113 Meiosis - yeast; ko04114 Oocyte meiosis; ko04120 Ubiquitin mediated proteolysis; ko04914 Progesterone-mediated oocyte maturation; ko05166 HTLV-I infection-0.41 0.037 0.4226574
K10380 ANK ankyrin ko05205 Proteoglycans in cancer 0.71 0.0146 0.406108274
K17095 ANXA7_11 annexin A7/11 NA 0.49 0.0037 0.406108274
K09864 AQP1 aquaporin-1 ko04964 Proximal tubule bicarbonate reclamation; ko04976 Bile secretion 0.75 0.0108 0.406108274
K09866 AQP4 aquaporin-4 ko04962 Vasopressin-regulated water reabsorption; ko04976 Bile secretion 0.40 0.0398 0.424389339
K09034 BATF ATF-like basic leucine zipper transcriptional factor NA -0.64 0.0072 0.406108274
K07820 B3GALT2 beta-1,3-galactosyltransferase 2 [EC:2.4.1.-] ko00601 Glycosphingolipid biosynthesis - lacto and neolacto series 0.39 0.0224 0.406108274
K04726 BID BH3 interacting domain death agonist ko04115 p53 signaling pathway; ko04210 Apoptosis; ko04650 Natural killer cell mediated cytotoxicity; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05014 Amyotrophic lateral sclerosis (ALS); ko05152 Tuberculosis; ko05200 Pathways in cancer; ko05416 Viral myocarditis0.65 0.0237 0.406108274
K05901 BLVRB biliverdin reductase / flavin reductase [EC:1.3.1.24 1.5.1.30] ko00740 Riboflavin metabolism; ko00860 Porphyrin and chlorophyll metabolism 0.79 0.0131 0.406108274
K01435 BTD biotinidase [EC:3.5.1.12] ko00780 Biotin metabolism; ko04977 Vitamin digestion and absorption 0.59 0.0482 0.426599288
K04739 PRKAR cAMP-dependent protein kinase regulator ko04210 Apoptosis; ko04910 Insulin signaling pathway 0.45 0.0120 0.406108274
K18245 CA2 carbonic anhydrase 2 [EC:4.2.1.1] NA 1.05 0.0146 0.406108274
K01379 CTSD cathepsin D [EC:3.4.23.5] ko04142 Lysosome; ko05152 Tuberculosis 0.57 0.0456 0.426599288
K01365 CTSL cathepsin L [EC:3.4.22.15] ko04142 Lysosome; ko04145 Phagosome; ko04612 Antigen processing and presentation; ko05205 Proteoglycans in cancer; ko05323 Rheumatoid arthritis-0.51 0.0063 0.406108274
K06454 CD4 CD4 antigen ko04514 Cell adhesion molecules (CAMs); ko04612 Antigen processing and presentation; ko04640 Hematopoietic cell lineage; ko04660 T cell receptor signaling pathway; ko05340 Primary immunodeficiency. 2 0.0444 0.426599288
K05022 CLIC2 chloride intracellular channel protein 2 NA 0.39 0.0034 0.406108274
K03899 F8 coagulation factor VIII ko04610 Complement and coagulation cascades 0.50 0.0089 0.406108274
K06236 COL1AS collagen, type I/II/III/V/XI/XXIV/XXVII, alpha ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko04974 Protein digestion and absorption; ko05146 Amoebiasis0.50 0. 3 0.428391933
K01331 C1S complement component 1, s subcomponent [EC:3.4.21.42] ko04610 Complement and coagulation cascades; ko05133 Pertussis; ko05150 Staphylococcus aureus infection; ko05322 Systemic lupus erythematosus0.44 0.0208 0.4061 8274
K03997 C8A complement component 8 subunit alpha ko04610 Complement and coagulation cascades; ko05020 Prion diseases; ko05146 Amoebiasis; ko05322 Systemic lupus erythematosus0.40 0.0 62 0.406108274
K01335 CFB component factor B [EC:3.4.21.47] ko04610 Complement and coagulation cascades; ko05150 Staphylococcus aureus infection 0.68 0.0471 0.426599288
K01334 CFD component factor D [EC:3.4.21.46] ko04610 Complement and coagulation cascades; ko05150 Staphylococcus aureus infection 0.45 0.0075 0.406108274
K10059 CLEC4E C-type lectin domain family 4 member E ko05152 Tuberculosis 0.67 0.0148 0.406108274
K05416 CXCL9 C-X-C motif chemokine 9 ko04060 Cytokine-cytokine receptor interaction; ko04062 Chemokine signaling pathway; ko04620 Toll-like receptor signaling pathway.39 0.0375 0.4226574
K04685 CDKN2B, P15, INK4B cyclin-dependent kinase inhibitor 2B ko04110 Cell cycle; ko04350 TGF-beta signaling pathway; ko05166 HTLV-I infection; ko05200 Pathways in cancer; ko05203 Viral carcinogenesis; ko05222 Small cell lung cancer0.90 0.0078 0.406108274
K17494 CSRNP cysteine/serine-rich nuclear protein NA 0.40 0.0027 0.406108274
K01883 CARS, cysS cysteinyl-tRNA synthetase [EC:6.1.1.16] ko00970 Aminoacyl-tRNA biosynthesis -0.70 0.0250 0.406108274
K01489 cdd, CDA cytidine deaminase [EC:3.5.4.5] ko00240 Pyrimidine metabolism; ko00983 Drug metabolism - other enzymes 0.70 0.0306 0.410911565
K18184 COX20 cytochrome c oxidase assembly protein subunit 20 NA -0.56 0.0017 0.366431979
K02265 COX5B cytochrome c oxidase subunit 5b ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.62 0.0061 0.406108274
K02270 COX7A cytochrome c oxidase subunit 7a ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.42 0.0179 0.406108274
K11995 DNASE1L deoxyribonuclease-1-like protein [EC:3.1.21.-] NA 0.59 0.0346 0.411688642
K10413 DYNC1H dynein heavy chain 1, cytosolic ko04145 Phagosome; ko04962 Vasopressin-regulated water reabsorption; ko05132 Salmonella infection0.48 0.0165 0.406108274
K10614 HERC3 E3 ubiquitin-protein ligase HERC3 [EC:6.3.2.19] ko04120 Ubiquitin mediated proteolysis 0.55 0.0155 0.406108274
K10615 HERC4 E3 ubiquitin-protein ligase HERC4 [EC:6.3.2.19] ko04120 Ubiquitin mediated proteolysis 0.70 0.0055 0.406108274
K03522 fixB, etfA electron transfer flavoprotein alpha subunit NA -0.59 0.0244 0.406108274
K10205 ELOVL2 elongation of very long chain fatty acids protein 2 [EC:2.3.1.199] ko00062 Fatty acid elongation; ko01040 Biosynthesis of unsaturated fatty acids -0.46 0.0180 0.406108274
K17286 STOM erythrocyte band 7 integral membrane protein NA 0.43 0.0251 0.406108274
K05079 EPOR erythropoietin receptor ko04060 Cytokine-cytokine receptor interaction; ko04151 PI3K-Akt signaling pathway; ko04630 Jak-STAT signaling pathway; ko04640 Hematopoietic cell lineage1. 7 0.0123 0.406108274
K08751 FABP2 fatty acid-binding protein 2, intestinal ko03320 PPAR signaling pathway; ko04975 Fat digestion and absorption 1.45 0.0342 0.411688642
K05097 FLT4, VEGFR3 FMS-like tyrosine kinase 4 [EC:2.7.10.1] ko04060 Cytokine-cytokine receptor interaction; ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion0.43 0.0154 0.406108274
K09409 FOXP forkhead box protein P NA 0.52 0.0328 0.410911565
K02133 ATPeF1B, ATP5B, ATP2F-type H+-transporting ATPase subunit beta [EC:3.6.3.14] ko00190 Oxidative phosphorylation; ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.49 0.0 6 0.406108274
K12900 FUSIP1 FUS-interacting serine-arginine-rich protein 1 ko03040 Spliceosome -0.53 0.0266 0.406108274
K17894 GATA2 GATA-binding protein 2 NA 0.94 0.0249 0.406108274
K02377 TSTA3, fcl GDP-L-fucose synthase [EC:1.1.1.271] ko00051 Fructose and mannose metabolism; ko00520 Amino sugar and nucleotide sugar metabolism1.16 0.0143 0.406108274
K00799 GST, gst glutathione S-transferase [EC:2.5.1.18] ko00480 Glutathione metabolism; ko00980 Metabolism of xenobiotics by cytochrome P450; ko00982 Drug metabolism - cytochrome P450; ko05204 Chemical carcinogenesis0.67 0.0092 0.406108274
K00049 GRHPR glyoxylate/hydroxypyruvate reductase [EC:1.1.1.79 1.1.1.81] ko00260 Glycine, serine and threonine metabolism; ko00620 Pyruvate metabolism; ko00630 Glyoxylate and dicarboxylate metabolism0.50 0.0412 0.424612243
K09223 GFI1 growth factor independent 1 NA 0.50 0.0177 0.406108274
K00542 GAMT guanidinoacetate N-methyltransferase [EC:2.1.1.2] ko00260 Glycine, serine and threonine metabolism; ko00330 Arginine and proline metabolism1.20 0.0407 0.424612243
K03283 HSPA1_8 heat shock 70kDa protein 1/8 ko03040 Spliceosome; ko04010 MAPK signaling pathway; ko04141 Protein processing in endoplasmic reticulum; ko04144 Endocytosis; ko04612 Antigen processing and presentation; ko04915 Estrogen signaling pathway; ko05134 Legionellosis; ko05145 Toxoplasmosis; ko05162 Measles; ko05164 Influenza A; ko05169 Epstein-Barr virus infection0.88 0.0258 0.406108274
K09414 HSF1 heat shock transcription factor 1 ko05134 Legionellosis 0.62 0.0485 0.426599288
K11295 HMGB2 high mobility group protein B2 NA 0.42 0.0109 0.406108274
K11251 H2A histone H2A ko05034 Alcoholism; ko05322 Systemic lupus erythematosus -0.51 0.0014 0.366431979
K01109 INPP4 inositol polyphosphate-4-phosphatase [EC:3.1.3.66] ko00562 Inositol phosphate metabolism; ko04070 Phosphatidylinositol signaling system 0.75 0.0054 0.406108274
K06566 IFITM interferon induced transmembrane protein NA 0.42 0.0013 0.366431979
K05076 IL13RA1 interleukin 13 receptor alpha-1 ko04060 Cytokine-cytokine receptor interaction; ko04630 Jak-STAT signaling pathway 0.43 0.0266 0.406108274
K05433 IL15 interleukin 15 ko04060 Cytokine-cytokine receptor interaction; ko04630 Jak-STAT signaling pathway; ko04668 TNF signaling pathway; ko04672 Intestinal immune network for IgA production; ko05166 HTLV-I infection; ko05168 Herpes simplex infection; ko05323 Rheumatoid arthritis0.42 0.0038 0.406108274
K07934 IFT27, RAYL, RABL4 intraflagellar transport protein 27 homolog NA -0.42 0.0077 0.406108274
K05636 LAMB1 laminin, beta 1 ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko05145 Toxoplasmosis; ko05146 Amoebiasis; ko05200 Pathways in cancer; ko05222 Small cell lung cancer0.43 0. 167 0.406108274
K02873 RP-L13e, RPL13 large subunit ribosomal protein L13e ko03010 Ribosome -0.61 0.0182 0.406108274
K02899 RP-L27, MRPL27, rpmAlarge subunit ribosomal protein L27 ko03010 Ribosome -0.39 0.0216 0.406108274
K10080 LMAN1, ERGIC53 lectin, mannose-binding 1 ko04141 Protein processing in endoplasmic reticulum 0.48 0.0175 0.406108274
K19363 LITAF lipopolysaccharide-induced tumor necrosis factor-alpha factor NA 0.55 0.0136 0.406108274
K01059 LPL lipoprotein lipase [EC:3.1.1.34] ko00561 Glycerolipid metabolism; ko03320 PPAR signaling pathway; ko05010 Alzheimer's disease0.40 0.0114 0.406108274
K15013 ACSBG long-chain-fatty-acid--CoA ligase ACSBG [EC:6.2.1.3] ko00071 Fatty acid degradation; ko03320 PPAR signaling pathway; ko04920 Adipocytokine signaling pathway0.63 0.0054 0.406108274
K12387 LAPTM lysosomal-associated transmembrane protein ko04142 Lysosome -0.42 0.0223 0.406108274
K06751 MHC1 major histocompatibility complex, class I ko04144 Endocytosis; ko04145 Phagosome; ko04514 Cell adhesion molecules (CAMs); ko04612 Antigen processing and presentation; ko04650 Natural killer cell mediated cytotoxicity; ko04940 Type I diabetes mellitus; ko05166 HTLV-I infection; ko05168 Herpes simplex infection; ko05169 Epstein-Barr virus infection; ko05203 Viral carcinogenesis; ko05320 Autoimmune thyroid disease; ko05330 Allograft rejection; ko05332 Graft-versus-host disease; ko05416 Viral myocarditis0.66 0.0014 0.366431979
K08888 MATK megakaryocyte-associated tyrosine kinase [EC:2.7.10.2] ko04722 Neurotrophin signaling pathway 0.69 0.0093 0.406108274
K17772 TOM6 mitochondrial import receptor subunit TOM6 NA -0.43 0.0400 0.424612243
K17771 TOM7 mitochondrial import receptor subunit TOM7 NA -0.38 0.0196 0.406108274
K04079 htpG, HSP90A molecular chaperone HtpG ko04141 Protein processing in endoplasmic reticulum; ko04151 PI3K-Akt signaling pathway; ko04612 Antigen processing and presentation; ko04621 NOD-like receptor signaling pathway; ko04626 Plant-pathogen interaction; ko04914 Progesterone-mediated oocyte maturation; ko04915 Estrogen signaling pathway; ko05200 Pathways in cancer; ko05215 Prostate cancer-0.49 0.0126 0.406108274
K15626 NUPR1, COM1 nuclear protein, 1 ko05202 Transcriptional misregulation in cancer 0.90 0.0472 0.426599288
K11797 PHIP, WDR11 PH-interacting protein NA 0.43 0.0015 0.366431979
K01530 E3.6.3.1 phospholipid-translocating ATPase [EC:3.6.3.1] NA -0.39 0.0281 0.407707745
K06263 GP9 platelet glycoprotein IX ko04512 ECM-receptor interaction; ko04640 Hematopoietic cell lineage 0.51 0.0330 0.410911565
K08672 PCSK6 proprotein convertase subtilisin/kexin type 6 [EC:3.4.21.-] NA 0.75 0.0203 0.406108274
K09649 PRSS16 protease, serine, 16 (thymus) [EC:3.4.-.-] NA 0.93 0.0171 0.406108274
K09667 OGT protein O-GlcNAc transferase [EC:2.4.1.255] ko00514 Other types of O-glycan biosynthesis 0.40 0.0319 0.410911565
K17566 PPP1R27 protein phosphatase 1 regulatory subunit 27 NA 0.42 0.0156 0.406108274
K00573 E2.1.1.77, pcm protein-L-isoaspartate(D-aspartate) O-methyltransferase [EC:2.1.1.77 NA 1.18 0.0025 0.406108274
K03783 punA purine-nucleoside phosphorylase [EC:2.4.2.1] ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko00760 Nicotinate and nicotinamide metabolism0.50 0.0396 0.424389339
K00773 tgt, QTRT1 queuine tRNA-ribosyltransferase [EC:2.4.2.29] NA 0.38 0.0003 0.366431979
K15045 RSAD2 radical S-adenosyl methionine domain-containing protein 2 ko05164 Influenza A 0.62 0.0063 0.406108274
K06478 PTPRC, CD45 receptor-type tyrosine-protein phosphatase C [EC:3.1.3.48] ko04514 Cell adhesion molecules (CAMs); ko04660 T cell receptor signaling pathway; ko04666 Fc gamma R-mediated phagocytosis; ko05340 Primary immunodeficiency0.42 0.0151 0.406108274
K11220 STAT1 signal transducer and activator of transcription 1 ko04062 Chemokine signaling pathway; ko04380 Osteoclast differentiation; ko04620 Toll-like receptor signaling pathway; ko04630 Jak-STAT signaling pathway; ko04917 Prolactin signaling pathway; ko05140 Leishmaniasis; ko05145 Toxoplasmosis; ko05152 Tuberculosis; ko05160 Hepatitis C; ko05161 Hepatitis B; ko05162 Measles; ko05164 Influenza A; ko05168 Herpes simplex infection; ko05200 Pathways in cancer; ko05212 Pancreatic cancer; ko05321 Inflammatory bowel disease (IBD)0.47 0.0134 0.406108274
K04692 STAT3 signal transducer and activator of transcription 3 ko04062 Chemokine signaling pathway; ko04066 HIF-1 signaling pathway; ko04630 Jak-STAT signaling pathway; ko04917 Prolactin signaling pathway; ko04920 Adipocytokine signaling pathway; ko05145 Toxoplasmosis; ko05160 Hepatitis C; ko05161 Hepatitis B; ko05162 Measles; ko05169 Epstein-Barr virus infection; ko05200 Pathways in cancer; ko05203 Viral carcinogenesis; ko05205 Proteoglycans in cancer; ko05206 MicroRNAs in cancer; ko05212 Pancreatic cancer; ko05221 Acute myeloid leukemia; ko05321 Inflammatory bowel disease (IBD)0.58 0.0446 0.426599288
K11099 SNRPG, SMG small nuclear ribonucleoprotein G ko03040 Spliceosome -0.40 0.0258 0.406108274
K02989 RP-S5e, RPS5 small subunit ribosomal protein S5e ko03010 Ribosome -0.52 0.0123 0.406108274
K02993 RP-S7e, RPS7 small subunit ribosomal protein S7e ko03010 Ribosome -0.53 0.0249 0.406108274
K05863 SLC25A4S, ANT solute carrier family 25 (mitochondrial adenine nucleotide translocat ko04020 Calcium signaling pathway; ko05012 Parkinson's disease; ko05016 Huntington's disease; ko05166 HTLV-I infection-0.40 0.0356 0.415769902
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K06573 SLC4A1, AE1 solute carrier family 4 (anion exchanger), member 1 ko04966 Collecting duct acid secretion 1.15 0.0178 0.406108274
K12827 SF3A3, SAP61, PRP9 splicing factor 3A subunit 3 ko03040 Spliceosome 0.42 0.0136 0.406108274
K12892 SFRS3 splicing factor, arginine/serine-rich 3 ko03040 Spliceosome; ko05168 Herpes simplex infection -0.50 0.0090 0.406108274
K10345 SPSB3, SSB3 SPRY domain-containing SOCS box protein 3 NA -0.55 0.0201 0.406108274
K09497 CCT5 T-complex protein 1 subunit epsilon NA -0.38 0.0399 0.424389339
K09585 TXNDC10 thioredoxin domain-containing protein 10 [EC:5.3.4.1] NA 0.65 0.0064 0.406108274
K10168 TLR5 toll-like receptor 5 ko04620 Toll-like receptor signaling pathway; ko05130 Pathogenic Escherichia coli infection; ko05132 Salmonella infection; ko05134 Legionellosis; ko05321 Inflammatory bowel disease (IBD)1.18 0.0445 0.426599288
K14736 TF transferrin ko04066 HIF-1 signaling pathway; ko04978 Mineral absorption 1.04 0.0088 0.406108274
K01312 PRSS trypsin [EC:3.4.21.4] ko04080 Neuroactive ligand-receptor interaction; ko04972 Pancreatic secretion; ko04974 Protein digestion and absorption; ko05164 Influenza A0.67 0.0132 0.406108274
K07375 TUBB tubulin beta ko04145 Phagosome; ko04540 Gap junction; ko05130 Pathogenic Escherichia coli infection 1.01 0.0225 0.406108274
K00815 TAT tyrosine aminotransferase [EC:2.6.1.5] ko00130 Ubiquinone and other terpenoid-quinone biosynthesis; ko00270 Cysteine and methionine metabolism; ko00350 Tyrosine metabolism; ko00360 Phenylalanine metabolism; ko00400 Phenylalanine, tyrosine and tryptophan biosynthesis; ko00401 Novobiocin biosynthesis; ko00950 Isoquinoline alkaloid biosynthesis; ko00960 Tropane, piperidine and pyridine alkaloid biosynthesis0.98 0.0004 0.366431979
K12621 LSM2 U6 snRNA-associated Sm-like protein LSm2 ko03018 RNA degradation; ko03040 Spliceosome -0.41 0.0280 0.407707745
K08770 UBC ubiquitin C ko03320 PPAR signaling pathway 0.47 0.0052 0.406108274
K12161 URM1 ubiquitin related modifier 1 ko04122 Sulfur relay system -0.39 0.0046 0.406108274
K02207 UBE2R, UBC3, CDC34 ubiquitin-conjugating enzyme E2 R [EC:6.3.2.19] ko04120 Ubiquitin mediated proteolysis; ko05168 Herpes simplex infection 0.47 0.0057 0.406108274
K00757 udp, UPP uridine phosphorylase [EC:2.4.2.3] ko00240 Pyrimidine metabolism; ko00983 Drug metabolism - other enzymes 0.79 0.0230 0.406108274
K01719 hemD, UROS uroporphyrinogen-III synthase [EC:4.2.1.75] ko00860 Porphyrin and chlorophyll metabolism 0.63 0.0162 0.406108274
K02149 ATPeV1D, ATP6M V-type H+-transporting ATPase subunit D ko00190 Oxidative phosphorylation; ko04145 Phagosome; ko04721 Synaptic vesicle cycle; ko04966 Collecting duct acid secretion; ko05110 Vibrio cholerae infection; ko05120 Epithelial cell signaling in Helicobacter pylori infection; ko05323 Rheumatoid arthritis-0.50 0.0327 0.410911565
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KOID Gene Abbreviation KEGG Annotation Class Log Fold Change P Value adj P Val
K13373 HSD17B7 17beta-estradiol 17-dehydrogenase / 3beta-hydroxysteroid 3-dehydrogenase [E ko00100 Steroid biosynthesis; ko00140 Steroid hormone biosynthesis; ko04913 Ovarian steroidogenesis-1.55 0.0001 0.097393314
K02730 PSMA6 20S proteasome subunit alpha 1 [EC:3.4.25.1] ko03050 Proteasome -0.43 0.0031 0.15204453
K02731 PSMA7 20S proteasome subunit alpha 4 [EC:3.4.25.1] ko03050 Proteasome -0.60 0.0000 0.092606071
K02732 PSMB1 20S proteasome subunit beta 6 [EC:3.4.25.1] ko03050 Proteasome -0.54 0.0186 0.200624952
K06692 PSMD5 26S proteasome non-ATPase regulatory subunit 5 NA -0.38 0.0088 0.172884702
K03029 PSMD4, RPN10 26S proteasome regulatory subunit N10 ko03050 Proteasome; ko05169 Epstein-Barr virus infection -0.38 0.0086 0.172822126
K03033 PSMD3, RPN3 26S proteasome regulatory subunit N3 ko03050 Proteasome; ko05169 Epstein-Barr virus infection -0.45 0.0195 0.203851854
K03035 PSMD12, RPN5 26S proteasome regulatory subunit N5 ko03050 Proteasome; ko05169 Epstein-Barr virus infection -0.46 0.0279 0.224952262
K03062 PSMC1, RPT2 26S proteasome regulatory subunit T2 ko03050 Proteasome; ko05169 Epstein-Barr virus infection; ko05203 Viral carcinogenesis -0.49 0.0221 0.212426584
K03063 PSMC4, RPT3 26S proteasome regulatory subunit T3 ko03050 Proteasome; ko05169 Epstein-Barr virus infection -0.60 0.0022 0.14321829
K03064 PSMC6, RPT4 26S proteasome regulatory subunit T4 ko03050 Proteasome; ko05169 Epstein-Barr virus infection -0.79 0.0062 0.165190087
K03066 PSMC5, RPT6 26S proteasome regulatory subunit T6 ko03050 Proteasome; ko05169 Epstein-Barr virus infection -0.42 0.0125 0.18692096
K14458 MOGAT1, MGAT1 2-acylglycerol O-acyltransferase 1 [EC:2.3.1.22] NA 1.15 0.0097 0.18029481
K14457 MOGAT2, MGAT2 2-acylglycerol O-acyltransferase 2 [EC:2.3.1.22] ko04975 Fat digestion and absorption 0.86 0.0034 0.152539243
K00457 HPD, hppD 4-hydroxyphenylpyruvate dioxygenase [EC:1.13.11.27] ko00130 Ubiquinone and other terpenoid-quinone biosynthesis; ko00350 Tyrosine metabolism; ko00360 Phenylalanine metabolism0.43 0. 195 0.203851854
K00213 DHCR7 7-dehydrocholesterol reductase [EC:1.3.1.21] ko00100 Steroid biosynthesis -1.33 0.0055 0.165190087
K17816 NUDT1, MTH1 8-oxo-dGTP diphosphatase / 2-hydroxy-dATP diphosphatase [EC:3.6.1.55 3. NA -0.43 0.0495 0.266543434
K01895 ACSS, acs acetyl-CoA synthetase [EC:6.2.1.1] ko00010 Glycolysis / Gluconeogenesis; ko00620 Pyruvate metabolism; ko00640 Propanoate metabolism; ko00680 Methane metabolism; ko00720 Carbon fixation pathways in prokaryotes0.69 0.002 0.143042222
K12348 ASAH1 acid ceramidase [EC:3.5.1.23] ko00600 Sphingolipid metabolism; ko04142 Lysosome 0.44 0.0328 0.237164916
K05757 ARPC1A_B actin related protein 2/3 complex, subunit 1A/1B ko04666 Fc gamma R-mediated phagocytosis; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05132 Salmonella infection.70 0.0064 0.165190087
K12314 ACTC1 actin, alpha cardiac muscle ko04260 Cardiac muscle contraction; ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy0.43 0.0115 0.186859932
K11340 ACTL6A, INO80K actin-like protein 6A NA -0.39 0.0314 0.232265167
K04675 ACVR1, ALK2 activin receptor type-1 [EC:2.7.11.30] ko04060 Cytokine-cytokine receptor interaction; ko04350 TGF-beta signaling pathway 0.51 0.0031 0.15204453
K17362 ACOT13 acyl-coenzyme A thioesterase 13 [EC:3.1.2.-] NA -0.50 0.0062 0.165190087
K00814 GPT, ALT alanine transaminase [EC:2.6.1.2] ko00250 Alanine, aspartate and glutamate metabolism; ko00710 Carbon fixation in photosynthetic organisms0.45 0.0063 0.165190087
K15537 AGMO alkylglycerol monooxygenase [EC:1.14.16.5] NA 0.76 0.0138 0.187508268
K09516 RETSAT all-trans-retinol 13,14-reductase [EC:1.3.99.23] ko00830 Retinol metabolism 0.38 0.0168 0.196890943
K15734 SDR16C5 all-trans-retinol dehydrogenase (NAD+) [EC:1.1.1.105] ko00830 Retinol metabolism 0.43 0.0051 0.165133463
K01176 E3.2.1.1, amyA, malS alpha-amylase [EC:3.2.1.1] ko00500 Starch and sucrose metabolism; ko04973 Carbohydrate digestion and absorption 0.92 0.0001 0.097393314
K11140 ANPEP aminopeptidase N [EC:3.4.11.2] ko00480 Glutathione metabolism; ko04614 Renin-angiotensin system; ko04640 Hematopoietic cell lineage-0.58 0.0113 0.186740724
K03349 APC2 anaphase-promoting complex subunit 2 ko04110 Cell cycle; ko04111 Cell cycle - yeast; ko04113 Meiosis - yeast; ko04114 Oocyte meiosis; ko04120 Ubiquitin mediated proteolysis; ko04914 Progesterone-mediated oocyte maturation; ko05166 HTLV-I infection-0.45 0.0005 0.143042222
K08767 ANGPTL4, PGAR angiopoietin-like 4 ko03320 PPAR signaling pathway 0.79 0.0047 0.165133463
K10327 ASB5 ankyrin repeat and SOCS box protein 5 NA -0.43 0.0100 0.18100852
K17091 ANXA1 annexin A1 NA 0.57 0.0158 0.193046798
K17093 ANXA4 annexin A4 NA 0.48 0.0224 0.212626738
K16646 ANXA5 annexin A5 NA 0.97 0.0057 0.165190087
K17095 ANXA7_11 annexin A7/11 NA 0.51 0.0029 0.15204453
K14462 APOB apolipoprotein B ko04975 Fat digestion and absorption; ko04977 Vitamin digestion and absorption 0.45 0.0111 0.186618503
K02434 gatB, PET112 aspartyl-tRNA(Asn)/glutamyl-tRNA(Gln) amidotransferase subunit B [EC:6 ko00970 Aminoacyl-tRNA biosynthesis -0.41 0.0134 0.187355725
K13184 DHX9 ATP-dependent RNA helicase A [EC:3.6.4.13] NA -0.45 0.0033 0.152539243
K18655 DDX19, DBP5 ATP-dependent RNA helicase DDX19/DBP5 [EC:3.6.4.13] NA 0.48 0.0240 0.216901595
K13182 DDX39 ATP-dependent RNA helicase DDX39 [EC:3.6.4.13] NA -0.53 0.0037 0.157088272
K14777 DDX47, RRP3 ATP-dependent RNA helicase DDX47/RRP3 [EC:3.6.4.13] NA -0.46 0.0137 0.187355725
K14810 DDX56, DBP9 ATP-dependent RNA helicase DDX56/DBP9 [EC:3.6.4.13] NA -0.45 0.0291 0.226747861
K16914 NO66 bifunctional lysine-specific demethylase and histidyl-hydroxylase NO66 [EC:1.1 NA -0.45 0.0376 0.249525502
K12409 GNE bifunctional UDP-N-acetylglucosamine 2-epimerase / N-acetylmannosamine kinase [ko00520 Amino sugar and nucleotide sugar metabolism 0.40 0.0351 0.24365317
K01435 BTD biotinidase [EC:3.5.1.12] ko00780 Biotin metabolism; ko04977 Vitamin digestion and absorption 0.78 0.0109 0.186087782
K04663 BMP5 bone morphogenetic protein 5 ko04350 TGF-beta signaling pathway; ko04390 Hippo signaling pathway 0.45 0.0180 0.198691113
K12332 CALCA calcitonin ko04270 Vascular smooth muscle contraction 1.23 0.0416 0.254344055
K17274 S100A10 calpactin-1 light chain NA 0.58 0.0393 0.251981833
K03927 CES2 carboxylesterase 2 [EC:3.1.1.1 3.1.1.84 3.1.1.56] ko00983 Drug metabolism - other enzymes 0.45 0.0085 0.172822126
K01294 CPE carboxypeptidase E [EC:3.4.17.10] ko04940 Type I diabetes mellitus -0.54 0.0014 0.143042222
K13022 CPZ carboxypeptidase Z [EC:3.4.17.-] NA 0.53 0.0033 0.152539243
K08765 CPT1A carnitine O-palmitoyltransferase 1, liver isoform [EC:2.3.1.21] ko00071 Fatty acid degradation; ko03320 PPAR signaling pathway; ko04920 Adipocytokine signaling pathway0.62 0.0028 0.15204453
K12801 CARD8, CARDINAL caspase recruitment domain-containing protein 8 ko04621 NOD-like receptor signaling pathway -0.54 0.0030 0.15204453
K03781 katE, CAT, catB, srpA catalase [EC:1.11.1.6] ko00380 Tryptophan metabolism; ko00630 Glyoxylate and dicarboxylate metabolism; ko04146 Peroxisome; ko05014 Amyotrophic lateral sclerosis (ALS)0.52 0.0107 .184946192
K00545 COMT catechol O-methyltransferase [EC:2.1.1.6] ko00140 Steroid hormone biosynthesis; ko00350 Tyrosine metabolism; ko00965 Betalain biosynthesis; ko04728 Dopaminergic synapse0.56 0.0156 0.191823694
K01371 CTSK cathepsin K [EC:3.4.22.38] ko04142 Lysosome; ko04380 Osteoclast differentiation; ko04620 Toll-like receptor signaling pathway; ko05323 Rheumatoid arthritis0.40 0.0015 0.143042222
K05512 CCL19, ELC C-C motif chemokine 19 ko04060 Cytokine-cytokine receptor interaction; ko04062 Chemokine signaling pathway; ko04064 NF-kappa B signaling pathway-1.23 0.0387 0.25121965
K10050 CEBPD CCAAT/enhancer binding protein (C/EBP), delta NA 0.44 0.0427 0.254716933
K06454 CD4 CD4 antigen ko04514 Cell adhesion molecules (CAMs); ko04612 Antigen processing and presentation; ko04640 Hematopoietic cell lineage; ko04660 T cell receptor signaling pathway; ko05340 Primary immunodeficiency0.57 0.0076 0.168745194
K04393 CDC42 cell division control protein 42 ko04010 MAPK signaling pathway; ko04011 MAPK signaling pathway - yeast; ko04062 Chemokine signaling pathway; ko04144 Endocytosis; ko04360 Axon guidance; ko04370 VEGF signaling pathway; ko04510 Focal adhesion; ko04520 Adherens junction; ko04530 Tight junction; ko04660 T cell receptor signaling pathway; ko04666 Fc gamma R-mediated phagocytosis; ko04670 Leukocyte transendothelial migration; ko04722 Neurotrophin signaling pathway; ko04810 Regulation of actin cytoskeleton; ko04912 GnRH signaling pathway; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05100 Bacterial invasion of epithelial cells; ko05120 Epithelial cell signaling in Helicobacter pylori infection; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05132 Salmonella infection; ko05200 Pathways in cancer; ko05203 Viral carcinogenesis; ko05205 Proteoglycans in cancer; ko05211 Renal cell carcinoma; ko05212 Pancreatic cancer-0.44 0.0019 0.143042222
K04710 CERS ceramide synthetase [EC:2.3.1.24] ko00600 Sphingolipid metabolism 0.46 0.0048 0.165133463
K13624 CP ceruloplasmin [EC:1.16.3.1] ko00860 Porphyrin and chlorophyll metabolism 0.58 0.0417 0.254344055
K04077 groEL, HSPD1 chaperonin GroEL ko03018 RNA degradation; ko04940 Type I diabetes mellitus; ko05134 Legionellosis; ko05152 Tuberculosis-0.68 0.0022 0.14321829
K05022 CLIC2 chloride intracellular channel protein 2 NA 0.44 0.0012 0.143042222
K07440 CYP46A1 cholesterol 24(S)-hydroxylase [EC:1.14.13.98] ko00120 Primary bile acid biosynthesis 0.48 0.0370 0.247118814
K00489 CYP7A1 cholesterol 7alpha-monooxygenase [EC:1.14.13.17] ko00120 Primary bile acid biosynthesis; ko00140 Steroid hormone biosynthesis; ko03320 PPAR signaling pathway; ko04976 Bile secretion2.61 0.0002 0.112669745
K11586 CBX3, HP1G chromobox protein 3 NA -0.43 0.0055 0.165190087
K17252 CLU clusterin NA 0.41 0.0064 0.165190087
K03899 F8 coagulation factor VIII ko04610 Complement and coagulation cascades 0.60 0.0022 0.14321829
K13195 CIRBP cold-inducible RNA-binding protein NA -0.54 0.0118 0.186859932
K06236 COL1AS collagen, type I/II/III/V/XI/XXIV/XXVII, alpha ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko04974 Protein digestion and absorption; ko05146 Amoebiasis1.00 0.0003 0.143042222
K06237 COL4A collagen, type IV, alpha ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko04974 Protein digestion and absorption; ko05146 Amoebiasis; ko05200 Pathways in cancer; ko05222 Small cell lung cancer0.45 0.0041 0.161328781
K04011 CR1, CD35 complement component (3b/4b) receptor 1 ko04610 Complement and coagulation cascades; ko04640 Hematopoietic cell lineage; ko05134 Legionellosis; ko05140 Leishmaniasis; ko05144 Malaria; ko05152 Tuberculosis0.38 0.0277 0.223998206
K01331 C1S complement component 1, s subcomponent [EC:3.4.21.42] ko04610 Complement and coagulation cascades; ko05133 Pertussis; ko05150 Staphylococcus aureus infection; ko05322 Systemic lupus erythematosus0.39 0.0389 0.251981833
K04002 C4BPA complement component 4 binding protein, alpha ko04610 Complement and coagulation cascades; ko05133 Pertussis 0.50 0.0123 0.186859932
K01334 CFD component factor D [EC:3.4.21.46] ko04610 Complement and coagulation cascades; ko05150 Staphylococcus aureus infection 1.05 0.0000 0.001870843
K06677 YCS4, CNAP1, CAPD2 condensin complex subunit 1 ko04111 Cell cycle - yeast 0.56 0.0011 0.143042222
K07213 ATOX1, ATX1, copZ copper chaperone ko04978 Mineral absorption -0.47 0.0160 0.193753298
K00933 E2.7.3.2 creatine kinase [EC:2.7.3.2] ko00330 Arginine and proline metabolism 0.41 0.0018 0.143042222
K17495 CSMD CUB and sushi domain-containing protein NA 0.48 0.0021 0.143042222
K09054 ATF6A cyclic AMP-dependent transcription factor ATF-6 alpha ko04141 Protein processing in endoplasmic reticulum; ko05010 Alzheimer's disease 0.49 0.0397 0.252610475
K00456 CDO1 cysteine dioxygenase [EC:1.13.11.20] ko00270 Cysteine and methionine metabolism; ko00430 Taurine and hypotaurine metabolism 0.54 0.0005 0.143042222
K08738 CYC cytochrome c ko00920 Sulfur metabolism; ko02020 Two-component system; ko04115 p53 signaling pathway; ko04210 Apoptosis; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05014 Amyotrophic lateral sclerosis (ALS); ko05016 Huntington's disease; ko05134 Legionellosis; ko05145 Toxoplasmosis; ko05152 Tuberculosis; ko05161 Hepatitis B; ko05164 Influenza A; ko05168 Herpes simplex infection; ko05200 Pathways in cancer; ko05210 Colorectal cancer; ko05222 Small cell lung cancer; ko05416 Viral myocarditis-0.38 .0179 0.19869111
K18182 COX16 cytochrome c oxidase assembly protein subunit 16 NA -0.54 0.0068 0.168745194
K02260 COX17 cytochrome c oxidase assembly protein subunit 17 ko00190 Oxidative phosphorylation -0.47 0.0098 0.180472394
K18184 COX20 cytochrome c oxidase assembly protein subunit 20 NA -0.61 0.0007 0.143042222
K02256 COX1 cytochrome c oxidase subunit 1 [EC:1.9.3.1] ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.40 0.0131 0.187355725
K02261 COX2 cytochrome c oxidase subunit 2 ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.41 0.0335 0.239193287
K02262 COX3 cytochrome c oxidase subunit 3 ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.55 0.0262 0.223131579
K02264 COX5A cytochrome c oxidase subunit 5a ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.54 0.0125 0.18692096
K02266 COX6A cytochrome c oxidase subunit 6a ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.42 0.0157 0.193046798
K02270 COX7A cytochrome c oxidase subunit 7a ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.53 0.0036 0.157088272
K02272 COX7C cytochrome c oxidase subunit 7c ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.38 0.0222 0.212506754
K07416 CYP2F cytochrome P450, family 2, subfamily F [EC:1.14.14.1] ko00980 Metabolism of xenobiotics by cytochrome P450 0.40 0.0178 0.198691113
K17858 CYP2X cytochrome P450, family 2, subfamily X NA 0.68 0.0360 0.246238756
K07424 CYP3A cytochrome P450, family 3, subfamily A [EC:1.14.14.1] ko00140 Steroid hormone biosynthesis; ko00591 Linoleic acid metabolism; ko00627 Aminobenzoate degradation; ko00830 Retinol metabolism; ko00980 Metabolism of xenobiotics by cytochrome P450; ko00982 Drug metabolism - cytochrome P450; ko00983 Drug metabolism - other enzymes; ko05204 Chemical carcinogenesis0.39 0.0422 0.254635449
K07427 CYP4V cytochrome P450, family 4, subfamily V NA 0.51 0.0300 0.22837528
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K15730 PTGES3 cytosolic prostaglandin-E synthase [EC:5.3.99.3] ko00590 Arachidonic acid metabolism -0.47 0.0222 0.212506754
K00222 TM7SF2, ERG24 delta14-sterol reductase [EC:1.3.1.70] ko00100 Steroid biosynthesis -0.87 0.0110 0.186503889
K11995 DNASE1L deoxyribonuclease-1-like protein [EC:3.1.21.-] NA 0.73 0.0108 0.185417043
K11160 DGAT2 diacylglycerol O-acyltransferase 2 [EC:2.3.1.20 2.3.1.75] ko00561 Glycerolipid metabolism; ko04975 Fat digestion and absorption 0.42 0.0257 0.221905228
K07766 E3.6.1.52 diphosphoinositol-polyphosphate diphosphatase [EC:3.6.1.52] NA -0.45 0.0078 0.168745194
K01597 MVD, mvaD diphosphomevalonate decarboxylase [EC:4.1.1.33] ko00900 Terpenoid backbone biosynthesis -0.69 0.0029 0.15204453
K12475 DAB2 disabled homolog 2 ko04144 Endocytosis 0.47 0.0374 0.249020182
K02540 MCM2 DNA replication licensing factor MCM2 [EC:3.6.4.12] ko03030 DNA replication; ko04110 Cell cycle; ko04111 Cell cycle - yeast; ko04113 Meiosis - yeast-0.40 0.0460 0.258205427
K02209 MCM5, CDC46 DNA replication licensing factor MCM5 [EC:3.6.4.12] ko03030 DNA replication; ko04110 Cell cycle; ko04111 Cell cycle - yeast; ko04113 Meiosis - yeast-0.64 0.0156 0.191823694
K02542 MCM6 DNA replication licensing factor MCM6 [EC:3.6.4.12] ko03030 DNA replication; ko04110 Cell cycle; ko04111 Cell cycle - yeast; ko04113 Meiosis - yeast-0.87 0.0104 0.182571981
K17693 ID2 DNA-binding protein inhibitor ID2 NA 0.58 0.0393 0.251981833
K03015 RPB7, POLR2G DNA-directed RNA polymerase II subunit RPB7 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko05016 Huntington's disease; ko05169 Epstein-Barr virus infection-0.44 0.0213 0.20698367
K03017 RPB9, POLR2I DNA-directed RNA polymerase II subunit RPB9 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko05016 Huntington's disease; ko05169 Epstein-Barr virus infection-0.44 0.0060 0.165190087
K03019 RPC11, POLR3K DNA-directed RNA polymerase III subunit RPC11 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko04623 Cytosolic DNA-sensing pathway; ko05169 Epstein-Barr virus infection-0.39 0.0203 0.205722905
K03020 RPC19, POLR1D DNA-directed RNA polymerases I and III subunit RPAC2 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko04623 Cytosolic DNA-sensing pathway; ko05169 Epstein-Barr virus infection-0.58 0.0010 0.143042222
K03013 RPB5, POLR2E DNA-directed RNA polymerases I, II, and III subunit RPABC1 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko04623 Cytosolic DNA-sensing pathway; ko05016 Huntington's disease; ko05169 Epstein-Barr virus infection-0.52 0.0074 0.168745194
K03007 RPB10, POLR2L DNA-directed RNA polymerases I, II, and III subunit RPABC5 ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko03020 RNA polymerase; ko04623 Cytosolic DNA-sensing pathway; ko05016 Huntington's disease; ko05169 Epstein-Barr virus infection-0.50 0.0018 0.143042222
K10880 XRCC3 DNA-repair protein XRCC3 ko03440 Homologous recombination -0.46 0.0000 0.063123807
K10415 DYNC1I, DNCI dynein intermediate chain, cytosolic ko04145 Phagosome; ko04962 Vasopressin-regulated water reabsorption; ko05132 Salmonella infection-0.44 0.0042 0.161328781
K10660 Mar-05 E3 ubiquitin-protein ligase MARCH5 [EC:6.3.2.19] NA -0.42 0.0033 0.152539243
K10601 SYVN1, HRD1 E3 ubiquitin-protein ligase synoviolin [EC:6.3.2.19] ko04120 Ubiquitin mediated proteolysis; ko04141 Protein processing in endoplasmic reticulum0.42 0.0362 0.246238756
K15901 CGI121, TPRKB EKC/KEOPS complex subunit CGI121/TPRKB NA -0.50 0.0007 0.143042222
K15902 PCC1, LAGE3 EKC/KEOPS complex subunit PCC1/LAGE3 NA -0.39 0.0085 0.172822126
K03522 fixB, etfA electron transfer flavoprotein alpha subunit NA -0.95 0.0007 0.143042222
K10205 ELOVL2 elongation of very long chain fatty acids protein 2 [EC:2.3.1.199] ko00062 Fatty acid elongation; ko01040 Biosynthesis of unsaturated fatty acids -0.45 0.0194 0.203851854
K01173 ENDOG endonuclease G, mitochondrial ko04210 Apoptosis -0.51 0.0133 0.187355725
K14286 AGXT2L1, ETNPPL ethanolamine-phosphate phospho-lyase [EC:4.2.3.2] NA 0.49 0.0117 0.186859932
K03681 RRP40, EXOSC3 exosome complex component RRP40 ko03018 RNA degradation -0.61 0.0003 0.143042222
K00787 FDPS farnesyl diphosphate synthase [EC:2.5.1.1 2.5.1.10] ko00900 Terpenoid backbone biosynthesis; ko05164 Influenza A; ko05166 HTLV-I infection -1.03 0.0030 0.15204453
K02373 FADD FAS-associated death domain protein ko04210 Apoptosis; ko04620 Toll-like receptor signaling pathway; ko04622 RIG-I-like receptor signaling pathway; ko04668 TNF signaling pathway; ko05010 Alzheimer's disease; ko05142 Chagas disease (American trypanosomiasis); ko05152 Tuberculosis; ko05161 Hepatitis B; ko05168 Herpes simplex infection; ko05200 Pathways in cancer-0.43 0.0164 0.195337521
K08751 FABP2 fatty acid-binding protein 2, intestinal ko03320 PPAR signaling pathway; ko04975 Fat digestion and absorption 1.70 0.0141 0.187641673
K08752 FABP3 fatty acid-binding protein 3, muscle and heart ko03320 PPAR signaling pathway 0.46 0.0211 0.206767944
K08755 FABP6 fatty acid-binding protein 6, ileal (gastrotropin) ko03320 PPAR signaling pathway 0.40 0.0040 0.161328781
K10285 FBXL19 F-box and leucine-rich repeat protein 19 NA 0.49 0.0293 0.226747861
K00522 FTH1 ferritin heavy chain [EC:1.16.3.2] ko00860 Porphyrin and chlorophyll metabolism; ko04978 Mineral absorption 0.42 0.0097 0.18029481
K09570 FKBP3 FK506-binding protein 3 [EC:5.2.1.8] NA -0.54 0.0135 0.187355725
K09409 FOXP forkhead box protein P NA 0.53 0.0306 0.229821398
K02133 ATPeF1B, ATP5B, ATP2 F-type H+-transporting ATPase subunit beta [EC:3.6.3.14] ko00190 Oxidative phosphorylation; ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease0.60 0.0013 0.143042222
K02128 ATPeF0C, ATP5G, ATP9 F-type H+-transporting ATPase subunit c ko00190 Oxidative phosphorylation; ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-1.05 0.0019 0.143042222
K12900 FUSIP1 FUS-interacting serine-arginine-rich protein 1 ko03040 Spliceosome -0.49 0.0378 0.249741275
K08266 GBL G protein beta subunit-like ko04150 mTOR signaling pathway; ko04151 PI3K-Akt signaling pathway -0.44 0.0040 0.161328781
K08426 GPR132 G protein-coupled receptor 132 NA 0.96 0.0010 0.143042222
K11257 FUT11 galactoside 3-L-fucosyltransferase 11 [EC:2.4.1.-] NA 0.42 0.0199 0.205299668
K17300 LGALS3BP galectin-3-binding protein NA 0.54 0.0099 0.180472394
K00699 UGT glucuronosyltransferase [EC:2.4.1.17] ko00040 Pentose and glucuronate interconversions; ko00053 Ascorbate and aldarate metabolism; ko00140 Steroid hormone biosynthesis; ko00500 Starch and sucrose metabolism; ko00830 Retinol metabolism; ko00860 Porphyrin and chlorophyll metabolism; ko00980 Metabolism of xenobiotics by cytochrome P450; ko00982 Drug metabolism - cytochrome P450; ko00983 Drug metabolism - other enzymes; ko05204 Chemical carcinogenesis0.64 .0019 0.143042222
K13990 FTCD glutamate formiminotransferase / formiminotetrahydrofolate cyclodeaminase [EC:ko00340 Histidine metabolism; ko00670 One carbon pool by folate 0.75 0.0191 0.203435986
K00252 GCDH, gcdH glutaryl-CoA dehydrogenase [EC:1.3.8.6] ko00071 Fatty acid degradation; ko00310 Lysine degradation; ko00380 Tryptophan metabolism -0.78 0.0001 0.097393314
K00432 E1.11.1.9 glutathione peroxidase [EC:1.11.1.9] ko00480 Glutathione metabolism; ko00590 Arachidonic acid metabolism; ko04918 Thyroid hormone synthesis0.75 0.0367 0.246725736
K00600 glyA, SHMT glycine hydroxymethyltransferase [EC:2.1.2.1] ko00260 Glycine, serine and threonine metabolism; ko00460 Cyanoamino acid metabolism; ko00630 Glyoxylate and dicarboxylate metabolism; ko00670 One carbon pool by folate; ko00680 Methane metabolism.42 0.0133 0.187355725
K01196 AGL glycogen debranching enzyme [EC:2.4.1.25 3.2.1.33] ko00500 Starch and sucrose metabolism 0.65 0.0004 0.143042222
K00049 GRHPR glyoxylate/hydroxypyruvate reductase [EC:1.1.1.79 1.1.1.81] ko00260 Glycine, serine and threonine metabolism; ko00620 Pyruvate metabolism; ko00630 Glyoxylate and dicarboxylate metabolism0.55 0.0259 0.221989249
K06232 GAS1 growth arrest-specific 1 ko04340 Hedgehog signaling pathway 0.49 0.0100 0.18100852
K04630 GNAI guanine nucleotide-binding protein G(i) subunit alpha ko04062 Chemokine signaling pathway; ko04360 Axon guidance; ko04530 Tight junction; ko04540 Gap junction; ko04670 Leukocyte transendothelial migration; ko04713 Circadian entrainment; ko04723 Retrograde endocannabinoid signaling; ko04724 Glutamatergic synapse; ko04725 Cholinergic synapse; ko04726 Serotonergic synapse; ko04727 GABAergic synapse; ko04728 Dopaminergic synapse; ko04730 Long-term depression; ko04914 Progesterone-mediated oocyte maturation; ko04915 Estrogen signaling pathway; ko04916 Melanogenesis; ko04971 Gastric acid secretion; ko05030 Cocaine addiction; ko05032 Morphine addiction; ko05034 Alcoholism; ko05133 Pertussis; ko05142 Chagas disease (American trypanosomiasis); ko05145 Toxoplasmosis.39 0.0044 0.165133463
K01139 spoT, HDDC3 guanosine-3',5'-bis(diphosphate) 3'-pyrophosphohydrolase [EC:3.1.7.2] ko00230 Purine metabolism -0.52 0.0094 0.178297363
K11128 GAR1, NOLA1 H/ACA ribonucleoprotein complex subunit 1 ko03008 Ribosome biogenesis in eukaryotes -0.61 0.0185 0.200420738
K11129 NHP2, NOLA2 H/ACA ribonucleoprotein complex subunit 2 ko03008 Ribosome biogenesis in eukaryotes -0.54 0.0469 0.260922686
K11130 NOP10, NOLA3 H/ACA ribonucleoprotein complex subunit 3 ko03008 Ribosome biogenesis in eukaryotes -0.55 0.0064 0.165190087
K09414 HSF1 heat shock transcription factor 1 ko05134 Legionellosis 0.66 0.0363 0.246238756
K13044 HNRNPABD heterogeneous nuclear ribonucleoprotein A/B/D NA -0.40 0.0176 0.198691113
K12894 HNRNPA0 heterogeneous nuclear ribonucleoprotein A0 NA -0.56 0.0411 0.254344055
K12885 RBMX, HNRNPG heterogeneous nuclear ribonucleoprotein G ko03040 Spliceosome -0.63 0.0459 0.258205427
K11296 HMGB3 high mobility group protein B3 NA -0.63 0.0362 0.246238756
K11307 MYST2, HBO1, KAT7 histone acetyltransferase MYST2 [EC:2.3.1.48] NA -0.45 0.0016 0.143042222
K11251 H2A histone H2A ko05034 Alcoholism; ko05322 Systemic lupus erythematosus -0.41 0.0077 0.168745194
K11252 H2B histone H2B ko05034 Alcoholism; ko05203 Viral carcinogenesis; ko05322 Systemic lupus erythematosus -0.54 0.0172 0.197085215
K08024 HHEX, HEX, PRH homeobox protein HEX ko04950 Maturity onset diabetes of the young; ko05202 Transcriptional misregulation in cancer0.44 0.0053 0.165190087
K09339 HLX1 homeobox protein HLX1 NA 0.48 0.0021 0.143042222
K08648 HABP2 hyaluronan binding protein 2 [EC:3.4.21.-] NA 0.75 0.0471 0.261133498
K11394 PRODH2 hydroxyproline oxidase [EC:1.5.-.-] ko00330 Arginine and proline metabolism 0.44 0.0141 0.187641673
K01507 ppa inorganic pyrophosphatase [EC:3.6.1.1] ko00190 Oxidative phosphorylation -0.42 0.0335 0.239193287
K05719 ITGB1 integrin beta 1 ko04145 Phagosome; ko04151 PI3K-Akt signaling pathway; ko04360 Axon guidance; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko04514 Cell adhesion molecules (CAMs); ko04670 Leukocyte transendothelial migration; ko04810 Regulation of actin cytoskeleton; ko05100 Bacterial invasion of epithelial cells; ko05130 Pathogenic Escherichia coli infection; ko05131 Shigellosis; ko05133 Pertussis; ko05140 Leishmaniasis; ko05145 Toxoplasmosis; ko05200 Pathways in cancer; ko05205 Proteoglycans in cancer; ko05222 Small cell lung cancer; ko05410 Hypertrophic cardiomyopathy (HCM); ko05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC); ko05414 Dilated cardiomyopathy0.66 0.0001 0.097393314
K06566 IFITM interferon induced transmembrane protein NA 0.45 0.0008 0.143042222
K04387 IL1R2 interleukin 1 receptor type II ko04010 MAPK signaling pathway; ko04060 Cytokine-cytokine receptor interaction; ko04640 Hematopoietic cell lineage; ko05146 Amoebiasis; ko05166 HTLV-I infection; ko05202 Transcriptional misregulation in cancer-0.39 0.0017 0.143042222
K05055 IL6R interleukin 6 receptor ko04060 Cytokine-cytokine receptor interaction; ko04066 HIF-1 signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04630 Jak-STAT signaling pathway; ko04640 Hematopoietic cell lineage; ko04932 Non-alcoholic fatty liver disease (NAFLD)0.52 0.0027 0.15204453
K13089 ILF2 interleukin enhancer-binding factor 2 NA -0.68 0.0015 0.143042222
K01823 idi, IDI isopentenyl-diphosphate delta-isomerase [EC:5.3.3.2] ko00900 Terpenoid backbone biosynthesis -1.17 0.0024 0.14835443
K17845 KLF2 krueppel-like factor 2 NA 0.41 0.0074 0.168745194
K05636 LAMB1 laminin, beta 1 ko04151 PI3K-Akt signaling pathway; ko04510 Focal adhesion; ko04512 ECM-receptor interaction; ko05145 Toxoplasmosis; ko05146 Amoebiasis; ko05200 Pathways in cancer; ko05222 Small cell lung cancer0.54 0.0037 0.157088272
K02873 RP-L13e, RPL13 large subunit ribosomal protein L13e ko03010 Ribosome -0.69 0.0078 0.168745194
K02888 RP-L21, MRPL21, rplU large subunit ribosomal protein L21 ko03010 Ribosome -0.41 0.0184 0.200096052
K02890 RP-L22, MRPL22, rplV large subunit ribosomal protein L22 ko03010 Ribosome -0.40 0.0051 0.165133463
K02891 RP-L22e, RPL22 large subunit ribosomal protein L22e ko03010 Ribosome -0.47 0.0180 0.198691113
K02893 RP-L23Ae, RPL23A large subunit ribosomal protein L23Ae ko03010 Ribosome -0.48 0.0057 0.165190087
K02896 RP-L24e, RPL24 large subunit ribosomal protein L24e ko03010 Ribosome -0.39 0.0117 0.186859932
K02899 RP-L27, MRPL27, rpmA large subunit ribosomal protein L27 ko03010 Ribosome -0.41 0.0154 0.191417951
K02910 RP-L31e, RPL31 large subunit ribosomal protein L31e ko03010 Ribosome -0.43 0.0168 0.196890943
K02911 RP-L32, MRPL32, rpmF large subunit ribosomal protein L32 ko03010 Ribosome -0.53 0.0086 0.172822126
K02912 RP-L32e, RPL32 large subunit ribosomal protein L32e ko03010 Ribosome -0.46 0.0370 0.247118814
K02916 RP-L35, MRPL35, rpmI large subunit ribosomal protein L35 ko03010 Ribosome -0.55 0.0020 0.143042222
K02919 RP-L36, MRPL36, rpmJ large subunit ribosomal protein L36 ko03010 Ribosome -0.48 0.0017 0.143042222
K17422 MRPL41 large subunit ribosomal protein L41 NA -0.50 0.0071 0.168745194
K17423 MRPL42 large subunit ribosomal protein L42 NA -0.51 0.0034 0.152539243
K17427 MRPL46 large subunit ribosomal protein L46 NA -0.73 0.0027 0.15204453
K17428 MRPL47, NCM1 large subunit ribosomal protein L47 NA -0.50 0.0292 0.226747861
K17430 MRPL49, NOF1 large subunit ribosomal protein L49 NA -0.44 0.0364 0.246332947
K17432 MRPL51 large subunit ribosomal protein L51 NA -0.41 0.0152 0.190267528
K17433 MRPL52 large subunit ribosomal protein L52 NA -0.54 0.0123 0.186859932
K02934 RP-L6e, RPL6 large subunit ribosomal protein L6e ko03010 Ribosome -1.58 0.0061 0.165190087
K02937 RP-L7e, RPL7 large subunit ribosomal protein L7e ko03010 Ribosome -0.41 0.0393 0.251981833
K00227 SC5DL, ERG3 lathosterol oxidase [EC:1.14.21.6] ko00100 Steroid biosynthesis -0.54 0.0020 0.143042222
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K00650 LCAT lecithin-cholesterol acyltransferase [EC:2.3.1.43] ko00564 Glycerophospholipid metabolism 0.46 0.0274 0.223998206
K01059 LPL lipoprotein lipase [EC:3.1.1.34] ko00561 Glycerolipid metabolism; ko03320 PPAR signaling pathway; ko05010 Alzheimer's disease0.51 0.0017 0.143042222
K12384 SCARB2, LIMP2, CD36L2 lysosome membrane protein 2 ko04142 Lysosome 0.66 0.0007 0.143042222
K03991 MBL mannose-binding lectin ko04145 Phagosome; ko04610 Complement and coagulation cascades; ko05150 Staphylococcus aureus infection1.35 0.0029 0.15204453
K15159 MED16 mediator of RNA polymerase II transcription subunit 16 NA 0.59 0.0092 0.175549137
K15135 MED18 mediator of RNA polymerase II transcription subunit 18 NA -0.42 0.0096 0.17983084
K04200 MC2R melanocortin 2 receptor ko04080 Neuroactive ligand-receptor interaction 0.43 0.0225 0.213229584
K14737 STEAP1 metalloreductase STEAP1 [EC:1.16.1.-] ko04978 Mineral absorption 0.39 0.0009 0.143042222
K14618 MMACHC methylmalonic aciduria homocystinuria type C protein ko04977 Vitamin digestion and absorption -0.43 0.0123 0.186859932
K00869 E2.7.1.36, MVK, mvaK1 mevalonate kinase [EC:2.7.1.36] ko00900 Terpenoid backbone biosynthesis; ko04146 Peroxisome -0.50 0.0048 0.165133463
K06258 SV2 MFS transporter, VNT family, synaptic vesicle glycoprotein 2 ko04512 ECM-receptor interaction -0.41 0.0213 0.20698367
K05309 PTGES2 microsomal prostaglandin-E synthase 2 [EC:5.3.99.3] ko00590 Arachidonic acid metabolism 0.46 0.0123 0.186859932
K14463 MTTP, MTP microsomal triglyceride transfer protein large subunit ko04975 Fat digestion and absorption 0.44 0.0139 0.187508268
K17780 TIM8 mitochondrial import inner membrane translocase subunit TIM8 NA -0.44 0.0254 0.220819904
K17777 TIM9 mitochondrial import inner membrane translocase subunit TIM9 NA -0.40 0.0386 0.25121965
K17770 TOM20 mitochondrial import receptor subunit TOM20 NA -0.40 0.0248 0.218040876
K11518 TOM40 mitochondrial import receptor subunit TOM40 ko05014 Amyotrophic lateral sclerosis (ALS) -0.64 0.0144 0.189571307
K17773 TOM5 mitochondrial import receptor subunit TOM5 NA -0.47 0.0021 0.14321829
K17772 TOM6 mitochondrial import receptor subunit TOM6 NA -0.49 0.0218 0.210559277
K03687 GRPE molecular chaperone GrpE NA -0.45 0.0060 0.165190087
K15448 TRM112, TRMT112 multifunctional methyltransferase subunit TRM112 NA -0.43 0.0237 0.216901595
K18458 ACY3 N-acyl-aromatic-L-amino acid amidohydrolase [EC:3.5.1.114] NA 0.45 0.0299 0.22837528
K13985 NAPEPLD N-acyl-phosphatidylethanolamine-hydrolysing phospholipase D [EC:3.1.4.54] ko04723 Retrograde endocannabinoid signaling 0.38 0.0017 0.143042222
K03945 NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 1 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease- .39 0.0078 0.168745194
K03956 NDUFA11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 11 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease- .38 0.0139 0.187508268
K03946 NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 2 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease- .43 0.0115 0.186859932
K03955 NDUFAB1 NADH dehydrogenase (ubiquinone) 1 alpha/beta subcomplex 1 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease- .60 0.0009 0.143042222
K03957 NDUFB1 NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 1 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease- .47 0.0044 0.165133463
K11351 NDUFB11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 11 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease- .40 0.0137 0.187355725
K03934 NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1 [EC:1.6.5.3 1.6.99.3] ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease.41 0.0130 0.187355725
K03938 NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5 ko00190 Oxidative phosphorylation; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease- .39 0.0102 0.181674235
K08011 NCF1, P47PHOX neutrophil cytosolic factor 1 ko04062 Chemokine signaling pathway; ko04145 Phagosome; ko04380 Osteoclast differentiation; ko04666 Fc gamma R-mediated phagocytosis; ko04670 Leukocyte transendothelial migration; ko05140 Leishmaniasis-1.15 0.0032 0.15204453
K04807 CHRNA5 nicotinic acetylcholine receptor alpha-5 ko04080 Neuroactive ligand-receptor interaction -0.40 0.0136 0.187355725
K17972 NAA20, NAT3 N-terminal acetyltransferase B complex catalytic subunit [EC:2.3.1.88] NA -0.41 0.0080 0.168788939
K12883 NCBP2, CBP20 nuclear cap-binding protein subunit 2 ko03013 RNA transport; ko03015 mRNA surveillance pathway; ko03040 Spliceosome -0.49 0.0031 0.15204453
K14302 NUP37 nuclear pore complex protein Nup37 ko03013 RNA transport -0.44 0.0271 0.223618949
K14840 NOP53, GLTSCR2 nucleolar protein 53 ko05168 Herpes simplex infection -0.51 0.0081 0.171859824
K13288 orn, REX2, REXO2 oligoribonuclease [EC:3.1.-.-] ko03008 Ribosome biogenesis in eukaryotes -0.42 0.0488 0.264832304
K14360 OSTALPHA, OSTA, SLC51A1 organic solute transporter subunit alpha ko04976 Bile secretion 0.42 0.0057 0.165190087
K05215 P2RX1 P2X purinoceptor 1 ko04020 Calcium signaling pathway; ko04080 Neuroactive ligand-receptor interaction -0.40 0.0273 0.223998206
K17659 PTCD3 pentatricopeptide repeat domain-containing protein 3 NA -0.64 0.0086 0.172822126
K12733 PPIL1 peptidyl-prolyl cis-trans isomerase-like 1 [EC:5.2.1.8] ko03040 Spliceosome -0.52 0.0225 0.213229584
K12734 PPIL3 peptidyl-prolyl cis-trans isomerase-like 3 [EC:5.2.1.8] NA -0.41 0.0079 0.168745194
K04794 PTH2 peptidyl-tRNA hydrolase, PTH2 family [EC:3.1.1.29] NA -0.44 0.0030 0.15204453
K14558 PWP2, UTP1 periodic tryptophan protein 2 ko03008 Ribosome biogenesis in eukaryotes -0.68 0.0128 0.187355725
K00500 phhA, PAH phenylalanine-4-hydroxylase [EC:1.14.16.1] ko00360 Phenylalanine metabolism; ko00400 Phenylalanine, tyrosine and tryptophan biosynthesis0.71 0.0103 0.182571981
K01889 FARSA, pheS phenylalanyl-tRNA synthetase alpha chain [EC:6.1.1.20] ko00970 Aminoacyl-tRNA biosynthesis -0.41 0.0056 0.165190087
K01080 PPAP2 phosphatidate phosphatase [EC:3.1.3.4] ko00561 Glycerolipid metabolism; ko00564 Glycerophospholipid metabolism; ko00565 Ether lipid metabolism; ko00600 Sphingolipid metabolism; ko04666 Fc gamma R-mediated phagocytosis; ko04975 Fat digestion and absorption-0.95 0.0060 0.16519 87
K19404 LIPH_I phosphatidic acid-selective&#160 NA 0.39 0.0297 0.227893755
K05929 E2.1.1.103, NMT phosphoethanolamine N-methyltransferase [EC:2.1.1.103] ko00564 Glycerophospholipid metabolism 0.56 0.0008 0.143042222
K01112 PHPT1 phosphohistidine phosphatase [EC:3.1.3.-] ko00051 Fructose and mannose metabolism -0.39 0.0007 0.143042222
K13618 PLA1A phospholipase A1 member A [EC:3.1.1.-] NA 0.54 0.0097 0.18029481
K01079 serB, PSPH phosphoserine phosphatase [EC:3.1.3.3] ko00260 Glycine, serine and threonine metabolism; ko00680 Methane metabolism -0.72 0.0257 0.221905228
K01315 PLG plasminogen [EC:3.4.21.7] ko04080 Neuroactive ligand-receptor interaction; ko04610 Complement and coagulation cascades; ko05150 Staphylococcus aureus infection; ko05164 Influenza A0.70 .04 5 0.254260306
K13126 PABPC polyadenylate-binding protein ko03013 RNA transport; ko03015 mRNA surveillance pathway; ko03018 RNA degradation -0.39 0.0410 0.254344055
K00710 GALNT polypeptide N-acetylgalactosaminyltransferase [EC:2.4.1.41] ko00512 Mucin type O-Glycan biosynthesis 0.79 0.0413 0.254344055
K12820 DHX15, PRP43 pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15/PRP43 [EC:3. ko03040 Spliceosome -0.39 0.0139 0.187508268
K00276 AOC3, AOC2, tynA primary-amine oxidase [EC:1.4.3.21] ko00260 Glycine, serine and threonine metabolism; ko00350 Tyrosine metabolism; ko00360 Phenylalanine metabolism; ko00410 beta-Alanine metabolism; ko00950 Isoquinoline alkaloid biosynthesis; ko00960 Tropane, piperidine and pyridine alkaloid biosynthesis0.43 0.0345 0.241701062
K04802 PCNA proliferating cell nuclear antigen ko03030 DNA replication; ko03410 Base excision repair; ko03420 Nucleotide excision repair; ko03430 Mismatch repair; ko04110 Cell cycle; ko05161 Hepatitis B; ko05166 HTLV-I infection-0.64 0.0102 0.181674235
K01830 E5.3.99.2, PTGDS prostaglandin-H2 D-isomerase [EC:5.3.99.2] ko00590 Arachidonic acid metabolism 0.48 0.0030 0.15204453
K11599 POMP, UMP1 proteasome maturation protein ko03050 Proteasome -0.40 0.0070 0.168745194
K02516 PRMT5, HSL7 protein arginine N-methyltransferase 5 [EC:2.1.1.125] ko03013 RNA transport; ko04111 Cell cycle - yeast -0.49 0.0091 0.175063798
K18266 NDRG1 protein NDRG1 NA 0.58 0.0360 0.246238756
K16219 METTL11, NTM1 protein N-terminal methyltransferase [EC:2.1.1.244] NA -0.44 0.0271 0.223618949
K17499 PPM1G, PP2CG protein phosphatase 1G [EC:3.1.3.16] NA -0.39 0.0035 0.153325268
K00573 E2.1.1.77, pcm protein-L-isoaspartate(D-aspartate) O-methyltransferase [EC:2.1.1.77 NA 0.88 0.0198 0.205299668
K03783 punA purine-nucleoside phosphorylase [EC:2.4.2.1] ko00230 Purine metabolism; ko00240 Pyrimidine metabolism; ko00760 Nicotinate and nicotinamide metabolism0.82 0.0015 0.143042222
K05762 RDX radixin ko04810 Regulation of actin cytoskeleton; ko05205 Proteoglycans in cancer; ko05206 MicroRNAs in cancer0.67 0.0095 0.179800348
K15306 RANBP1 Ran-binding protein 1 ko05166 HTLV-I infection; ko05203 Viral carcinogenesis -0.42 0.0056 0.165190087
K07906 RAB25 Ras-related protein Rab-25 NA 0.58 0.0245 0.218040876
K08526 NR2B3, RXRG retinoid X receptor gamma ko03320 PPAR signaling pathway; ko04920 Adipocytokine signaling pathway; ko05200 Pathways in cancer; ko05202 Transcriptional misregulation in cancer; ko05216 Thyroid cancer; ko05222 Small cell lung cancer; ko05223 Non-small cell lung cancer0.46 0.0097 0.18029481
K10743 RNASEH2A ribonuclease H2 subunit A [EC:3.1.26.4] ko03030 DNA replication -0.42 0.0045 0.165133463
K00784 rnz ribonuclease Z [EC:3.1.26.11] ko03013 RNA transport -0.61 0.0015 0.143042222
K14530 RPP40 ribonucleases P/MRP protein subunit RPP40 [EC:3.1.26.5] ko03008 Ribosome biogenesis in eukaryotes; ko03013 RNA transport -0.40 0.0086 0.172822126
K15433 CGI99, CLE7, RLLM1 RLL motif containing protein 1 NA -0.42 0.0303 0.229821398
K13094 RBM5_10 RNA-binding protein 5/10 NA 0.39 0.0086 0.172822126
K00121 frmA, ADH5, adhC S-(hydroxymethyl)glutathione dehydrogenase / alcohol dehydrogenase ko00010 Glycolysis / Gluconeogenesis; ko00071 Fatty acid degradation; ko00350 Tyrosine metabolism; ko00625 Chloroalkane and chloroalkene degradation; ko00626 Naphthalene degradation; ko00680 Methane metabolism; ko00830 Retinol metabolism; ko00980 Metabolism of xenobiotics by cytochrome P450; ko00982 Drug metabolism - cytochrome P450; ko05204 Chemical carcinogenesis0.80 0.0239 0.216901595
K12382 PSAP, SGP1 saposin ko04142 Lysosome 0.39 0.0047 0.165133463
K16312 STK40, SHIK serine/threonine-protein kinase 40 [EC:2.7.11.1] NA 0.63 0.0136 0.187355725
K08269 ULK1_2_3, ATG1 serine/threonine-protein kinase ULK/ATG1 [EC:2.7.11.1] ko04140 Regulation of autophagy; ko04150 mTOR signaling pathway 0.38 0.0103 0.182571981
K15637 PGAM5 serine/threonine-protein phosphatase PGAM5 [EC:3.1.3.16] ko04668 TNF signaling pathway -0.41 0.0021 0.143042222
K16141 ALB serum albumin NA 0.40 0.0087 0.172822126
K05304 NANS, SAS sialic acid synthase [EC:2.5.1.56 2.5.1.57] ko00520 Amino sugar and nucleotide sugar metabolism -0.53 0.0061 0.165190087
K11220 STAT1 signal transducer and activator of transcription 1 ko04062 Chemokine signaling pathway; ko04380 Osteoclast differentiation; ko04620 Toll-like receptor signaling pathway; ko04630 Jak-STAT signaling pathway; ko04917 Prolactin signaling pathway; ko05140 Leishmaniasis; ko05145 Toxoplasmosis; ko05152 Tuberculosis; ko05160 Hepatitis C; ko05161 Hepatitis B; ko05162 Measles; ko05164 Influenza A; ko05168 Herpes simplex infection; ko05200 Pathways in cancer; ko05212 Pancreatic cancer; ko05321 Inflammatory bowel disease (IBD)0.41 0.0277 0.223998206
K11096 SNRPD2, SMD2 small nuclear ribonucleoprotein D2 ko03040 Spliceosome -0.49 0.0010 0.143042222
K11098 SNRPF, SMF small nuclear ribonucleoprotein F ko03040 Spliceosome -0.57 0.0013 0.143042222
K11099 SNRPG, SMG small nuclear ribonucleoprotein G ko03040 Spliceosome -0.49 0.0075 0.168745194
K02948 RP-S11, MRPS11, rpsK small subunit ribosomal protein S11 ko03010 Ribosome -0.68 0.0066 0.165190087
K02950 RP-S12, MRPS12, rpsL small subunit ribosomal protein S12 ko03010 Ribosome -0.53 0.0057 0.165190087
K02954 RP-S14, MRPS14, rpsN small subunit ribosomal protein S14 ko03010 Ribosome -0.47 0.0190 0.202958509
K02960 RP-S16e, RPS16 small subunit ribosomal protein S16e ko03010 Ribosome -0.39 0.0051 0.165133463
K02962 RP-S17e, RPS17 small subunit ribosomal protein S17e ko03010 Ribosome -0.42 0.0393 0.251981833
K16174 MRPS18B, MRPS18-2 small subunit ribosomal protein S18b, mitochondrial ko05203 Viral carcinogenesis -0.42 0.0112 0.186740724
K02969 RP-S20e, RPS20 small subunit ribosomal protein S20e ko03010 Ribosome -0.49 0.0060 0.165190087
K02970 RP-S21, MRPS21, rpsU small subunit ribosomal protein S21 ko03010 Ribosome -0.42 0.0099 0.180472394
K17404 MRPS25 small subunit ribosomal protein S25 NA -0.52 0.0011 0.143042222
K02975 RP-S25e, RPS25 small subunit ribosomal protein S25e ko03010 Ribosome -0.50 0.0043 0.163642877
K02976 RP-S26e, RPS26 small subunit ribosomal protein S26e ko03010 Ribosome -0.56 0.0121 0.186859932
K17412 MRPS34 small subunit ribosomal protein S34 NA -0.59 0.0051 0.165133463
K02989 RP-S5e, RPS5 small subunit ribosomal protein S5e ko03010 Ribosome -0.59 0.0050 0.165133463
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K02990 RP-S6, MRPS6, rpsF small subunit ribosomal protein S6 ko03010 Ribosome -0.39 0.0348 0.242713867
K02991 RP-S6e, RPS6 small subunit ribosomal protein S6e ko03010 Ribosome; ko04066 HIF-1 signaling pathway; ko04150 mTOR signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04910 Insulin signaling pathway; ko05205 Proteoglycans in cancer-0.47 0.0132 0.187355725
K02992 RP-S7, MRPS7, rpsG small subunit ribosomal protein S7 ko03010 Ribosome -0.44 0.0341 0.241125045
K02998 RP-SAe, RPSA small subunit ribosomal protein SAe ko03010 Ribosome -0.56 0.0435 0.256044303
K12160 SUMO, SMT3 small ubiquitin-related modifier ko03013 RNA transport -0.63 0.0041 0.161328781
K05863 SLC25A4S, ANT solute carrier family 25 (mitochondrial adenine nucleotide translocat ko04020 Calcium signaling pathway; ko05012 Parkinson's disease; ko05016 Huntington's disease; ko05166 HTLV-I infection-0.38 0.0433 0.255943021
K08746 SLC27A2, FACVL1, FATP2 solute carrier family 27 (fatty acid transporter), member 2 ko03320 PPAR signaling pathway; ko04146 Peroxisome 0.56 0.0039 0.161227988
K06519 CD98, SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid ko04974 Protein digestion and absorption 0.52 0.0031 0.15204453
K00511 SQLE, ERG1 squalene monooxygenase [EC:1.14.13.132] ko00909 Sesquiterpenoid and triterpenoid biosynthesis -0.50 0.0121 0.186859932
K07431 CYP8B1 sterol 12-alpha-hydroxylase [EC:1.14.13.95 1.14.13.96] ko00120 Primary bile acid biosynthesis; ko03320 PPAR signaling pathway 0.65 0.0028 0.15204453
K05917 CYP51 sterol 14-demethylase [EC:1.14.13.70] ko00100 Steroid biosynthesis -1.40 0.0010 0.143042222
K07748 E1.1.1.170, NSDHL, ERG26 sterol-4alpha-carboxylate 3-dehydrogenase (decarboxylating ko00100 Steroid biosynthesis -0.46 0.0047 0.165133463
K09494 CCT2 T-complex protein 1 subunit beta NA -0.41 0.0338 0.239980947
K10758 QSOX thiol oxidase [EC:1.8.3.2] NA 0.49 0.0133 0.187355725
K00758 deoA, TYMP thymidine phosphorylase [EC:2.4.2.4] ko00240 Pyrimidine metabolism; ko00983 Drug metabolism - other enzymes; ko05219 Bladder cancer0.78 0.0363 0.246238756
K09058 TEF thyrotrophic embryonic factor NA 1.02 0.0173 0.197085215
K07754 DIO3 thyroxine 5-deiodinase [EC:1.97.1.11] NA 0.65 0.0093 0.177625461
K03909 TFPI tissue factor pathway inhibitor ko04610 Complement and coagulation cascades 0.65 0.0020 0.143042222
K14619 TCN2 transcobalamin-2 ko04977 Vitamin digestion and absorption 0.42 0.0180 0.198691113
K09036 MAFB transcription factor MAFB NA 0.44 0.0302 0.229640822
K03237 EIF2S1 translation initiation factor 2 subunit 1 ko03013 RNA transport; ko04141 Protein processing in endoplasmic reticulum; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05160 Hepatitis C; ko05162 Measles; ko05164 Influenza A; ko05168 Herpes simplex infection-0.50 0.0123 0.186859932
K03246 EIF3I translation initiation factor 3 subunit I ko03013 RNA transport -0.42 0.0199 0.205547989
K15029 EIF3L translation initiation factor 3 subunit L NA -0.39 0.0266 0.223618949
K03259 EIF4E translation initiation factor 4E ko03013 RNA transport; ko04066 HIF-1 signaling pathway; ko04150 mTOR signaling pathway; ko04151 PI3K-Akt signaling pathway; ko04910 Insulin signaling pathway-0.71 0.0067 0.168046036
K03264 EIF6 translation initiation factor 6 ko03008 Ribosome biogenesis in eukaryotes -0.53 0.0021 0.143042222
K09637 TMPRSS6 transmembrane protease, serine 6 [EC:3.4.21.-] NA 0.41 0.0087 0.172822126
K17599 TMEM132 transmembrane protein 132 NA 0.41 0.0172 0.197085215
K17966 TMEM70 transmembrane protein 70, mitochondrial NA -0.38 0.0066 0.165190087
K00555 TRMT1, trm1 tRNA (guanine26-N2/guanine27-N2)-dimethyltransferase [EC:2.1.1.215 2.1. NA -0.45 0.0002 0.112669745
K15429 TRM5, TRMT5 tRNA (guanine37-N1)-methyltransferase [EC:2.1.1.228] NA -0.41 0.0071 0.168745194
K06173 truA, PUS1 tRNA pseudouridine38-40 synthase [EC:5.4.99.12] NA -0.40 0.0245 0.218040876
K10375 TPM4 tropomyosin 4 ko04260 Cardiac muscle contraction; ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy0.40 0.0046 0.165133463
K12045 TNNT2 troponin T, cardiac muscle ko04260 Cardiac muscle contraction; ko05410 Hypertrophic cardiomyopathy (HCM); ko05414 Dilated cardiomyopathy0.39 0.0025 0.148961431
K17292 TBCA tubulin-specific chaperone A NA -0.46 0.0212 0.206767944
K07604 KRT1 type I keratin, acidic NA 0.68 0.0024 0.14835443
K01562 DIO1 type I thyroxine 5'-deiodinase [EC:1.97.1.10] NA 0.46 0.0480 0.263205722
K00815 TAT tyrosine aminotransferase [EC:2.6.1.5] ko00130 Ubiquinone and other terpenoid-quinone biosynthesis; ko00270 Cysteine and methionine metabolism; ko00350 Tyrosine metabolism; ko00360 Phenylalanine metabolism; ko00400 Phenylalanine, tyrosine and tryptophan biosynthesis; ko00401 Novobiocin biosynthesis; ko00950 Isoquinoline alkaloid biosynthesis; ko00960 Tropane, piperidine and pyridine alkaloid biosynthesis0.90 0.0011 0.143042222
K18026 PTPN2, PTPT tyrosine-protein phosphatase non-receptor type 2 [EC:3.1.3.48] NA -0.45 0.0152 0.190267528
K01866 YARS, tyrS tyrosyl-tRNA synthetase [EC:6.1.1.1] ko00970 Aminoacyl-tRNA biosynthesis -0.57 0.0001 0.112669745
K11095 SNRPC U1 small nuclear ribonucleoprotein C ko03040 Spliceosome -0.38 0.0198 0.205299668
K13153 SNRNP25 U11/U12 small nuclear ribonucleoprotein 25 kDa protein NA -0.42 0.0032 0.152539243
K11094 SNRPB2 U2 small nuclear ribonucleoprotein B'' ko03040 Spliceosome -0.43 0.0019 0.143042222
K14566 UTP24, FCF1 U3 small nucleolar RNA-associated protein 24 ko03008 Ribosome biogenesis in eukaryotes -0.46 0.0140 0.187641673
K12845 SNU13, NHP2L U4/U6 small nuclear ribonucleoprotein SNU13 ko03008 Ribosome biogenesis in eukaryotes; ko03040 Spliceosome -1.12 0.0020 0.143042222
K12620 LSM1 U6 snRNA-associated Sm-like protein LSm1 ko03018 RNA degradation -0.54 0.0010 0.143042222
K12622 LSM3 U6 snRNA-associated Sm-like protein LSm3 ko03018 RNA degradation; ko03040 Spliceosome -0.48 0.0051 0.165133463
K12623 LSM4 U6 snRNA-associated Sm-like protein LSm4 ko03018 RNA degradation; ko03040 Spliceosome -0.48 0.0030 0.15204453
K00416 QCR6, UQCRH ubiquinol-cytochrome c reductase subunit 6 ko00190 Oxidative phosphorylation; ko04260 Cardiac muscle contraction; ko04932 Non-alcoholic fatty liver disease (NAFLD); ko05010 Alzheimer's disease; ko05012 Parkinson's disease; ko05016 Huntington's disease-0.51 0.0126 0.187355725
K12161 URM1 ubiquitin related modifier 1 ko04122 Sulfur relay system -0.39 0.0041 0.161328781
K06689 UBE2D_E, UBC4, UBC5 ubiquitin-conjugating enzyme E2 D/E [EC:6.3.2.19] ko04120 Ubiquitin mediated proteolysis; ko04141 Protein processing in endoplasmic reticulum0.41 0.0130 0.187355725
K00365 uaZ urate oxidase [EC:1.7.3.3] ko00230 Purine metabolism; ko00232 Caffeine metabolism 0.59 0.0122 0.186859932
K00757 udp, UPP uridine phosphorylase [EC:2.4.2.3] ko00240 Pyrimidine metabolism; ko00983 Drug metabolism - other enzymes 0.93 0.0083 0.172822126
K00963 UGP2, galU, galF UTP--glucose-1-phosphate uridylyltransferase [EC:2.7.7.9] ko00040 Pentose and glucuronate interconversions; ko00052 Galactose metabolism; ko00500 Starch and sucrose metabolism; ko00520 Amino sugar and nucleotide sugar metabolism0.47 0.0247 0.218040876
K14208 XPNPEP2 Xaa-Pro aminopeptidase 2 [EC:3.4.11.9] ko04974 Protein digestion and absorption 0.54 0.0091 0.175171915
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Additive Limit 
Vitamin A  No limit (for fish) 
Vitamin D3 3000 I.U/kg or 0.075 mg/kg 
Vitamin E No limit 
Vitamin K3 No limit 
  
Vitamin B1 No limit 
Vitamin B2 No limit 
Vitamin B6 No limit 
Vitamin B12 No limit 
Vitamin B3 /Vitamin PP/ Niacin No limit 
Vitamin B5 (Calcium d-pantothenate) No limit 
Folic acid (vitamin B9) No limit 
Biotin No limit 
  
Vitamin C  No limit 
  
Cobalt No longer approved 
Iodide and iodate 20 mg/kg 
Selenium 0.5 mg/kg 
Iron  max. 750 mg/kg 
Manganese sulphate 100 mg/kg 
Copper sulphate 25 mg/kg   
Zinc sulphate monohydrate 180 mg/kg for salmonids, 150 mg/kg for other fish species 
  
Taurine No information 
Histidine No limit 
 1102 
 1103 
